


**CUMULATIVE
SUPPLEMENT 8
AUGUST 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 8

August 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 08
August 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

BD RX INC
(BD RX)

CITRON PHARMA LLC
(CITRON PHARMA LLC)

PROSAM LABS LLC
(PROSAM LABS)

HIKMA MAPLE LTD
(HIKMA MAPLE)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

FRESENIUS KABI USA LLC
(FRESENIUS KABI USA)

CASPER PHARMA LLC
(CASPER PHARMA LLC)

OXFORD PHARMACEUTICALS LLC
(OXFORD PHARMS)

EUROHEALTH INTERNATIONAL SARL
(EUROHLTH INTL SARL)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS	17151	17251	17528		
LISTED SINGLE	2664	2693	2664		
SOURCE	(15.5%)	(15.6%)	(15.2%)		
MULTISOURCE	14487	14558	14864		
	(84.5%)	(84.4%)	(84.8%)		
THERAPEUTICALLY	14366	14434	14731		
EQUIVALENT	(83.8%)	(83.7%)	(84%)		
NOT THERAPEUTICALLY	121	124	133		
EQUIVALENT	(0.7%)	(0.7%)	(0.8%)		
EXCEPTIONS ¹	73	73	73		
	(0.4%)	(0.4%)	(0.4%)		
NEW MOLECULAR	28	9	20		
ENTITIES APPROVED					
NUMBER OF	1011	1007	1023		
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action.

The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

AB	+	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	May CRLD
----	---	-------------------	-------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION; IV (INFUSION)
ACETAMINOPHEN

AP		PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	May NEWA
AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar NEWA
		OFIRMEV					
AP	+	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Mar CFTG

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN

>A>	AA	CNTY LINE PHARMS	325MG; 50MG	A205120	001	Oct 30, 2015	Aug CAHN
>D>	AA	TEDOR PHARMA INC	325MG; 50MG	A205120	001	Oct 30, 2015	Aug CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	+	MAYNE PHARMA INC	325MG; 50MG; 40MG	A089007	001	Mar 17, 1986	Aug CAHN
>D>	+	METRIC	325MG; 50MG; 40MG	A089007	001	Mar 17, 1986	Aug CAHN
	+		325MG; 50MG; 40MG	A089007	001	Mar 17, 1986	Jun CAHN

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
@ INGENUS PHARMS NJ 325MG; 50MG; 40MG
@ SUN PHARM INDS 325MG; 50MG; 40MG
FIORICET

AA		ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984	May CMFD
----	--	---------------------	-------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
FIORICET W/ CODEINE

AB	+	ACTAVIS LABS UT INC	325MG; 50MG; 40MG; 30MG	N020232	001	Jul 30, 1992	Jul CAHN
AB	+	ALLERGAN SALES LLC	325MG; 50MG; 40MG; 30MG	N020232	001	Jul 30, 1992	Apr CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
@ FRONTIDA BIOPHARM 300MG; 60MG
@ SUN PHARM INDS 300MG; 60MG

A089673	001	Feb 10, 1988	Jul CAHN
A089673	001	Feb 10, 1988	Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
ZYFREL

AA		CYPRESS PHARM INC	325MG/15ML; 7.5MG/15ML	A090468	001	Apr 14, 2016	Apr NEWA
----	--	-------------------	------------------------	---------	-----	--------------	----------

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ACTAVIS LABS FL INC	300MG; 5MG	A206470	001	Jun 02, 2016	May NEWA
AA			300MG; 7.5MG	A206470	002	Jun 02, 2016	May NEWA
AA			300MG; 10MG	A206470	003	Jun 02, 2016	May NEWA
	@	ALLERGAN SALES LLC	500MG; 10MG	A040148	002	Feb 14, 1997	Jun CAHN
AA		AMNEAL PHARMS NY	325MG; 7.5MG	A040746	002	May 10, 2016	Apr NEWA
AA		LARKEN LABS INC	325MG; 5MG	A202935	002	Jun 15, 2016	Jun NEWA
AA			325MG; 7.5MG	A202935	003	Jun 15, 2016	Jun NEWA
AA			325MG; 10MG	A202935	004	Jun 15, 2016	Jun NEWA
AA		PAR PHARM	300MG; 5MG	A205001	001	Jul 05, 2016	Jun NEWA
AA			300MG; 7.5MG	A205001	002	Jul 05, 2016	Jun NEWA
AA			300MG; 10MG	A205001	003	Jul 05, 2016	Jun NEWA
AA		RHODES PHARMS	325MG; 5MG	A202991	001	Apr 12, 2016	Mar NEWA
AA			325MG; 7.5MG	A202991	002	Apr 12, 2016	Mar NEWA
AA			325MG; 10MG	A202991	003	Apr 12, 2016	Mar NEWA
AA		TRIS PHARMA INC	300MG; 5MG	A202214	004	Mar 15, 2016	Jun NEWA
AA			300MG; 7.5MG	A202214	005	Mar 15, 2016	Jun NEWA
AA			300MG; 10MG	A202214	006	Mar 15, 2016	Jun NEWA
		NORCO					
AA		ALLERGAN SALES LLC	325MG; 2.5MG	A040148	004	Jul 07, 2014	Jun CAHN
AA	+		325MG; 5MG	A040099	001	Jun 25, 1997	Jun CAHN

TABLET;ORAL
NORCO

AA		325MG;5MG	A040148	005	Jul 07, 2014	Jun CAHN
AA	+	325MG;7.5MG	A040148	003	Sep 12, 2000	Jun CAHN
AA	+	325MG;10MG	A040148	001	Feb 14, 1997	Jun CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	MALLINCKRODT INC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Aug CRLD	
>A>	AA	+	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Aug CRLD	
	AA		325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	May CMFD	
>D>		ROXICET						
>D>	AA	+	ROXANE	325MG/5ML;5MG/5ML	A089351	001	Dec 03, 1986	Aug DISC
>A>		@	325MG/5ML;5MG/5ML	A089351	001	Dec 03, 1986	Aug DISC	

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA		ALVOGEN MALTA	325MG;5MG	A202677	003	Mar 08, 2016	Feb NEWA
AA			325MG;7.5MG	A202677	001	Jul 26, 2012	Jan CAHN
AA			325MG;10MG	A202677	002	Jul 26, 2012	Jan CAHN
AA		AMNEAL PHARMS NY	325MG;7.5MG	A040778	002	Jun 27, 2014	Apr NEWA
AA		MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20, 2008	Feb CAHN
AA			325MG;5MG	A090177	002	Oct 20, 2008	Feb CAHN
AA			325MG;7.5MG	A090177	003	Oct 20, 2008	Feb CAHN
AA			325MG;10MG	A090177	004	Oct 20, 2008	Feb CAHN
		@	500MG;7.5MG	A090177	005	Oct 20, 2008	Feb CAHN
		@	650MG;10MG	A090177	006	Oct 20, 2008	Feb CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ATLAS PHARMS LLC	325MG;37.5MG	A202076	001	Mar 30, 2012	May CAHN
----	--	------------------	--------------	---------	-----	--------------	----------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar NEWA
----	--	------------------	-------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP		AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb NEWA
----	--	----------------------	---------------------	---------	-----	--------------	----------

TABLET, EFFERVESCENT;ORAL

CETYLEV

		ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Jan NEWA
	+		2.5GM	N207916	002	Jan 29, 2016	Jan NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

>A>	AB	IMPAX LABS INC	10MG	A202552	001	Dec 23, 2015	Aug CAHN
>A>	AB		17.5MG	A202552	002	Dec 23, 2015	Aug CAHN
>A>	AB		22.5MG	A202552	003	Dec 23, 2015	Aug CAHN
>A>	AB		25MG	A202552	004	Dec 23, 2015	Aug CAHN
>D>	AB	WATSON LABS INC	10MG	A202552	001	Dec 23, 2015	Aug CAHN
>D>	AB		17.5MG	A202552	002	Dec 23, 2015	Aug CAHN
>D>	AB		22.5MG	A202552	003	Dec 23, 2015	Aug CAHN
>D>	AB		25MG	A202552	004	Dec 23, 2015	Aug CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

	+	AUXILIUM PHARMS INC	8MG;60MG	N019806	001	Mar 25, 1994	Mar CAHN
--	---	---------------------	----------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

		@ RANBAXY	200MG	A074975	001	Sep 30, 1998	Feb DISC
AB		ZYDUS PHARMS USA INC	200MG	A204313	001	Mar 25, 2016	Mar NEWA

OINTMENT; TOPICAL							
ACYCLOVIR							
AB	FOUGERA PHARMS INC	5%	A206633	001	May 11, 2016	Apr	NEWA
TABLET; BUCCAL							
SITAVIG							
+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan	CAHN
TABLET; ORAL							
ACYCLOVIR							
@	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Feb	DISC
@		800MG	A074980	002	Sep 30, 1998	Feb	DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION							
ACYCLOVIR SODIUM							
@	AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Jun	CAHN
@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Jun	CAHN
@	BEDFORD	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Feb	DISC
@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	DISC
AP	+	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CTEC
@	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Apr	CAHN
@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Apr	CAHN
AP	HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb	NEWA
+		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb	CRLD
AP		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb	NEWA

ADAPALENE

GEL; TOPICAL							
ADAPALENE							
AB	TARO	0.3%	A208322	001	Jun 23, 2016	Jun	NEWA

ADENOSINE

INJECTABLE;INJECTION							
ADENOSINE							
AP	EUROHLTH INTL SARL	3MG/ML		A076404	001	Jun 16, 2004	Apr CAHN
SOLUTION;IV (INFUSION)							
ADENOSINE							
AP	+ TEVA PHARMS USA	60MG/20ML (3MG/ML)		A077425	001	Aug 29, 2013	Apr CRLD
AP	+	90MG/30ML (3MG/ML)		A077425	002	Aug 29, 2013	Apr CRLD

ALBUTEROL SULFATE

SOLUTION; INHALATION							
ALBUTEROL SULFATE							
AN	@ HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar	DISC
	@ LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar	DISC
	+ NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar	CRLD
	@ TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar	DISC
	@ WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar	DISC
TABLET; ORAL							
ALBUTEROL SULFATE							
AB	SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar	CAHN
AB		EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION							
DUONEB							
@	MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	Jun	DISC

ALENDRONATE SODIUM

SOLUTION;ORAL							
ALENDRONATE SODIUM							
>D> AA	ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Aug	CRLD
>A>	+	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Aug	CRLD
>D>	FOSAMAX						
>D> AA	+ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Aug	DISC
>A>	@	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Aug	DISC
TABLET;ORAL							
ALENDRONATE SODIUM							
>A> AB	IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008	Aug	CAHN
>A> AB		EQ 10MG BASE	A075710	002	Feb 06, 2008	Aug	CAHN
>A> AB		EQ 35MG BASE	A075710	003	Feb 06, 2008	Aug	CAHN
>A> AB		EQ 40MG BASE	A075710	004	Feb 06, 2008	Aug	CAHN
>A> AB		EQ 70MG BASE	A075710	005	Feb 06, 2008	Aug	CAHN

TABLET;ORAL

ALENDRONATE SODIUM

AB	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun CAHN
AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun CAHN
AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun CAHN
AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun CAHN
>D> AB	TEVA PHARMS	EQ 5MG BASE	A075710	001	Feb 06, 2008	Aug CAHN
>D> AB		EQ 10MG BASE	A075710	002	Feb 06, 2008	Aug CAHN
>D> AB		EQ 35MG BASE	A075710	003	Feb 06, 2008	Aug CAHN
>D> AB		EQ 40MG BASE	A075710	004	Feb 06, 2008	Aug CAHN
>D> AB		EQ 70MG BASE	A075710	005	Feb 06, 2008	Aug CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

>D>	@ MERCK	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005	Aug CMFD
>A>		EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005	Aug CMFD
>D>	@	EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007	Aug CMFD
>A>	+	EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007	Aug CMFD

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB	UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan NEWA
----	------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB	INDOCO REMEDIES	100MG	A204467	001	Jul 28, 2016	Jul NEWA
AB		300MG	A204467	002	Jul 28, 2016	Jul NEWA
AB	SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar CAHN
	ZYLOPRIM					
AB	SEBELA IRELAND LTD	100MG	N016084	001		Jan CAHN
AB	+	300MG	N016084	002		Jan CAHN

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb NEWA
AB		EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

LOTIRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

@	ACTAVIS LABS FL INC	0.5MG
@		1MG
@		2MG
@		3MG
@	COREPHARMA	0.5MG
@		1MG
@		2MG
@		3MG
@	IMPAX LABS	0.5MG
@		1MG
@		2MG
@		3MG

A077198	001	May 13, 2010	Jan DISC
A077198	002	May 13, 2010	Jan DISC
A077198	003	May 13, 2010	Jan DISC
A077198	004	May 13, 2010	Jan DISC
A077996	001	Jan 31, 2007	Mar DISC
A077996	002	Jan 31, 2007	Mar DISC
A077996	003	Jan 31, 2007	Mar DISC
A077996	004	Jan 31, 2007	Mar DISC
A077968	004	May 24, 2007	Jan DISC
A077968	003	May 24, 2007	Jan DISC
A077968	002	May 24, 2007	Jan DISC
A077968	001	May 24, 2007	Jan DISC

ALPROSTADIL

INJECTABLE;INJECTION

EDEX

	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN

INJECTABLE; INJECTION
EDEX

+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN
	SUPPOSITORY; URETHRAL					
	MUSE					
+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
+		0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
+		0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
AP		EUROHLTH INTL SARL	EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
		CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1
		CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1
		CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1
		CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	011	Mar 26, 1997	Mar CMS1
		CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	012	Mar 26, 1997	Mar CMS1
		CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	008	Mar 26, 1997	Mar CMS1
		CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	016	Mar 26, 1997	Mar CMS1
		CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	017	Mar 26, 1997	Mar CMS1
		CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	018	Mar 26, 1997	Mar CMS1
		CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	019	Mar 26, 1997	Mar CMS1
		CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	021	Mar 26, 1997	Mar CMS1

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%	N208081	001	May 10, 2016	May NEWA
---	-------------	-----	---------	-----	--------------	----------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@	IDT AUSTRALIA LTD	100MG	A085261	003		May CAHN
@		100MG	A085262	002		May CAHN
@		200MG	A085261	002		May CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	May NEWA
----	----------------------	-------	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar DISC
	@		10MG	A089399	002	Jul 14, 1987	Mar DISC
AB			10MG	A089399	002	Jul 14, 1987	Mar CAHN
	@		25MG	A040816	001	Jun 27, 2008	Mar DISC
	@		25MG	A089399	001	Jul 14, 1987	Mar DISC
AB			25MG	A089399	001	Jul 14, 1987	Mar CAHN
	@		50MG	A040816	003	Jun 27, 2008	Mar DISC
	@		50MG	A089399	003	Jul 14, 1987	Mar DISC
AB			50MG	A089399	003	Jul 14, 1987	Mar CAHN
	@		75MG	A040816	004	Jun 27, 2008	Mar DISC
	@		75MG	A089399	004	Jul 14, 1987	Mar DISC
AB			75MG	A089399	004	Jul 14, 1987	Mar CAHN
	@		100MG	A040816	005	Jun 27, 2008	Mar DISC
	@		100MG	A089399	005	Jul 14, 1987	Mar DISC
AB			100MG	A089399	005	Jul 14, 1987	Mar CAHN
	@		150MG	A040816	006	Jun 27, 2008	Mar DISC
	@		150MG	A089399	006	Jul 14, 1987	Mar DISC
AB			150MG	A089399	006	Jul 14, 1987	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	FRONTIDA BIOPHARM	EQ 12.5MG BASE; 5MG	A070765	001	Dec 10, 1986	Jul CAHN
@		EQ 25MG BASE; 10MG	A070766	001	Dec 10, 1986	Jul CAHN
@	SUN PHARM INDS	EQ 12.5MG BASE; 5MG	A070765	001	Dec 10, 1986	Mar CAHN
@		EQ 25MG BASE; 10MG	A070766	001	Dec 10, 1986	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	10MG; 2MG	A071077	001	Nov 12, 1986	Mar CAHN
@		10MG; 4MG	A071078	001	Nov 12, 1986	Mar CAHN
@		25MG; 2MG	A070297	001	Nov 12, 1986	Mar CAHN
@		25MG; 4MG	A071079	001	Nov 12, 1986	Mar CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016	May NEWA	
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb CAHN	
AB		EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb CAHN	
AB		EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb CAHN	
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016	Jun NEWA	
AB		EQ 5MG BASE	A207821	002	Jul 11, 2016	Jun NEWA	
AB		EQ 10MG BASE	A207821	003	Jul 11, 2016	Jun NEWA	
	@	SUN PHARM INDS	EQ 2.5MG BASE	A078081	001	Jan 31, 2008	Mar CAHN
	@		EQ 5MG BASE	A078081	002	Jan 31, 2008	Mar CAHN
	@		EQ 10MG BASE	A078081	003	Jan 31, 2008	Mar CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A206512	001	Apr 22, 2016	Apr NEWA
AB		EQ 5MG BASE;320MG	A206512	002	Apr 22, 2016	Apr NEWA
AB		EQ 10MG BASE;160MG	A206512	003	Apr 22, 2016	Apr NEWA
AB		EQ 10MG BASE;320MG	A206512	004	Apr 22, 2016	Apr NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr CRLD
	LAC-HYDRIN					
	@ RANBAXY	EQ 12% BASE	N020508	001	Aug 29, 1996	Apr DISC

LOTION; TOPICAL

AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr CRLD
	LAC-HYDRIN					
	@ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Apr DISC

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 250MG
@ 500MG

A065016 001 Apr 08, 1999 Feb DISC
A065016 002 Apr 08, 1999 Feb DISC

TABLET; ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 500MG
@ 875MG

A065059 001 Nov 24, 2000 Feb DISC
A065059 002 Nov 24, 2000 Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 125MG
@ 250MG

A065021 001 Dec 23, 1999 Feb DISC
A065021 002 Dec 23, 1999 Feb DISC

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+ VERNALIS R AND D LTD 775MG

N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb DISC

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A> AB	HIKMA PHARMS	875MG;EQ 125MG BASE	A203824	001	Aug 23, 2016	Aug NEWA
	@ SUN PHARM INDS LTD	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SANDOZ 200MG;EQ 28.5MG BASE
@ 400MG;EQ 57MG BASE
@ SUN PHARM INDS LTD 200MG;EQ 28.5MG BASE
@ 400MG;EQ 57MG BASE

A065065 001 Apr 18, 2002 Jul DISC
A065065 002 Apr 18, 2002 Jul DISC
A065161 001 Dec 03, 2003 Feb DISC
A065161 002 Dec 03, 2003 Feb DISC

AUGMENTIN '125'

@ DR REDDYS LABS INC 125MG;EQ 31.25MG BASE
125MG;EQ 31.25MG BASE

N050597 001 Jul 22, 1985 Jul DISC
N050597 001 Jul 22, 1985 Mar CTEC

AUGMENTIN '250'

@ DR REDDYS LABS INC 250MG;EQ 62.5MG BASE
250MG;EQ 62.5MG BASE

N050597 002 Jul 22, 1985 Jul DISC
N050597 002 Jul 22, 1985 Mar CRLD

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
ADZENYS XR-ODT

NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan NEWA
	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan NEWA
	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan NEWA
	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan NEWA
	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan NEWA
+	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	May CRLD
	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

@ ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
@	100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

>A>	AP	MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug CAHN
>A>	AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug CAHN
>A>	AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Aug CAHN
>A>	AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Aug CAHN
>D>	AP	STRIDES ARCOLAB LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug CAHN
>D>	AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug CAHN
>D>	AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Aug CAHN
>D>	AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Aug CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

>D>	AB	SANDOZ	1MG	A079007	001	Jun 28, 2010	Aug DISC
>A>		@	1MG	A079007	001	Jun 28, 2010	Aug DISC

ARIPIPRAZOLE

INJECTABLE;INTRAMUSCULAR

ABILIFY

@ OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun DISC
----------	-------------------------	---------	-----	--------------	----------

SOLUTION;ORAL

ARIPIPRAZOLE

AA	+	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
----	---	---------------	--------	---------	-----	--------------	----------

TABLET;ORAL

ARIPIPRAZOLE

>A>	AB	AJANTA PHARMA LTD	2MG	A206174	001	Sep 12, 2016	Aug NEWA
>A>	AB		5MG	A206174	002	Sep 12, 2016	Aug NEWA

TABLET;ORAL
ARIPIPIRAZOLE

>A>	AB	10MG	A206174	003	Sep 12, 2016	Aug NEWA
>A>	AB	15MG	A206174	004	Sep 12, 2016	Aug NEWA
>A>	AB	20MG	A206174	005	Sep 12, 2016	Aug NEWA
>A>	AB	30MG	A206174	006	Sep 12, 2016	Aug NEWA
	AB	AMNEAL PHARMS 2MG	A204838	001	Jun 17, 2016	Jun NEWA
	AB	5MG	A204838	002	Jun 17, 2016	Jun NEWA
	AB	10MG	A204838	003	Jun 17, 2016	Jun NEWA
	AB	15MG	A204838	004	Jun 17, 2016	Jun NEWA
	AB	20MG	A204838	005	Jun 17, 2016	Jun NEWA
	AB	30MG	A204838	006	Jun 17, 2016	Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

@ OTSUKA 10MG
@ 15MG

N021729 002 Jun 07, 2006 May DISC
N021729 003 Jun 07, 2006 May DISC

ARIPIPIRAZOLE

+ ALEMBIC PHARMS LTD 10MG
15MG

A202102 001 Apr 28, 2015 May CRLD
A202102 002 Apr 28, 2015 May CTEC

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB MYLAN PHARMS INC 50MG
AB 150MG
AB 250MG

A200043 001 Jun 01, 2012 Apr CMFD
A200043 002 Jun 01, 2012 Apr CMFD
A200043 003 Jun 01, 2012 Apr CMFD

NUVIGIL

AB CEPHALON 50MG
AB 150MG
AB + 250MG

N021875 001 Jun 15, 2007 Apr CTEC
N021875 003 Jun 15, 2007 Apr CTEC
N021875 004 Jun 15, 2007 Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL

N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

FOREST LABS LLC EQ 2.5 BASE

N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC 325MG;50MG;40MG
FIORINAL

A078149 001 Jun 13, 2007 Jan CAHN

AA + ALLERGAN SALES LLC 325MG;50MG;40MG

N017534 005 Apr 16, 1986 Apr CAHN

TABLET;ORAL

FIORINAL

@ ALLERGAN SALES LLC 325MG;50MG;40MG

N017534 003 Apr 16, 1986 Apr CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE

>D> AB COASTAL PHARMS 325MG;50MG;40MG;30MG
>A> AB MAYNE PHARMA INC 325MG;50MG;40MG;30MG
FIORINAL W/CODEINE
AB + ALLERGAN SALES LLC 325MG;50MG;40MG;30MG

A203335 001 Oct 30, 2015 Aug CAHN
A203335 001 Oct 30, 2015 Aug CAHN
N019429 003 Oct 26, 1990 Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

AB + HERITAGE PHARMS INC 325MG;200MG
AB INGENUS PHARMS NJ 325MG;200MG
SOMA COMPOUND
@ MEDA PHARMS 325MG;200MG

A089594 001 Mar 31, 1989 Jun CRLD
A040832 001 Jan 07, 2010 Jan CAHN
N012365 005 Jul 11, 1983 Jun DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar CMFD
	@		325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan CAHN
AB	+	SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Mar CTEC
	+		325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan CRLD
		SOMA COMPOUND W/ CODEINE					
	@	MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

	@	AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	Apr DISC
AB			25MG;200MG	A206392	001	Mar 08, 2016	Feb NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

>D>	AA	COASTAL PHARMS	325MG;4.8355MG	A091670	001	Mar 16, 2011	Aug CAHN
>A>	AA	MAYNE PHARMA INC	325MG;4.8355MG	A091670	001	Mar 16, 2011	Aug CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

	@	SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998	Mar CAHN
	@		325MG;4.5MG;0.38MG	A087794	001	May 26, 1982	Mar CAHN

ATENOLOL

TABLET;ORAL

ATENOLOL

AB		ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan CAHN
AB			50MG	A072303	001	Jul 15, 1988	Jan CAHN
AB			100MG	A072304	001	Jul 15, 1988	Jan CAHN
>D>	AB	NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009	Aug DISC
>A>	@		25MG	A078254	001	Sep 25, 2009	Aug DISC
>D>	AB		50MG	A078254	002	Sep 25, 2009	Aug DISC
>A>	@		50MG	A078254	002	Sep 25, 2009	Aug DISC
>D>	AB		100MG	A078254	003	Sep 25, 2009	Aug DISC
>A>	@		100MG	A078254	003	Sep 25, 2009	Aug DISC
		TENORMIN					
AB		ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan CAHN
AB			50MG	N018240	001		Jan CAHN
AB	+		100MG	N018240	002		Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan CAHN
AB			100MG;25MG	A072302	001	May 31, 1990	Jan CAHN
AB		SUN PHARM INDS	100MG;25MG	A073582	001	Apr 29, 1993	Mar CAHN
		TENORETIC 100					
AB	+	ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan CAHN
		TENORETIC 50					
AB		ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May NEWA
AB			EQ 20MG BASE	A205519	002	May 19, 2016	May NEWA
AB			EQ 40MG BASE	A205519	003	May 19, 2016	May NEWA
AB			EQ 80MG BASE	A205519	004	May 19, 2016	May NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@	SUN PHARM INDS	0.025MG;2.5MG	A085506	001		Mar CAHN
>D>		LONOX					
>D>	AA	SANDOZ	0.025MG;2.5MG	A085311	002		Aug DISC
>A>	@		0.025MG;2.5MG	A085311	002		Aug DISC

AURANOFINCAPSULE;ORAL
RIDAURA

+	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Jan CAHN
---	--------------------	-----	---------	-----	--------------	----------

AXITINIBTABLET;ORAL
INLYTA

	PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr CAHN
+		5MG	N202324	002	Jan 27, 2012	Apr CAHN

AZACITIDINEINJECTABLE;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Apr NEWA
----	---------------------	------------	---------	-----	--------------	----------

POWDER;IV (INFUSION), SUBCUTANEOUS
AZACITIDINE

	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Apr NEWA
--	-------------	------------	---------	-----	--------------	----------

AZATHIOPRINETABLET;ORAL
IMURAN

	@ SEBELA IRELAND LTD	25MG	N016324	002		Jan CAHN
AB	+	50MG	N016324	001		Jan CAHN

AZATHIOPRINE SODIUMINJECTABLE;INJECTION
IMURAN

	@ SEBELA IRELAND LTD	EQ 100MG BASE/VIAL	N017391	001		Jan CAHN
--	----------------------	--------------------	---------	-----	--	----------

AZILSARTAN KAMEDOXOMILTABLET;ORAL
EDARBI

	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jan CAHN
+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jan CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONETABLET;ORAL
EDARBYCLOR

	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan CAHN
+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan CAHN

AZITHROMYCINFOR SUSPENSION;ORAL
AZITHROMYCIN

BX	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Apr CTEC
BX		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Apr CTEC

AZTREONAMINJECTABLE;INJECTION
AZTREONAM

	@ EUROHLTH INTL SARL	1GM/VIAL	A065286	001	Mar 23, 2011	Mar DISC
	@	2GM/VIAL	A065286	002	Mar 23, 2011	Mar DISC

BACLOFENINJECTABLE;INTRATHECAL
BACLOFEN

AP	SINTETICA SA	0.05MG/ML	A091193	001	May 03, 2016	Apr NEWA
AP		0.5MG/ML	A091193	002	May 03, 2016	Apr NEWA
AP		2MG/ML	A091193	003	May 03, 2016	Apr NEWA

LIORESAL

AP	+ SAOL THERAPS RES LTD	0.05MG/ML	N020075	003	Nov 07, 1996	May CAHN
AP	+	0.5MG/ML	N020075	001	Jun 17, 1992	May CAHN
AP	+	2MG/ML	N020075	002	Jun 17, 1992	May CAHN

TABLET;ORAL
BACLOFEN

AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009	Jan NEWA
----	--------------------	------	---------	-----	--------------	----------

BARIUM SULFATEFOR SUSPENSION; ORAL
E-Z-HD

+ BRACCO 334GM/BOTTLE

N208036 001 Jan 11, 2016 Jan NEWA

SUSPENSION; ORAL

READI-CAT 2

+ BRACCO 2% (9GM/450ML)

N208143 001 Jan 15, 2016 Jan NEWA

READI-CAT 2 SMOOTHIES

BRACCO 2% (9GM/450ML)

N208143 002 Jan 15, 2016 Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@ ACTAVIS LABS FL INC 5MG

A076267 001 Feb 11, 2004 Jan DISC

@ 10MG

A076267 002 Feb 11, 2004 Jan DISC

@ 20MG

A076267 003 Feb 11, 2004 Jan DISC

@ 40MG

A076267 004 Feb 11, 2004 Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ACTAVIS LABS FL INC 5MG; 6.25MG

A076342 001 Feb 11, 2004 Jan DISC

@ 10MG; 12.5MG

A076342 002 Feb 11, 2004 Jan DISC

@ 20MG; 12.5MG

A076342 003 Feb 11, 2004 Jan DISC

@ 20MG; 25MG

A076342 004 Feb 11, 2004 Jan DISC

@ IVAX SUB TEVA PHARMS 5MG; 6.25MG

A076348 001 Feb 11, 2004 Mar DISC

@ 10MG; 12.5MG

A076348 002 Feb 11, 2004 Mar DISC

@ 20MG; 12.5MG

A076348 003 Feb 11, 2004 Mar DISC

@ 20MG; 25MG

A076348 004 Feb 11, 2004 Mar DISC

@ SUN PHARM INDS LTD 5MG; 6.25MG

A077483 001 Sep 08, 2005 Mar DISC

@ 10MG; 12.5MG

A077483 002 Sep 08, 2005 Mar DISC

@ 20MG; 12.5MG

A077483 003 Sep 08, 2005 Mar DISC

@ 20MG; 25MG

A077483 004 Sep 08, 2005 Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP ACCORD HLTHCARE 25MG/VIAL

A205574 001 May 19, 2016 May NEWA

AP 100MG/VIAL

A205574 002 May 19, 2016 May NEWA

AP GLENMARK PHARMS LTD 25MG/VIAL

A204771 001 Mar 24, 2016 Mar NEWA

AP 100MG/VIAL

A204771 002 Mar 24, 2016 Mar NEWA

AP HOSPIRA INC 25MG/VIAL

A204086 001 May 20, 2016 May NEWA

AP 100MG/VIAL

A204086 002 May 20, 2016 May NEWA

AP INNOPHARMA LICENSING 25MG/VIAL

A205476 001 Mar 24, 2016 Mar NEWA

AP 100MG/VIAL

A205476 002 Mar 24, 2016 Mar NEWA

TREANDA

AP + CEPHALON 25MG/VIAL

N022249 002 May 01, 2009 Mar CFTG

AP + 100MG/VIAL

N022249 001 Mar 20, 2008 Mar CFTG

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA BIONPHARMA INC 100MG

A081297 001 Jan 29, 1993 Jan CAHN

AA 200MG

A081297 002 Oct 30, 2007 Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A> AB TOLMAR 5%; 1.2%

A203688 001 Aug 25, 2016 Aug NEWA

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

+ CUTANEA 5%; 3%

N050769 001 Nov 27, 2000 Feb CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@ IMPAX LABS 50MG

A040845 001 Nov 18, 2008 Mar DISC

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Jul	CAHN
AA		1MG	A204713	002	Apr 14, 2015	Jul	CAHN
AA		2MG	A204713	003	Apr 14, 2015	Jul	CAHN
	@ FRONTIDA BIOPHARM	2MG	A081265	001	Jan 23, 1992	Jul	CAHN

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb	NEWA
---	--------------------	---------------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS	EQ 0.05% BASE; 1%	A202894	001	Oct 30, 2015	Mar	CAHN
----	-----------------	-------------------	---------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan	CAHN
----	---------------------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ IMPAX LABS

5MG

A040739 001 Nov 01, 2006 Mar DISC

@

10MG

A040741 001 Nov 01, 2006 Mar DISC

@

25MG

A040740 001 Nov 01, 2006 Mar DISC

@

50MG

A040721 004 Nov 01, 2006 Mar DISC

DUVOID

AA	BI-COASTAL PHARMA	10MG	A086262	001		Jul	CAHN
----	-------------------	------	---------	-----	--	-----	------

AA		25MG	A086263	001		Jul	CAHN
----	--	------	---------	-----	--	-----	------

AA		50MG	A085882	003		Jul	CAHN
----	--	------	---------	-----	--	-----	------

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016	Apr	NEWA
----	------------	-------	---------	-----	--------------	-----	------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

@ SEBELA IRELAND LTD

262.4MG, N/A, N/A, N/A, 250MG, N/A, N/A, N/A, 500MG

N050719 001 Aug 15, 1996 Jan CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

@ FRONTIDA BIOPHARM

5MG

A075474 001 Oct 25, 2002 Jul CAHN

@

10MG

A075474 002 Oct 25, 2002 Jul CAHN

>D>	AB	MYLAN	10MG	A075831	002	Dec 14, 2005	Aug	CRLD
-----	----	-------	------	---------	-----	--------------	-----	------

>A>	AB	+	10MG	A075831	002	Dec 14, 2005	Aug	CRLD
-----	----	---	------	---------	-----	--------------	-----	------

@ SUN PHARM INDS

5MG

A075474 001 Oct 25, 2002 Mar CAHN

@

10MG

A075474 002 Oct 25, 2002 Mar CAHN

>D> ZEBETA

>D>	AB	TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Aug	DISC
-----	----	-------------	-----	---------	-----	--------------	-----	------

>A>		@	5MG	N019982	002	Jul 31, 1992	Aug	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

>D>	AB	+	10MG	N019982	001	Jul 31, 1992	Aug	DISC
-----	----	---	------	---------	-----	--------------	-----	------

>A>		@	10MG	N019982	001	Jul 31, 1992	Aug	DISC
-----	--	---	------	---------	-----	--------------	-----	------

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

@ MERCK SHARP DOHME

200MG

N202258 001 May 13, 2011 Jun DISC

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVIACT

+	UBC INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb NEWA
+	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	May CMS1

SOLUTION;ORAL

BRIVIACT

+	UCB INC	10MG/ML	N205838	001	May 12, 2016	May CMS1
+		10MG/ML	N205838	001	Feb 18, 2016	Feb NEWA

TABLET;ORAL

BRIVIACT

	UCB INC	10MG	N205836	001	May 12, 2016	May CMS1
		10MG	N205836	001	Feb 18, 2016	Feb NEWA
		25MG	N205836	002	May 12, 2016	May CMS1
		25MG	N205836	002	Feb 18, 2016	Feb NEWA
		50MG	N205836	003	May 12, 2016	May CMS1
		50MG	N205836	003	Feb 18, 2016	Feb NEWA
		75MG	N205836	004	May 12, 2016	May CMS1
		75MG	N205836	004	Feb 18, 2016	Feb NEWA
+		100MG	N205836	005	May 12, 2016	May CMS1
+		100MG	N205836	005	Feb 18, 2016	Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMSITE

+	INSITE VISION INC	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Apr NEWA
+	SUN PHARMA GLOBAL	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jul CAHN

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan CRLD
----	---	-------	-------------	---------	-----	--------------	----------

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN
		PARLODEL					
AB		US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr CMFD
	@		EQ 2.5MG BASE	N017962	001		Jan DISC

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

>D>	AB	ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Aug CAHN
	AB		3MG	A206623	001	Apr 08, 2016	Mar NEWA
>A>	AB	MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Aug CAHN

ENTOCORT EC

AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan CAHN
AB	+	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May CAHN

SUSPENSION;INHALATION

BUDESONIDE

	AN	APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun CMFD
	AN		0.5MG/2ML	A078202	002	Mar 30, 2009	Jun CMFD
>A>	AN	IMPAX LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Aug CAHN
>A>	AN		0.5MG/2ML	A078404	002	Jul 31, 2012	Aug CAHN
	AN	TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb NEWA
>D>	AN	WATSON LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Aug CAHN
>D>	AN		0.5MG/2ML	A078404	002	Jul 31, 2012	Aug CAHN

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	+	AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun CAHN
AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May NEWA
AP			0.5%	A207183	002	May 13, 2016	May NEWA

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP	CLARIS	0.75%	A207266	001	Jul 25, 2016	Jul NEWA
----	--------	-------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT;IMPLANTATION

PROBUPHINE

+	BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun CAHN
+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	May NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan NEWA
AB		EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 8MG BASE;EQ 2MG BASE	A201633	002	Aug 05, 2016	Jul NEWA
----	--------------------	-------------------------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A201633	001	Aug 05, 2016	Jul NEWA
----	--------------------	---------------------------	---------	-----	--------------	----------

ZUBSOLV

	OREXO US INC	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul CAHN
		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul CAHN
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul CAHN
		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul CAHN
		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

>A> AB	HERITAGE PHARMA	75MG	A206975	001	Aug 19, 2016	Aug NEWA
>A> AB		100MG	A206975	002	Aug 19, 2016	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
>A> AB3		150MG	A206556	001	Aug 26, 2016	Aug NEWA
AB1		150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1		200MG	A206674	003	Feb 09, 2016	Jan NEWA
>A> AB3		300MG	A206556	002	Aug 26, 2016	Aug NEWA
AB1	SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1		150MG	A205794	002	Mar 01, 2016	Feb NEWA
>A> AB2		150MG	A206122	001	Aug 17, 2016	Aug NEWA
AB1		200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014	Apr CAHN
---	----------	----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
AB		10MG	A204582	002	Sep 18, 2015	Jun CAHN
AB		15MG	A204582	003	Sep 18, 2015	Jun CAHN
AB		30MG	A204582	004	Sep 18, 2015	Jun CAHN
>A> AB	IMPAX LABS INC	5MG	A074253	001	Mar 28, 2001	Aug CAHN
>A> AB		10MG	A074253	002	Mar 28, 2001	Aug CAHN
>A> AB		15MG	A074253	003	Mar 13, 2002	Aug CAHN
>D> AB	WATSON LABS	5MG	A074253	001	Mar 28, 2001	Aug CAHN
>D> AB		10MG	A074253	002	Mar 28, 2001	Aug CAHN
>D> AB		15MG	A074253	003	Mar 13, 2002	Aug CAHN

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	---------------------	--------	---------	-----	--------------	----------

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

@ PERRIGO PHARMA INTL 2%

N019881 001 Feb 07, 1997 Jun CAHN

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

AP @ CLARIS 2MG/ML A075697 001 Oct 23, 2001 Jan CAHN
 EUROHLTH INTL SARL 2MG/ML A075046 001 Aug 12, 1998 Apr CAHN
 BUTORPHANOL TARTRATE PRESERVATIVE FREE
 @ CLARIS 1MG/ML A075695 001 Oct 23, 2001 Mar CAHN
 @ 2MG/ML A075695 002 Oct 23, 2001 Mar CAHN
 AP EUROHLTH INTL SARL 1MG/ML A075045 001 Aug 12, 1998 Apr CAHN
 AP 2MG/ML A075045 002 Aug 12, 1998 Apr CAHN

CABERGOLINE

TABLET;ORAL

CABERGOLINE

@ IMPAX LABS INC 0.5MG

A077843 001 Jul 03, 2007 Mar DISC

CABOZANTINIB S-MALATE

TABLET;ORAL

CABOMETYX

EXELIXIS INC EQ 20MG BASE N208692 001 Apr 25, 2016 Apr NEWA
 EQ 40MG BASE N208692 002 Apr 25, 2016 Apr NEWA
 + EQ 60MG BASE N208692 003 Apr 25, 2016 Apr NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

+ HORIZON PHARMA 100MG;2MG

A086557 001 Oct 04, 1983 Jan CAHN

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL

RAYALDEE

+ OPKO IRELAND GLOBAL 0.03MG

N208010 001 Jun 17, 2016 Jun NEWA

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

AB GLENMARK PHARMS 0.005%

A205772 001 Jun 09, 2015 Mar CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB BIONPHARMA INC 0.25MCG A091174 001 May 24, 2013 Jan CAHN
 AB 0.5MCG A091174 002 May 24, 2013 Jan CAHN

INJECTABLE;INJECTION

CALCITRIOL

AKORN 0.001MG/ML A078066 001 Jan 29, 2008 Feb CTEC
 @ ROCKWELL MEDCL 0.001MG/ML A076206 001 Sep 17, 2003 Feb DISC

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB LOTUS PHARM CO LTD EQ 169MG CALCIUM

A203298 001 Jul 26, 2016 Jul NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML;15.2MG/10 N018379 002 Feb DISC
 0ML;567MG/100ML;392MG/100ML

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML;15.2MG/10 N018379 003 Feb DISC
 0ML;567MG/100ML;392MG/100ML

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML;15.2MG/10 N018379 007 Jun 24, 1988 Feb DISC
 0ML;567MG/100ML;392MG/100ML

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML;15.2 N018379 001 Feb DISC

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

MG/100ML;567MG/100ML;392MG/100ML

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982	Feb DISC
-------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982	Feb DISC
-------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988	Feb DISC
-------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982	Feb DISC
-------------------	--	---------	-----	--------------	----------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

>D> AP	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N016682	001	Aug CRLD
--------	-----------------	---	---------	-----	----------

>A> AP	+	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N016682	001	Aug CRLD
--------	---	---	---------	-----	----------

CANGRELOR

POWDER;IV (INFUSION)

KENGREAL

+	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015	Jul CAHN
---	----------------	-----------	---------	-----	--------------	----------

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ROXANE	150MG	A200483	001	Jul 14, 2016	Jul NEWA
AB		500MG	A200483	002	Jul 14, 2016	Jul NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@	APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar DISC
@		25MG	A074737	002	Oct 28, 1998	Mar DISC
@		50MG	A074737	003	Oct 28, 1998	Mar DISC
@		100MG	A074737	004	Oct 28, 1998	Mar DISC
AB	HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun CAHN
AB		25MG	A074505	002	Feb 13, 1996	Jun CAHN
AB		50MG	A074505	003	Feb 13, 1996	Jun CAHN
AB		100MG	A074505	004	Feb 13, 1996	Jun CAHN
AB	PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jul CMFD
AB		25MG	A074477	002	Feb 13, 1996	Jul CMFD
AB		50MG	A074477	003	Feb 13, 1996	Jul CMFD
AB		100MG	A074477	004	Feb 13, 1996	Jul CMFD
@	SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan DISC
@		25MG	A074363	002	Nov 09, 1995	Jan DISC
@		50MG	A074363	003	Nov 09, 1995	Jan DISC
@		100MG	A074363	004	Nov 09, 1995	Jan DISC
@	STASON	12.5MG	A074677	004	May 30, 1997	Mar DISC
@		25MG	A074677	002	May 30, 1997	Mar DISC
@		50MG	A074677	001	May 30, 1997	Mar DISC
@		100MG	A074677	003	May 30, 1997	Mar DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan CAHN
AB		200MG	A076697	002	May 20, 2011	Jan CAHN
AB		300MG	A076697	003	May 20, 2011	Jan CAHN

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

	@	IDT AUSTRALIA LTD	10MG;100MG	A073586	001	Jun 29, 1995	May	CAHN
	@		25MG;100MG	A073587	001	Jun 29, 1995	May	CAHN
	@		25MG;250MG	A073620	001	Jun 29, 1995	May	CAHN
>A>	AB	MAYNE PHARMA	10MG;100MG	A073618	001	Aug 28, 1992	Aug	CAHN
>A>	AB		25MG;100MG	A073589	001	Aug 28, 1992	Aug	CAHN
>A>	AB		25MG;250MG	A073607	001	Aug 28, 1992	Aug	CAHN
>D>	AB	TEVA	10MG;100MG	A073618	001	Aug 28, 1992	Aug	CAHN
>D>	AB		25MG;100MG	A073589	001	Aug 28, 1992	Aug	CAHN
>D>	AB		25MG;250MG	A073607	001	Aug 28, 1992	Aug	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

MIKART INC

6MG

A207484	001	May 31, 2016	May	NEWA
---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

	@	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr	DISC
	@		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr	DISC
	@		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr	DISC
	@		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr	DISC
AP		SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb	CAHN
AP			150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb	CAHN
AP			450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb	CAHN
AP		SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	NEWA
AP			150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	NEWA
AP			450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	NEWA

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

ONYX THERAP

30MG/VIAL

+

60MG/VIAL

N202714	002	Jun 03, 2016	Jun	NEWA
N202714	001	Jul 20, 2012	Feb	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan	CAHN
AB	STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	May	CAHN
AA		350MG	A205513	002	Nov 12, 2015	May	CAHN

CARVEDILOL

TABLET; ORAL

COREG

AB	SMITHKLINE BEECHAM	3.125MG	N020297	004	May 29, 1997	May	CAHN
AB		6.25MG	N020297	003	Sep 14, 1995	May	CAHN
AB	+	12.5MG	N020297	002	Sep 14, 1995	May	CAHN
AB		25MG	N020297	001	Sep 14, 1995	May	CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

SMITHKLINE BEECHAM

10MG

20MG

+

40MG

80MG

N022012	001	Oct 20, 2006	May	CAHN
N022012	002	Oct 20, 2006	May	CAHN
N022012	003	Oct 20, 2006	May	CAHN
N022012	004	Oct 20, 2006	May	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION; ORAL
CEFADROXIL

@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb DISC
@	EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb DISC
@	EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb DISC

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan NEWA
----	-------------	------------------	---------	-----	--------------	----------

CEFDITOREN PIVOXILTABLET; ORAL
SPECTRACEF

@ VANSSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Apr DISC
@	400MG	N021222	002	Jul 21, 2008	Apr DISC

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan NEWA
AP		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan NEWA
AP		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan NEWA

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb NEWA
CLAFORAN						
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun DISC
	@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun DISC
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan CAHN
	@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan CAHN

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan CAHN	
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan CAHN
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER						
+	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun CMS2
+		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun CMS2

CEFOXITIN SODIUMINJECTABLE; INJECTION
CEFOXITIN

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May CAHN
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May CAHN
AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May CAHN
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER						
>D> AP	B BRAUN	EQ 1GM BASE/VIAL	N065214	001	Mar 10, 2006	Aug CRLD
>A> AP	+	EQ 1GM BASE/VIAL	N065214	001	Mar 10, 2006	Aug CRLD
>D> AP		EQ 2GM BASE/VIAL	N065214	002	Mar 10, 2006	Aug CRLD
>A> AP	+	EQ 2GM BASE/VIAL	N065214	002	Mar 10, 2006	Aug CRLD

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

@ SUN PHARM INDS LTD

EQ 50MG BASE/5ML

A065082 001 May 31, 2002 Feb DISC

@

EQ 100MG BASE/5ML

A065082 002 May 31, 2002 Feb DISC

TABLET; ORAL

CEFPODOXIME PROXETIL

@ SUN PHARM INDS LTD

EQ 100MG BASE

A065083 001 Aug 20, 2003 Feb DISC

@

EQ 200MG BASE

A065083 002 Aug 20, 2003 Feb DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

@ PERNIX THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995 Jun DISC

FOR SUSPENSION; ORAL

CEDAX

@ PERNIX THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995 Jun DISC

@

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995 Jun DISC

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

@ HOSPIRA INC

EQ 1GM BASE/VIAL

A065231 001 Aug 02, 2005 Apr DISC

@

EQ 1GM BASE/VIAL

A202563 001 Aug 20, 2012 Apr DISC

@

EQ 2GM BASE/VIAL

A065231 002 Aug 02, 2005 Apr DISC

@

EQ 2GM BASE/VIAL

A202563 002 Aug 20, 2012 Apr DISC

ROCEPHIN

@ HOFFMANN LA ROCHE

EQ 500MG BASE/VIAL

A063239 002 Aug 13, 1993 Apr DISC

@

EQ 1GM BASE/VIAL

A063239 003 Aug 13, 1993 Apr DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

@ BEDFORD

EQ 250MG BASE/VIAL

A065465 001 Aug 18, 2008 Jun DISC

@

EQ 500MG BASE/VIAL

A065465 002 Aug 18, 2008 Jun DISC

@

EQ 1GM BASE/VIAL

A065465 003 Aug 18, 2008 Jun DISC

@

EQ 2GM BASE/VIAL

A065465 004 Aug 18, 2008 Jun DISC

AP QILU PHARM CO LTD

EQ 250MG BASE/VIAL

A203702 001 Jun 29, 2016 Jun NEWA

AP

EQ 500MG BASE/VIAL

A203702 002 Jun 29, 2016 Jun NEWA

AP

EQ 1GM BASE/VIAL

A203702 003 Jun 29, 2016 Jun NEWA

AP

EQ 2GM BASE/VIAL

A203702 004 Jun 29, 2016 Jun NEWA

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

N050672 001 Jun 30, 1994 Feb CTEC

+

EQ 250MG BASE/5ML

N050672 002 Apr 29, 1997 Feb CTEC

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD

EQ 125MG BASE/5ML

A065323 001 Feb 05, 2008 Feb DISC

@

EQ 250MG BASE/5ML

A065323 002 Feb 05, 2008 Feb DISC

TABLET; ORAL

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD

EQ 125MG BASE

A065118 001 Apr 25, 2003 Feb DISC

@

EQ 250MG BASE

A065118 002 Apr 25, 2003 Feb DISC

@

EQ 500MG BASE

A065118 003 Apr 25, 2003 Feb DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

AP + IGI LABS INC

EQ 1.5GM BASE/VIAL

N050558 003 Oct 19, 1983 Jan CAHN

AP

EQ 7.5GM BASE/VIAL

N050558 004 Oct 23, 1986 Jan CAHN

ZINACEF IN PLASTIC CONTAINER

@ IGI LABS INC

EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Jan CAHN

+

EQ 30MG BASE/ML

N050643 002 Apr 28, 1989 Jan CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB + IGI LABS INC

EQ 750MG BASE/VIAL

N050558 002 Oct 19, 1983 Jan CAHN

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB	AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan NEWA
AB		100MG	A206827	002	Feb 01, 2016	Jan NEWA
AB		200MG	A206827	003	Feb 01, 2016	Jan NEWA
AB		400MG	A206827	004	Feb 01, 2016	Jan NEWA
AB	MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb NEWA
AB		100MG	A204590	002	Mar 16, 2016	Feb NEWA
AB		200MG	A204590	003	Mar 16, 2016	Feb NEWA
AB		400MG	A204590	004	Mar 16, 2016	Feb NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

	@ SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb DISC
	@	EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb DISC
	KEFLEX					
AB	PRAGMA PHARMS LLC	EQ 250MG BASE	N050405	002		Jul CAHN
	@	EQ 333MG BASE	N050405	004	May 12, 2006	Jul CAHN
AB		EQ 500MG BASE	N050405	003		Jul CAHN
AB	+	EQ 750MG BASE	N050405	005	May 12, 2006	Jul CAHN
	FOR SUSPENSION;ORAL					
	KEFLEX					
	@ PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N050406	003		Mar CAHN
	@	EQ 125MG BASE/5ML	N050406	001		Mar CAHN
	@	EQ 250MG BASE/5ML	N050406	002		Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN
>D> AA	PERRIGO R AND D	5MG/5ML	A078398	001	Jun 17, 2008	Aug CRLD
>A> AA	+	5MG/5ML	A078398	001	Jun 17, 2008	Aug CRLD
	@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Apr DISC
>D>	ZYRTEC					
>D> AA	+	J AND J CONSUMER INC 5MG/5ML	N020346	001	Sep 27, 1996	Aug DISC
>A>	@	5MG/5ML	N020346	001	Sep 27, 1996	Aug DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

LIBRAX

+	VALEANT PHARMS	5MG;2.5MG	N012750	001		Jul NEWA
---	----------------	-----------	---------	-----	--	----------

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIOGARD

AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan NEWA
----	----------------------	-------	---------	-----	--------------	----------

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

@	IMPAX LABS	EQ 150MG BASE	A080880	001		Mar DISC
@		EQ 300MG BASE	A040516	001	Aug 29, 2003	Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL

CHLORPHENIRAMINE MALEATE

@	AUROLIFE PHARMA LLC	4MG	A080961	001		Mar CAHN
@	SUN PHARM INDS	4MG	A080700	001		Jun CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

@	SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun DISC
---	-------------	------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Feb CAHN
----	------------------	----------------------------	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC

100MG

A088725 001 Aug 31, 1984 Mar CAHN

@

250MG

A088726 001 Aug 31, 1984 Mar CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB MYLAN

25MG

A086831 002

Jan CTEC

AB SUN PHARM INDS

25MG

A089286 002 Jul 21, 1986

Jan NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC

250MG

A089852 001 May 04, 1988 Feb CAHN

@

500MG

A089853 001 May 04, 1988 Feb CAHN

+ MIKART

750MG

A040861 002 Jun 01, 2010 Apr CRLD

+ MIKART INC

250MG

A207483 001 Jun 24, 2016 Jun NEWA

@ SUN PHARM INDS

500MG

A089970 001 Sep 27, 1990 Mar CAHN

AA + WATSON LABS

500MG

A089859 001 May 04, 1988 Jul CRLD

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

>A> AB IMPAX LABS INC

EQ 45MG FENOFIBRIC ACID

A200264 001 Sep 07, 2016 Aug NEWA

>A> AB

EQ 135MG FENOFIBRIC ACID

A200264 002 Sep 07, 2016 Aug NEWA

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+ TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008 Jan CRLD

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAMUSCULAR

PRIMAXIN

@ MERCK

EQ 500MG BASE/VIAL; 500MG/VIAL

N050630 001 Dec 14, 1990 May DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ FRONTIDA BIOPHARM

50MG

A077208 002 Mar 29, 2006 Jul CAHN

@

100MG

A077208 001 Mar 29, 2006 Jul CAHN

@ SUN PHARM INDS

50MG

A077208 002 Mar 29, 2006 Jun CAHN

@

100MG

A077208 001 Mar 29, 2006 Jun CAHN

AB + TEVA

50MG

A077027 001 Nov 24, 2004 Jun CRLD

AB +

100MG

A077027 002 Nov 24, 2004 Jun CRLD

PLETAL

@ OTSUKA

50MG

N020863 001 Jan 15, 1999 Jun DISC

@

100MG

N020863 002 Jan 15, 1999 Jun DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT TELIGENT PHARMA INC

EQ 0.3% BASE

A076754 001 Jun 09, 2004 Jul CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ IDT AUSTRALIA LTD

EQ 100MG BASE

A075939 001 Mar 03, 2005 May CAHN

@

EQ 250MG BASE

A075939 002 Jun 09, 2004 May CAHN

@

EQ 500MG BASE

A075939 003 Jun 09, 2004 May CAHN

@

EQ 750MG BASE

A075939 004 Jun 09, 2004 May CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDESOLUTION/DROPS;OTIC
OTOVEL

+ LABORATORIOS SALVAT EQ 0.3% BASE;0.025%

N208251 001 Apr 29, 2016 Apr NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
CIPROFLOXACIN EXTENDED RELEASE@ ACTAVIS LABS FL INC 212.6MG;EQ 287.5MG BASE
@ 425.2MG;EQ 574.9MG BASEA077417 001 Nov 30, 2010 Jan DISC
A077809 001 Nov 30, 2010 Jan DISCCITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

@ SUN PHARM INDS EQ 10MG BASE
@ EQ 20MG BASE
@ EQ 40MG BASEA077052 001 Jul 03, 2006 Mar CAHN
A077052 002 Jul 03, 2006 Mar CAHN
A077052 003 Jul 03, 2006 Mar CAHNCLARITHROMYCIN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB ALLIED PHARMA INC 500MG
@ IDT AUSTRALIA LTD 500MG
>A> AB + MAYNE PHARMA 500MG
>D> AB + TEVA 500MGA203243 001 Feb 29, 2016 Feb NEWA
A065250 001 Aug 25, 2005 May CAHN
A065154 001 May 18, 2005 Aug CAHN
A065154 001 May 18, 2005 Aug CAHNCLEVIDIPINE

EMULSION;INTRAVENOUS

CLEVIPREX

>A> + CHIESI USA INC 25MG/50ML (0.5MG/ML)
>A> + 50MG/100ML (0.5MG/ML)
>A> + 125MG/250ML (0.5MG/ML)
>D> + THE MEDICINES CO 25MG/50ML (0.5MG/ML)
>D> + 50MG/100ML (0.5MG/ML)
>D> + 125MG/250ML (0.5MG/ML)N022156 001 Aug 01, 2008 Aug CAHN
N022156 002 Aug 01, 2008 Aug CAHN
N022156 003 Nov 08, 2013 Aug CAHN
N022156 001 Aug 01, 2008 Aug CAHN
N022156 002 Aug 01, 2008 Aug CAHN
N022156 003 Nov 08, 2013 Aug CAHNCLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA MYLAN PHARMS INC EQ 75MG BASE/5ML

A203063 001 May 25, 2016 May NEWA

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL

CLINDESSE

+ PERRIGO PHARMA INTL EQ 2% BASE

N050793 001 Nov 30, 2004 Jun CAHN

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

AP EUROHLTH INTL SARL EQ 150MG BASE/ML

A065206 001 Sep 24, 2004 Apr CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

VELTIN

BX + AQUA PHARMS LLC 1.2%;0.025%

N050803 001 Jul 16, 2010 Jan CAHN

CLOBETASOL PROPIONATE

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB + FOUGERA PHARMS 0.05%

A074407 001 Feb 23, 1996 Mar CRLD

TEMOVATE

@ FOUGERA PHARMS 0.05%

N019323 001 Dec 27, 1985 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

ANAFRANIL

AB + MALLINCKRODT LLC 25MG
AB 50MGN019906 001 Dec 29, 1989 Jan CRLD
N019906 002 Dec 29, 1989 Jan CRLD

CLONIDINEFILM, EXTENDED RELEASE;TRANSDERMAL
CLONIDINE

>D>	AB	BARR	0.1MG/24HR	A079090	001	Aug 20, 2010	Aug CAHN
>D>	AB		0.2MG/24HR	A079090	002	Aug 20, 2010	Aug CAHN
>D>	AB		0.3MG/24HR	A079090	003	Aug 20, 2010	Aug CAHN
>A>	AB	MAYNE PHARMA	0.1MG/24HR	A079090	001	Aug 20, 2010	Aug CAHN
>A>	AB		0.2MG/24HR	A079090	002	Aug 20, 2010	Aug CAHN
>A>	AB		0.3MG/24HR	A079090	003	Aug 20, 2010	Aug CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb CAHN
	@		0.2MG	A070886	001	Aug 31, 1988	Feb CAHN
	@		0.3MG	A071294	001	Aug 31, 1988	Feb CAHN
AB		FRONTIDA BIOPHARM	0.1MG	A070925	001	Sep 04, 1987	Jul CAHN
AB			0.2MG	A070924	001	Sep 04, 1987	Jul CAHN
AB			0.3MG	A070923	001	Sep 04, 1987	Jul CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

	@	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Jun DISC
AB		SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@	AUROLIFE PHARMA LLC	3.75MG
@		7.5MG
@		15MG

A072219	001	Aug 26, 1988	Apr CAHN
A072220	001	Aug 26, 1988	Feb CAHN
A072112	001	Aug 26, 1988	Feb CAHN

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@	AUROLIFE PHARMA LLC	3.75MG
@		7.5MG
@		15MG
	TRANXENE	
@	RECORDATI RARE	3.75MG

A072512	001	May 11, 1990	Mar CAHN
A072513	001	May 11, 1990	Mar CAHN
A072514	001	May 11, 1990	Feb CAHN
N017105	006		Jun DISC

CLOZAPINE

TABLET;ORAL

CLOZAPINE

>D>	AB	ACTAVIS LABS FL INC	25MG	A203807	001	Sep 17, 2015	Aug CAHN
>D>	AB		100MG	A203807	002	Sep 17, 2015	Aug CAHN
>A>	AB	MAYNE PHARMA	25MG	A203807	001	Sep 17, 2015	Aug CAHN
>A>	AB		100MG	A203807	002	Sep 17, 2015	Aug CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		NOSTRUM LABS INC	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Feb CAHN
----	--	------------------	---------------------	---------	-----	--------------	----------

COLCHICINE

CAPSULE;ORAL

MITIGARE

+ HIKMA INTL PHARMS 0.6MG

N204820	001	Sep 26, 2014	Mar CRLD
---------	-----	--------------	----------

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

AB		INGENUS PHARMS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Jan CAHN
----	--	-------------------	-------------	---------	-----	--------------	----------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

+ ENDO PHARMS INC EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG
BASE/ML;0.5MG/ML

N050356	001		Feb CAHN
---------	-----	--	----------

CORTICOTROPIN

INJECTABLE;INJECTION
PURIFIED CORTROPHIN GEL

@ ANI PHARMS 40 UNITS/ML
@ 80 UNITS/ML

N008975 001
N008975 002

Feb CAHN
Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION
CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML

N009854 001

Feb CAHN

CROFELEMER

TABLET, DELAYED RELEASE;ORAL
FULYZAQ

+ NAPO PHARMS INC 125MG

N202292 001 Dec 31, 2012 Jun CAHN

CROTAMITON

LOTION;TOPICAL
CROTAN

>A> AT MARNEL PHARMS 10%
>D> AT SUMMERS 10%

A087204 001
A087204 001

Aug CAHN
Aug CAHN

CYANOCOBALAMIN

INJECTABLE;INJECTION
CYANOCOBALAMIN

AP SOMERSET THERAPS LLC 1MG/ML

A206503 001 Dec 11, 2015 Mar CAHN

SPRAY, METERED;NASAL
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY

N021642 001 Jan 31, 2005 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB FRONTIDA BIOPHARM 5MG
AB 10MG

A073541 002 Apr 06, 2006 Jul CAHN
A073541 001 May 23, 1995 Jul CAHN

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL
@ 1GM/VIAL
@ 2GM/VIAL

N012142 003 Mar DISC
N012142 004 Aug 30, 1982 Mar DISC
N012142 005 Aug 30, 1982 Mar DISC

CYCLOSPORINE

CAPSULE;ORAL
CYCLOSPORINE

>A> AB1 MAYNE PHARMA 25MG
>A> AB1 100MG
>D> AB1 WATSON LABS INC 25MG
>D> AB1 100MG

A065044 002 Dec 20, 2000 Aug CAHN
A065044 001 Dec 20, 2000 Aug CAHN
A065044 002 Dec 20, 2000 Aug CAHN
A065044 001 Dec 20, 2000 Aug CAHN

SOLUTION;ORAL
CYCLOSPORINE

>A> AB1 MAYNE PHARMA 100MG/ML
>D> AB1 WATSON LABS 100MG/ML

A065054 001 Dec 18, 2001 Aug CAHN
A065054 001 Dec 18, 2001 Aug CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA INGENUS PHARMS NJ 4MG

A205087 001 Sep 23, 2015 Jan CAHN

CYTARABINE

INJECTABLE;INJECTION
CYTARABINE

AP MYLAN PHARMS INC 20MG/ML
AP 20MG/ML

A200915 001 Dec 13, 2011 Mar CAHN
A200916 001 Dec 13, 2011 Mar CAHN

DACLATASVIR DIHYDROCHLORIDETABLET; ORAL
DAKLINZA

BRISTOL-MYERS SQUIBB EQ 90MG BASE

N206843 003 Apr 13, 2016 Apr NEWA

DACTINOMYCININJECTABLE; INJECTION
DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL

A090304 001 Mar 16, 2010 Feb DISC

DALBAVANCIN HYDROCHLORIDEPOWDER; IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL

N021883 001 May 23, 2014 Jan CDFR

DANTROLENE SODIUMFOR SUSPENSION; INTRAVENOUS
RYANODEX

+ EAGLE PHARMS 250MG/VIAL

N205579 001 Jul 22, 2014 Jun CRLD

INJECTABLE; INJECTION
DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL

A205239 001 Feb 18, 2016 Feb NEWA

DAPSONEGEL; TOPICAL
ACZONE

+ ALLERGAN INC 7.5%

N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL
DAPSONE

AB ALVOGEN 25MG

A205429 001 Jan 07, 2016 Mar CAHN

AB 100MG

A205429 002 Jan 07, 2016 Mar CAHN

AB NORTH CREEK PHARMS 25MG

A204074 001 May 10, 2016 Apr NEWA

AB 100MG

A204074 002 May 10, 2016 Apr NEWA

AB NOSTRUM LABS INC 25MG

A203887 001 May 06, 2016 Apr NEWA

AB 100MG

A203887 002 May 06, 2016 Apr NEWA

DAPTOMYCINPOWDER; INTRAVENOUS
CUBICIN

>D> AP + CUBIST 500MG/VIAL

N021572 002 Sep 12, 2003 Aug CAHN

AP + 500MG/VIAL

N021572 002 Sep 12, 2003 Jan CDFR

>A> AP + CUBIST PHARMS LLC 500MG/VIAL

N021572 002 Sep 12, 2003 Aug CAHN

>A> CUBICIN RF

>A> + CUBIST PHARMS LLC 500MG/VIAL

N021572 003 Jul 06, 2016 Aug NEWA

DAPTOMYCIN

AP CRANE PHARMS LLC 500MG/VIAL

A206005 001 Jun 15, 2016 Jun NEWA

AP HOSPIRA INC 500MG/VIAL

A202857 001 Sep 12, 2014 Jan CDFR

AP TEVA PARENTERAL 500MG/VIAL

A091039 001 Mar 25, 2016 Mar NEWA

POWDER; IV (INFUSION)
CUBICIN

>D> @ CUBIST 250MG/VIAL

N021572 001 Sep 12, 2003 Aug CAHN

@ 250MG/VIAL

N021572 001 Sep 12, 2003 Jan CDFR

>A> @ CUBIST PHARMS LLC 250MG/VIAL

N021572 001 Sep 12, 2003 Aug CAHN

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE

>A> AB CIPLA LTD EQ 7.5MG BASE

A207664 001 Sep 01, 2016 Aug NEWA

>A> AB EQ 15MG BASE

A207664 002 Sep 01, 2016 Aug NEWA

ENABLEX

AB APIL EQ 7.5MG BASE

N021513 001 Dec 22, 2004 Jan CAHN

AB + EQ 15MG BASE

N021513 002 Dec 22, 2004 Jan CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET, EXTENDED RELEASE; ORAL
VIEKIRA XR

+ ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG

N208624 001 Jul 22, 2016 Jul NEWA

DASATINIBTABLET; ORAL
DASATINIB

AB	APOTEX INC	20MG	A202103	001	Jun 10, 2016	May NEWA
AB		50MG	A202103	002	Jun 10, 2016	May NEWA
AB		70MG	A202103	003	Jun 10, 2016	May NEWA
AB		100MG	A202103	004	Jun 10, 2016	May NEWA
	SPRYCEL					
AB	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May CFTG
AB		50MG	N021986	002	Jun 28, 2006	May CFTG
AB		70MG	N021986	003	Jun 28, 2006	May CFTG
AB	+	100MG	N021986	004	May 30, 2008	May CFTG

DAUNORUBICIN CITRATEINJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

@	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	May DISC
---	------------	----------------	---------	-----	--------------	----------

DEFERASIROXTABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB	ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB		250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB		500MG	A203560	003	Jan 26, 2016	Jan NEWA
	EXJADE					
AB	NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB		250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+	500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFIBROTIDE SODIUMSOLUTION; IV (INFUSION)
DEFITELIO

>D>	+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Aug CAHN
	+		200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
>A>	+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Aug CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar DISC
@		300MG	A065094	002	Mar 22, 2004	Mar DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
AB	HERITAGE PHARMS INC	10MG	A207433	001	May 05, 2016	Jun CAHN
AB		25MG	A207433	002	May 05, 2016	Jun CAHN
AB		50MG	A207433	003	May 05, 2016	Jun CAHN
AB		75MG	A207433	004	May 05, 2016	Jun CAHN
AB		100MG	A207433	005	May 05, 2016	Jun CAHN
AB		150MG	A207433	006	May 05, 2016	Jun CAHN
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr NEWA
AB		25MG	A207433	002	May 05, 2016	Apr NEWA
AB		50MG	A207433	003	May 05, 2016	Apr NEWA
AB		75MG	A207433	004	May 05, 2016	Apr NEWA
AB		100MG	A207433	005	May 05, 2016	Apr NEWA
AB		150MG	A207433	006	May 05, 2016	Apr NEWA
	NORPRAMIN					
AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
AB		25MG	N014399	001		Jan CAHN
AB		50MG	N014399	003		Jan CAHN
AB		75MG	N014399	004		Jan CAHN
AB	+	100MG	N014399	005		Jan CAHN
AB		150MG	N014399	006		Jan CAHN

DESLORATADINESOLUTION;ORAL
DESLORATADINE

AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May NEWA
----	------	----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATESPRAY, METERED;NASAL
STIMATE (NEEDS NO REFRIGERATION)

>D>	+	CSL BEHRING	1.5MG/SPRAY	N020355	002	Oct 24, 2007	Aug CPOT
>A>	+		0.15MG/SPRAY	N020355	002	Oct 24, 2007	Aug CPOT

TABLET;ORAL
DESMOPRESSIN ACETATE

	@	FERRING	0.1MG	N021795	001	May 08, 2008	Jun DISC
	@		0.2MG	N021795	002	May 08, 2008	Jun DISC
>A>	AB	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006	Aug CAHN
>A>	AB		0.2MG	A077122	002	Jan 25, 2006	Aug CAHN
>D>	AB	TEVA PHARMS	0.1MG	A077122	001	Jan 25, 2006	Aug CAHN
>D>	AB		0.2MG	A077122	002	Jan 25, 2006	Aug CAHN

DESOGESTREL; ETHINYL ESTRADIOLTABLET;ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

>A>	AB	MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Aug CAHN
>A>	AB		0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Aug CAHN
>D>	AB	WATSON LABS	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Aug CAHN
>D>	AB		0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Aug CAHN

VOLNEA

>A>	AB	SANDOZ INC	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug NEWA
-----	----	------------	--------------------------	---------	-----	--------------	----------

DESONIDECREAM;TOPICAL
DESONIDE

AB	G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan CAHN
----	------------------	-------	---------	-----	--------------	----------

DESOXIMETASONEGEL;TOPICAL
DESOXIMETASONE

>A>	AB	GROUPE PARIMA INC	0.05%	A204675	001	Aug 12, 2016	Aug NEWA
-----	----	-------------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL
DESOXIMETASONE

AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr NEWA
AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May CAHN
AB	TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb NEWA

DESVENLAFAXINE SUCCINATETABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	Jul NEWA
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	Jul NEWA
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	Jul NEWA
AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb NEWA
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb NEWA
	PRISTIQ					
AB	WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul CFTG

DEXAMETHASONETABLET;ORAL
DEXAMETHASONE

@	IDT AUSTRALIA LTD	0.75MG
@	SUN PHARM INDS	0.25MG
@		0.25MG
@		0.5MG
@		0.5MG
@		0.75MG
@		0.75MG
@		1.5MG
@		1.5MG

A080399	001		May CAHN
A084013	001		Mar CAHN
A084764	001		Mar CAHN
A084084	001		Mar CAHN
A084766	001		Mar CAHN
A084081	001		Mar CAHN
A084765	001		Mar CAHN
A084086	001		Mar CAHN
A084763	001		Mar CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP + FRESenius KABI USA EQ 10MG PHOSPHATE/ML A040491 001 Apr 11, 2003 Mar CTNA

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB

+ TAKEDA PHARMS USA 30MG N208056 001 Jan 26, 2016 Jan NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP ACCORD HLTHCARE INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204023 001 Feb 09, 2016 Jan NEWA

AP AUROBINDO PHARMA LTD EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A205867 001 Mar 17, 2016 Mar NEWA

AP SANDOZ INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A091465 001 Jun 14, 2016 May NEWA

PRECEDEX

+ HOSPIRA EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) N021038 004 Nov 14, 2014 Feb CRLD

DESMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DESMETHYLPHENIDATE HYDROCHLORIDE

>A> AB IMPAX LABS INC 5MG A079108 001 Aug 05, 2015 Aug CAHN

>A> AB 10MG A079108 002 Aug 05, 2015 Aug CAHN

>A> AB 15MG A079108 003 May 19, 2014 Aug CAHN

>A> AB 20MG A079108 004 Dec 21, 2015 Aug CAHN

>A> AB 30MG A079108 005 Nov 21, 2013 Aug CAHN

>D> AB WATSON LABS INC 5MG A079108 001 Aug 05, 2015 Aug CAHN

>D> AB 10MG A079108 002 Aug 05, 2015 Aug CAHN

>D> AB 15MG A079108 003 May 19, 2014 Aug CAHN

>D> AB 20MG A079108 004 Dec 21, 2015 Aug CAHN

>D> AB 30MG A079108 005 Nov 21, 2013 Aug CAHN

TABLET;ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

AB SUN PHARM INDS 2.5MG A201231 001 Sep 24, 2015 Feb CAHN

AB 5MG A201231 002 Sep 24, 2015 Feb CAHN

AB 10MG A201231 003 Sep 24, 2015 Feb CAHN

>A> AB TRIS PHARMA INC 2.5MG A207901 001 Aug 26, 2016 Aug NEWA

>A> AB 5MG A207901 002 Aug 26, 2016 Aug NEWA

>A> AB 10MG A207901 003 Aug 26, 2016 Aug NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION
TOTECT

+ CLINIGEN HLTHCARE EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 Mar CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

>D> AB BARR 5MG A076137 001 Jan 18, 2002 Aug CAHN

>D> AB 10MG A076137 002 Jan 18, 2002 Aug CAHN

>D> AB 15MG A076137 003 Jan 18, 2002 Aug CAHN

>A> AB MAYNE PHARMA 5MG A076137 001 Jan 18, 2002 Aug CAHN

>A> AB 10MG A076137 002 Jan 18, 2002 Aug CAHN

>A> AB 15MG A076137 003 Jan 18, 2002 Aug CAHN

AB MYLAN PHARMS INC 5MG A206735 001 Jan 27, 2016 Jan NEWA

AB 10MG A206735 002 Jan 27, 2016 Jan NEWA

AB 15MG A206735 003 Jan 27, 2016 Jan NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

>A> @ IDT AUSTRALIA LTD 5MG A085370 001 Aug CAHN

AA NESHER PHARMS 5MG A206588 001 Mar 28, 2016 Mar NEWA

AA 10MG A206588 002 Mar 28, 2016 Mar NEWA

AA NOVEL LABS INC 5MG A204330 001 Mar 16, 2016 Feb NEWA

AA 10MG A204330 002 Mar 16, 2016 Feb NEWA

>D> @ SANDOZ 5MG A085370 001 Aug CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS 15MG/5ML;6.25MG/5ML N011265 002 Apr 02, 1984 Feb CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML;2 N017484 001 Feb CMS1
0MG/100ML;12MG/100ML;260MG/100MLDEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML; N018840 001 Jun 29, 1983 Feb CMS1
120MG/100ML;220MG/100MLDIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL 5MG/ML A070313 001 Dec 16, 1985 Jan CAHN

SOLUTION;ORAL

DIAZEPAM

AA LANNETT HOLDINGS INC 5MG/5ML A206477 001 Jun 24, 2016 Jun NEWA

AA + ROXANE 5MG/5ML A070928 001 Apr 03, 1987 Jun CFTG

TABLET;ORAL

DIAZEPAM

DAVA PHARMS INC 2MG A070228 002 Sep 26, 1985 Jan NEWA

5MG A070228 003 Sep 26, 1985 Jan NEWA

>A> AB MAYNE PHARMA 2MG A071134 001 Feb 03, 1987 Aug CAHN

>A> AB 5MG A071135 001 Feb 03, 1987 Aug CAHN

>A> AB 10MG A071136 001 Feb 03, 1987 Aug CAHN

>D> AB WATSON LABS 2MG A071134 001 Feb 03, 1987 Aug CAHN

>D> AB 5MG A071135 001 Feb 03, 1987 Aug CAHN

>D> AB 10MG A071136 001 Feb 03, 1987 Aug CAHN

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB BIONPHARMA INC 25MG A204648 001 Feb 23, 2016 Feb NEWA

ZIPSOR

AB + DEPOMED INC 25MG N022202 001 Jun 16, 2009 Feb CFTG

FOR SOLUTION;ORAL

CAMBIA

AB + DEPOMED INC 50MG N022165 001 Jun 17, 2009 Apr CFTG

DICLOFENAC POTASSIUM

AB PAR FORM 50MG A202964 001 May 02, 2016 Apr NEWA

TABLET;ORAL

CATAFLAM

@ NOVARTIS 50MG N020142 002 Nov 24, 1993 Mar DISC

DICLOFENAC POTASSIUM

AB + MYLAN 50MG A075463 001 Jul 26, 1999 Mar CRLD

@ SUN PHARM INDS 50MG A075470 001 Feb 21, 2002 Jun CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB AMNEAL PHARMS 1% A208077 001 Mar 18, 2016 Mar NEWA

>A> AB GLENMARK PHARMS LTD 3% A208301 001 Sep 13, 2016 Aug NEWA

AB TARO 3% A206298 001 Apr 28, 2016 Apr NEWA

VOLTAREN

AB + GLAXOSMITHKLINE CONS 1% N022122 001 Oct 17, 2007 Mar CFTG

SOLUTION;TOPICAL

DICLOFENAC SODIUM

>A> AT AMNEAL PHARMS 1.5% A206116 001 Sep 02, 2016 Aug NEWA

AT TELIGENT PHARMA INC 1.5% A202769 001 Jul 08, 2015 May CAHN

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT RISING PHARMS INC 0.1% A078553 001 Dec 28, 2007 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL					
DICLOFENAC SODIUM					
AB	+ ACTAVIS ELIZABETH 100MG	A075910	001	Jan 07, 2002	Feb CRLD
	VOLTAREN-XR				
	@ NOVARTIS 100MG	N020254	001	Mar 08, 1996	Feb DISC
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>					
TABLET, DELAYED RELEASE;ORAL					
DICLOFENAC SODIUM AND MISOPROSTOL					
AB	EXELA PHARMA SCS LLC 50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB	75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN
<u>DICYCLOMINE HYDROCHLORIDE</u>					
CAPSULE;ORAL					
DICYCLOMINE HYDROCHLORIDE					
	@ SUN PHARM INDS 10MG	A084505	001	Oct 21, 1986	Mar CAHN
INJECTABLE;INJECTION					
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)					
AP	EUROHLTH INTL SARL 10MG/ML	A040465	001	Jun 30, 2003	Mar CMS1
SYRUP;ORAL					
DICYCLOMINE HYDROCHLORIDE					
	+ MIKART 10MG/5ML	A040169	001	Mar 24, 2005	Jan CRLD
TABLET;ORAL					
DICYCLOMINE HYDROCHLORIDE					
	@ SUN PHARM INDS 20MG	A084600	001	Jul 29, 1985	Mar CAHN
<u>DIENOEST; ESTRADIOL VALERATE</u>					
TABLET;ORAL					
ESTRADIOL VALERATE AND DIENOEST					
AB	WATSON LABS INC N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	A202349	001	May 06, 2016	Apr NEWA
NATAZIA					
AB	+ BAYER HLTHCARE N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	N022252	001	May 06, 2010	Apr CFTG
<u>DIETHYLPROPION HYDROCHLORIDE</u>					
TABLET;ORAL					
DIETHYLPROPION HYDROCHLORIDE					
	@ COREPHARMA 25MG	A040828	001	Nov 05, 2008	Mar DISC
TENUATE					
AA	+ ACTAVIS LABS UT INC 25MG	N011722	002		Apr CAHN
AA	+ ALLERGAN SALES LLC 25MG	N011722	002		Mar CAHN
TABLET, EXTENDED RELEASE;ORAL					
TENUATE DOSPAN					
AB	+ ACTAVIS LABS UT INC 75MG	N012546	001		Apr CAHN
AB	+ ALLERGAN SALES LLC 75MG	N012546	001		Mar CAHN
<u>DIFLUNISAL</u>					
TABLET;ORAL					
DIFLUNISAL					
	@ IDT AUSTRALIA LTD 500MG	A074604	001	Jun 10, 1996	May CAHN
<u>DIGOXIN</u>					
INJECTABLE;INJECTION					
LANOXIN					
AP	+ COVIS PHARMA SARL 0.25MG/ML	N009330	002		Jun CAHN
LANOXIN PEDIATRIC					
	+ COVIS PHARMA SARL 0.1MG/ML	N009330	004		Jun CAHN
<u>DIHYDROERGOTAMINE MESYLATE</u>					
INJECTABLE;INJECTION					
DIHYDROERGOTAMINE MESYLATE					
AP	EUROHLTH INTL SARL 1MG/ML	A040453	001	Jun 09, 2003	Apr CAHN
<u>DILTIAZEM HYDROCHLORIDE</u>					
CAPSULE, EXTENDED RELEASE;ORAL					
DILACOR XR					
	@ ALLERGAN SALES LLC 120MG	N020092	001	May 29, 1992	Jul CAHN
	@ 180MG	N020092	002	May 29, 1992	Jul CAHN
	@ 240MG	N020092	003	May 29, 1992	Jul CAHN

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan DISC
	@		180MG	A074852	002	Oct 10, 1997	Jan DISC
	@		240MG	A074852	003	Oct 10, 1997	Jan DISC
AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074617	001	Feb 28, 1996	Jun CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996	Apr CAHN

DINOPROSTONEINSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

	+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan CAHN
--	---	--------------------	------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	@	HIKMA INTL PHARMS	50MG	A083567	001		Jul CAHN
	@	HIKMA PHARMS	50MG	A083567	001		Feb CAHN
	@	SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987	Mar CAHN
	@		50MG	A089489	001	Jan 02, 1987	Jun CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074939	001	Apr 13, 1998	Jun CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074939	001	Apr 13, 1998	Apr CAHN

TABLET;ORAL

DIPYRIDAMOLE

	@	IDT AUSTRALIA LTD	25MG	A086944	002	Apr 16, 1991	May CAHN
	@		50MG	A087562	001	Feb 25, 1992	May CAHN
	@		75MG	A087561	001	Feb 25, 1992	May CAHN
>D> AB		LANNETT	25MG	A040898	001	Apr 23, 2008	Aug DISC
>A>	@		25MG	A040898	001	Apr 23, 2008	Aug DISC
>D> AB			50MG	A040898	002	Apr 23, 2008	Aug DISC
>A>	@		50MG	A040898	002	Apr 23, 2008	Aug DISC
>D> AB			75MG	A040898	003	Apr 23, 2008	Aug DISC
>A>	@		75MG	A040898	003	Apr 23, 2008	Aug DISC
	@	PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990	Jul DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

	@	AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb CAHN
	@		EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb CAHN
>A> AB		MAYNE PHARMA	EQ 100MG BASE	A070173	001	May 31, 1985	Aug CAHN
>A> AB			EQ 150MG BASE	A070174	001	May 31, 1985	Aug CAHN
	@	SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985	Mar CAHN
	@		EQ 150MG BASE	A070352	001	Dec 17, 1985	Mar CAHN
>D> AB		WATSON LABS	EQ 100MG BASE	A070173	001	May 31, 1985	Aug CAHN
>D> AB			EQ 150MG BASE	A070174	001	May 31, 1985	Aug CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan CAHN
----	--	---------------	-------	---------	-----	--------------	----------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

	@	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb DISC
	@		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

@ TELIGENT PHARMA INC EQ 12.5MG BASE/ML A074098 001 Feb 21, 1995 Jan CAHN

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

HOSPIRA INC 20MG/ML (20MG/ML) N022234 004 Jun 23, 2016 Jun NEWA
80MG/4ML (20MG/ML) N022234 005 Jun 23, 2016 Jun NEWA
120MG/6ML (20MG/ML) N022234 006 Jun 23, 2016 Jun NEWA

SOLUTION; IV (INFUSION)
DOCETAXEL

EAGLE PHARMS 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Jan CAHN
80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Jan CAHN
160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Jan CAHN

DOFETILIDE

CAPSULE; ORAL
DOFETILIDE

AB TIGER PHARMS LLC 0.125MG A207058 001 Jun 06, 2016 May NEWA
AB 0.25MG A207058 002 Jun 06, 2016 May NEWA
AB 0.5MG A207058 003 Jun 06, 2016 May NEWA
TIKOSYN
AB PFIZER 0.125MG N020931 001 Oct 01, 1999 May CFTG
AB 0.25MG N020931 002 Oct 01, 1999 May CFTG
AB + 0.5MG N020931 003 Oct 01, 1999 May CFTG

DOLASETRON MESYLATE

INJECTABLE; INJECTION
ANZEMET

+ US PHARM HOLDINGS 12.5MG/0.625ML (20MG/ML) N020624 002 Sep 11, 1997 Jan CAHN
+ 12.5MG/0.625ML (20MG/ML) N020624 002 Sep 11, 1997 Jan CAHN
+ 100MG/5ML (20MG/ML) N020624 001 Sep 11, 1997 Jan CAHN
@ 500MG/25ML (20MG/ML) N020624 003 Dec 11, 2001 Jun DISC
+ 500MG/25ML (20MG/ML) N020624 003 Dec 11, 2001 Jan CAHN

TABLET; ORAL
ANZEMET

US PHARM HOLDINGS 50MG N020623 001 Sep 11, 1997 Jan CAHN
+ 100MG N020623 002 Sep 11, 1997 Jan CAHN

DOLUTEGRAVIR SODIUM

TABLET; ORAL
TIVICAY

VIIV HLTHCARE EQ 10MG BASE N204790 002 Jun 09, 2016 Jun NEWA
EQ 25MG BASE N204790 003 Jun 09, 2016 Jun NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB DEXCEL PHARMA 23MG A203713 001 Feb 19, 2016 Feb NEWA
AB INDICUS PHARMA 23MG A203419 001 Apr 12, 2016 Mar NEWA
AB OSMOTICA PHARM CORP 23MG A203114 001 Jan 26, 2016 Jan NEWA
AB OSMOTICA PHARM US 23MG A203114 001 Jan 26, 2016 Jun CAHN
AB UNICHEM LABS LTD 5MG A203656 001 Jun 23, 2016 Jun NEWA
AB 10MG A203656 002 Jun 23, 2016 Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
DONEPEZIL HYDROCHLORIDE

@ SUN PHARM INDS 5MG A077975 002 Dec 11, 2009 Mar CAHN
@ 10MG A077975 001 Dec 11, 2009 Mar CAHN

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
NAMZARIC

>A> FOREST LABS LLC 10MG; 7MG N206439 003 Jul 18, 2016 Aug NEWA
>A> 10MG; 21MG N206439 004 Jul 18, 2016 Aug NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D> AT	LANNETT HOLDINGS INC	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014	Aug DISC
>A>	@	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014	Aug DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	20MG/ML	A076266	001	Jan 10, 2003	Jun CAHN
AP	EUROHLTH INTL SARL	20MG/ML	A076266	001	Jan 10, 2003	Apr CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar CAHN
@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar CAHN
@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar CAHN
@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

@	SUN PHARM INDS	EQ 25MG BASE	A071502	001	Feb 18, 1988	Mar CAHN
@		EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar CAHN
@		EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar CAHN
@		EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar CAHN

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan NEWA

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

>A> AB	RISING PHARMS INC	0.5MCG	A201518	001	Sep 09, 2016	Aug NEWA
>A> AB		1MCG	A201518	002	Sep 09, 2016	Aug NEWA
>A> AB		2.5MCG	A201518	003	Sep 09, 2016	Aug NEWA

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar NEWA
AP	HECTOROL					
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	May CRLD
AP		200MG/100ML	A203622	002	Jun 27, 2014	May CRLD
AP	+ PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	May CRLD
AP	+	200MG/100ML	N050629	002	May 03, 1988	May CRLD

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar CAHN
AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar CAHN
AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb NEWA
AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb NEWA
AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb NEWA

TABLET;ORAL

DOXYCYCLINE

@	SUN PHARM INDS	EQ 50MG BASE	A065471	001	Apr 17, 2009	Jun CAHN
@		EQ 75MG BASE	A065471	002	Apr 17, 2009	Jun CAHN
@		EQ 100MG BASE	A065471	003	Apr 17, 2009	Jun CAHN

DOXYCYCLINE HYCLATE

CAPSULE;ORAL							
ACTICLATE CAP							
	+ AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Apr	NEWA
DOXYCYCLINE HYCLATE							
AB	AMNEAL PHARMS	EQ 100MG BASE	A207289	001	Jun 27, 2016	Jun	NEWA
AB	SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar	CAHN
TABLET;ORAL							
DOXYCYCLINE HYCLATE							
	@ COREPHARMA	EQ 20MG BASE	A065182	001	May 13, 2005	Mar	DISC
AB	SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar	CAHN
AB		EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar	CAHN
	@ VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar	DISC
TABLET, DELAYED RELEASE;ORAL							
DORYX							
AB	MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jul	CTNA
AB		EQ 50MG BASE	N050795	006	Dec 19, 2014	May	CFTG
AB		EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	CFTG
AB	+ DORYX MPC	EQ 200MG BASE	N050795	005	Apr 11, 2013	May	CFTG
	MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Jul	CTNA
		EQ 60MG BASE	N050795	007	May 20, 2016	May	NEWA
		EQ 120MG BASE	N050795	008	May 20, 2016	Jul	CTNA
		EQ 120MG BASE	N050795	008	May 20, 2016	May	NEWA
DOXYCYCLINE HYCLATE							
	@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar	DISC
	@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar	DISC
AB	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May	NEWA
AB		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	NEWA
AB		EQ 200MG BASE	A090431	005	May 19, 2016	May	NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL							
DICLEGIS							
>D>	+ DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Aug	CFTG
>A> AB	+ DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Aug	CFTG
>A>	DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE						
>A> AB	ACTAVIS LABS FL INC	10MG;10MG	A205811	001	Aug 19, 2016	Aug	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL							
MELAMISA							
AB	NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan	NEWA
TABLET;ORAL-28							
DROSPIRENONE AND ETHINYL ESTRADIOL							
AB	GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar	NEWA
>A> AB	MAYNE PHARMA	3MG;0.03MG	A090081	001	Sep 07, 2010	Aug	CAHN
>D> AB	WATSON LABS	3MG;0.03MG	A090081	001	Sep 07, 2010	Aug	CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL							
DULOXETINE HYDROCHLORIDE							
AB	HETERO LABS LTD III	EQ 20MG BASE	A204343	001	Aug 03, 2016	Jul	NEWA
AB		EQ 30MG BASE	A204343	002	Aug 03, 2016	Jul	NEWA
AB		EQ 60MG BASE	A204343	003	Aug 03, 2016	Jul	NEWA

DUTASTERIDE

CAPSULE;ORAL							
DUTASTERIDE							
AB	AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr	CAHN
AB	BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan	CAHN
AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb	NEWA
AB	MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May	NEWA
AB	STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar	CAHN

DYPHYLLINE

TABLET;ORAL							
LUFYLLIN							
	@ MEDA PHARMS	200MG	A084566	001		Jun	DISC
	@	400MG	A084566	002		Jun	DISC

ECONAZOLE NITRATE

	AEROSOL, FOAM;TOPICAL							
	ECOZA							
	+ EXELTIS SUISSE	1%	N205175	001	Oct 24, 2013	Jul	CAHN	
	CREAM;TOPICAL							
	ECONAZOLE NITRATE							
AB	TELIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004	May	CAHN	
	SPECTAZOLE							
	@ ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Jul	CAHN	

EDROPHONIUM CHLORIDE

	INJECTABLE;INJECTION							
	TENSILON							
	@ TELIGENT PHARMA INC	10MG/ML	N007959	001		Jan	CAHN	
	TENSILON PRESERVATIVE FREE							
	@ TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan	CAHN	

EFAVIRENZ

	TABLET;ORAL							
	EFAVIRENZ							
AB	MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Feb	NEWA	
AB	MYLAN PHARMS INC	600MG	A091471	001	Feb 17, 2016	Jun	CAHN	
	SUSTIVA							
AB	+ BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb	CFTG	

ELBASVIR; GRAZOPREVR

	TABLET;ORAL							
	ZEPATIER							
	+ MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016	Jan	NEWA	

ELUXADOLINE

	TABLET;ORAL							
	VIBERZI							
	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015	May	CAHN	
	+	100MG	N206940	002	May 27, 2015	May	CAHN	

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

	TABLET;ORAL							
	ODEFSEY							
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Apr	CAIN	

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET;ORAL							
	ODEFSEY							
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Mar	NEWA	

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

	TABLET;ORAL							
	DESCOVY							
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Apr	NEWA	

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET;ORAL							
	TRUVADA							
	GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Mar	NEWA	
		133MG;200MG	N021752	003	Mar 10, 2016	Mar	NEWA	
		167MG;250MG	N021752	004	Mar 10, 2016	Mar	NEWA	

ENALAPRILAT

	INJECTABLE;INJECTION							
	ENALAPRILAT							
AP	+ AMPHASTAR PHARMS INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jun	CAHN	
AP	+ EUROHLTH INTL SARL	1.25MG/ML	A075634	001	Aug 22, 2000	Apr	CAHN	

>D> ENFLURANE

>D>	LIQUID;INHALATION							
>D>	ENFLURANE							
>D> AN	PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994	Aug	DISC	
>A>	@	99.9%	A074396	001	Jul 29, 1994	Aug	DISC	

>D>	LIQUID; INHALATION								
>D>	ETHRANE								
>D> AN	+ BAXTER HLTHCARE	99.9%		N017087	001			Aug	DISC
>A>	@	99.9%		N017087	001			Aug	DISC
<u>EPHEDRINE SULFATE</u>									
	SOLUTION; INTRAVENOUS								
	AKOAZ								
	+ FLAMEL IRELAND LTD	50MG/ML		N208289	001	Apr 29, 2016		Apr	NEWA
<u>EPINASTINE HYDROCHLORIDE</u>									
	SOLUTION/DROPS; OPHTHALMIC								
	EPINASTINE HYDROCHLORIDE								
AT	SOMERSET THERAPS LLC	0.05%		A090951	001	Oct 31, 2011		Mar	CAHN
<u>EPINEPHRINE</u>									
	INJECTABLE; INJECTION								
	SUS-PHRINE SULFITE FREE								
	@ FOREST LABS	1.5MG/AMP		N007942	003	Feb 05, 1999		Mar	CMS1
	@	5MG/ML		N007942	001			Mar	CMS1
	INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS								
	AUVI-Q								
BX	+ KALEO INC	EQ 0.15MG/DELIVERY		N201739	002	Aug 10, 2012		Mar	CAHN
BX		EQ 0.3MG/DELIVERY		N201739	001	Aug 10, 2012		Mar	CAHN
	TWINJECT 0.15								
	@ AMEDRA PHARMS	EQ 0.15MG/DELIVERY		N020800	002	May 28, 2004		May	DISC
	TWINJECT 0.3								
	@ AMEDRA PHARMS	EQ 0.3MG/DELIVERY		N020800	001	May 30, 2003		May	DISC
	SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS								
	EPINEPHRINE								
	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		N205029	001	Jul 29, 2014		Jul	CAIN
<u>EPINEPHRINE HYDROCHLORIDE</u>									
	SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS								
	EPINEPHRINE								
	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		N205029	001	Jul 29, 2014		Feb	CDFR
<u>EPIRUBICIN HYDROCHLORIDE</u>									
	INJECTABLE; INJECTION								
	EPIRUBICIN HYDROCHLORIDE								
>A> AP	IMPAX LABS INC	50MG/25ML (2MG/ML)		A065331	001	Aug 09, 2007		Aug	CAHN
>A> AP		200MG/100ML (2MG/ML)		A065331	002	Aug 09, 2007		Aug	CAHN
>D> AP	TEVA PHARMS USA	50MG/25ML (2MG/ML)		A065331	001	Aug 09, 2007		Aug	CAHN
>D> AP		200MG/100ML (2MG/ML)		A065331	002	Aug 09, 2007		Aug	CAHN
<u>EPTIFIBATIDE</u>									
	INJECTABLE; INJECTION								
	EPTIFIBATIDE								
>D> AP	TEVA PHARMS USA	75MG/100ML		A091555	001	Jun 05, 2015		Aug	DISC
>A>	@	75MG/100ML		A091555	001	Jun 05, 2015		Aug	DISC
<u>ERGOCALCIFEROL</u>									
	CAPSULE; ORAL								
	DRISDOL								
AA	+ US PHARM HOLDINGS	50,000 IU		N003444	001			Jan	CAHN
	VITAMIN D								
AA	BIONPHARMA INC	50,000 IU		A080704	001			Jan	CAHN
<u>ERGOLOID MESYLATES</u>									
	TABLET; ORAL								
	ERGOLOID MESYLATES								
AB	SUN PHARM INDS	1MG		A081113	001	Oct 31, 1991		Mar	CAHN
	TABLET; SUBLINGUAL								
	ERGOLOID MESYLATES								
	@ SUN PHARM INDS	0.5MG		A087407	001			Jun	CAHN
	@	1MG		A087552	001			Jun	CAHN

ERGOTAMINE TARTRATETABLET;SUBLINGUAL
ERGOMAR

>D>	+	ROSEDALE THERAPEUTIC	2MG	A087693	001	Feb 24, 1983	Aug CAHN
>A>	+	TERSERA THERAP	2MG	A087693	001	Feb 24, 1983	Aug CAHN

ERYTHROMYCINSOLUTION;TOPICAL
C-SOLVE-2

	@	FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb DISC
	@	HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb DISC
AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan CRLD
AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan CRLD

ESCITALOPRAM OXALATESOLUTION;ORAL
ESCITALOPRAM OXALATE

AA		MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754	001	Mar 31, 2016	Mar NEWA
----	--	---------------------	-----------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

+	HQ	SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016	Apr NEWA
+	HQ	SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun CRLD
			2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Apr NEWA

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr NEWA
AB			EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr NEWA
BX		HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr CTEC
BX			EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr CTEC

ESOMEPRAZOLE SODIUMINJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP		AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Jul NEWA
AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul NEWA

ESTAZOLAMTABLET;ORAL
ESTAZOLAM

>A>	AB	MAYNE PHARMA	1MG	A074921	001	Jul 10, 1997	Aug CAHN
>A>	AB	+	2MG	A074921	002	Jul 10, 1997	Aug CAHN
>D>	AB	TEVA	1MG	A074921	001	Jul 10, 1997	Aug CAHN
>D>	AB	+	2MG	A074921	002	Jul 10, 1997	Aug CAHN

ESTRADIOLCREAM;VAGINAL
ESTRACE

+	ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr CAHN
---	--------------------	-------	---------	-----	--------------	----------

FILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

BX		ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX			0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX			0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX			0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

TABLET;ORAL
ESTRADIOL

>A>	AB	MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Aug CAHN
>A>	AB		1MG	A040114	001	Mar 14, 1996	Aug CAHN
>A>	AB		2MG	A040114	002	Mar 14, 1996	Aug CAHN
>D>	AB	WATSON LABS	0.5MG	A040114	003	Mar 14, 1996	Aug CAHN
>D>	AB		1MG	A040114	001	Mar 14, 1996	Aug CAHN
>D>	AB		2MG	A040114	002	Mar 14, 1996	Aug CAHN

		TABLET;VAGINAL							
		ESTRADIOL							
>D>		@ AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	Aug	CMFD	
>A>	AB		10MCG	A205256	001	May 29, 2015	Aug	CMFD	
		VAGIFEM							
>D>		+ NOVO NORDISK INC	10MCG	N020908	002	Nov 25, 2009	Aug	CTEC	
>A>	AB	+	10MCG	N020908	002	Nov 25, 2009	Aug	CTEC	
<u>ESTRADIOL ACETATE</u>									
		INSERT, EXTENDED RELEASE;VAGINAL							
		FEMRING							
		APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan	CAHN	
		+	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan	CAHN	
		TABLET;ORAL							
		FEMTRACE							
		APIL	0.45MG	N021633	001	Aug 20, 2004	Jan	CAHN	
			0.9MG	N021633	002	Aug 20, 2004	Jan	CAHN	
		+	1.8MG	N021633	003	Aug 20, 2004	Jan	CAHN	
<u>ESTRADIOL HEMIHYDRATE</u>									
		EMULSION;TOPICAL							
		ESTRASORB							
		+ EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun	CAHN	
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>									
		TABLET;ORAL							
		AMABELZ							
AB		LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016	Jun	NEWA	
AB			1MG;0.5MG	A203339	002	Jun 20, 2016	Jun	NEWA	
<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>									
		TABLET;ORAL							
		CENESTIN							
		@ TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	DISC	
		@	0.45MG	N020992	005	Feb 05, 2004	Jun	DISC	
		@	0.625MG	N020992	002	Mar 24, 1999	Jun	DISC	
		@	0.9MG	N020992	003	Mar 24, 1999	Jun	DISC	
		@	1.25MG	N020992	004	Mar 13, 2000	Jun	DISC	
<u>ESTROGENS, CONJUGATED SYNTHETIC B</u>									
		TABLET;ORAL							
		ENJUUIA							
		@ TEVA WOMENS	0.625MG	N021443	003	May 10, 2004	Jun	DISC	
<u>ETHACRYNATE SODIUM</u>									
		INJECTABLE;INJECTION							
		ETHACRYNATE SODIUM							
>A>	AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A204634	001	Aug 23, 2016	Aug	NEWA	
<u>ETHACRYNIC ACID</u>									
		TABLET;ORAL							
		EDECIN							
AB		+ ATON	25MG	N016092	001		Jun	CFTG	
		ETHACRYNIC ACID							
AB		EDENBRIDGE PHARMS	25MG	A205609	001	Jun 30, 2016	Jun	NEWA	
<u>ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE</u>									
		TABLET;ORAL-28							
		ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL							
AB		JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan	NEWA	
		ZOVIA 1/35E-28							
>A>	AB	MAYNE PHARMA	0.035MG;1MG	A072721	001	Dec 30, 1991	Aug	CAHN	
>D>	AB	WATSON LABS	0.035MG;1MG	A072721	001	Dec 30, 1991	Aug	CAHN	
		ZOVIA 1/50E-28							
AB		+ WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan	CTEC	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

FAYOSIM

AB	LUPIN LTD	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	A205943	001	Mar 29, 2016	Mar NEWA
----	-----------	--	---------	-----	--------------	----------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	AMNEAL PHARMS	0.03MG; 0.15MG	A203871	001	Nov 13, 2015	Jul CAHN
----	---------------	----------------	---------	-----	--------------	----------

AB	HAUPT PHARMA	0.03MG, 0.01MG; 0.15MG, N/A	A203872	001	Dec 22, 2015	Jul CMS1
----	--------------	-----------------------------	---------	-----	--------------	----------

>A> AB	MAYNE PHARMA	0.02MG, 0.01MG; 0.1MG, N/A	A200407	001	Oct 25, 2011	Aug CAHN
--------	--------------	----------------------------	---------	-----	--------------	----------

>D> AB	WATSON LABS	0.02MG, 0.01MG; 0.1MG, N/A	A200407	001	Oct 25, 2011	Aug CAHN
--------	-------------	----------------------------	---------	-----	--------------	----------

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

>A> AB	MAYNE PHARMA	0.03MG, 0.01MG; 0.15MG, N/A	A078834	001	May 31, 2011	Aug CAHN
--------	--------------	-----------------------------	---------	-----	--------------	----------

>D> AB	WATSON LABS	0.03MG, 0.01MG; 0.15MG, N/A	A078834	001	May 31, 2011	Aug CAHN
--------	-------------	-----------------------------	---------	-----	--------------	----------

QUARTETTE

AB	+ TEVA BRANDED PHARM	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	N204061	001	Mar 28, 2013	Mar CFTG
----	----------------------	--	---------	-----	--------------	----------

TABLET; ORAL-21

TRIVORA-21

>A>	@ MAYNE PHARMA	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A074538	001	Dec 18, 1997	Aug CAHN
-----	----------------	--	---------	-----	--------------	----------

>D>	@ WATSON LABS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A074538	001	Dec 18, 1997	Aug CAHN
-----	---------------	--	---------	-----	--------------	----------

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	AMNEAL PHARMS	0.02MG; 0.1MG	A201108	001	Feb 05, 2014	May CAHN
-----	---------------	---------------	---------	-----	--------------	----------

AB		0.03MG; 0.15MG	A201095	001	Dec 08, 2014	Jul CAHN
----	--	----------------	---------	-----	--------------	----------

>A> AB1	+ MAYNE PHARMA	0.02MG; 0.1MG	A076625	001	Nov 18, 2004	Aug CAHN
---------	----------------	---------------	---------	-----	--------------	----------

>A> AB2	+	0.02MG; 0.1MG	A077681	001	May 31, 2006	Aug CAHN
---------	---	---------------	---------	-----	--------------	----------

>D> AB1	+ WATSON LABS	0.02MG; 0.1MG	A076625	001	Nov 18, 2004	Aug CAHN
---------	---------------	---------------	---------	-----	--------------	----------

>D> AB2	+	0.02MG; 0.1MG	A077681	001	May 31, 2006	Aug CAHN
---------	---	---------------	---------	-----	--------------	----------

LEVORA 0.15/30-28

>A> AB	+ MAYNE PHARMA	0.03MG; 0.15MG	A073594	001	Dec 13, 1993	Aug CAHN
--------	----------------	----------------	---------	-----	--------------	----------

>D> AB	+ WATSON LABS	0.03MG; 0.15MG	A073594	001	Dec 13, 1993	Aug CAHN
--------	---------------	----------------	---------	-----	--------------	----------

TRIVORA-28

>A> AB	+ MAYNE PHARMA	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A074538	002	Dec 18, 1997	Aug CAHN
--------	----------------	--	---------	-----	--------------	----------

>D> AB	+ WATSON LABS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A074538	002	Dec 18, 1997	Aug CAHN
--------	---------------	--	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BREVICON 21-DAY

@ ALLERGAN SALES LLC	0.035MG; 0.5MG	N017566	001		Apr CAHN
----------------------	----------------	---------	-----	--	----------

NORINYL 1+35 21-DAY

AB	ALLERGAN SALES LLC	0.035MG; 1MG	N017565	001		Mar CAHN
----	--------------------	--------------	---------	-----	--	----------

TRI-NORINYL 21-DAY

>D>	@ ACTAVIS LABS UT INC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	001	Apr 13, 1984	Aug CAHN
-----	-----------------------	--	---------	-----	--------------	----------

>A>	@ MAYNE PHARMA	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	001	Apr 13, 1984	Aug CAHN
-----	----------------	--	---------	-----	--------------	----------

TABLET; ORAL-28

BREVICON 28-DAY

AB	ALLERGAN SALES LLC	0.035MG; 0.5MG	N017743	001		Mar CAHN
----	--------------------	----------------	---------	-----	--	----------

NORETHINDRONE AND ETHINYL ESTRADIOL

>A> AB	MAYNE PHARMA	0.035MG; 0.5MG	A070686	001	Jan 29, 1987	Aug CAHN
--------	--------------	----------------	---------	-----	--------------	----------

>D> AB	WATSON LABS	0.035MG; 0.5MG	A070686	001	Jan 29, 1987	Aug CAHN
--------	-------------	----------------	---------	-----	--------------	----------

NORINYL 1+35 28-DAY

AB	ALLERGAN SALES LLC	0.035MG; 1MG	N017565	002		Mar CAHN
----	--------------------	--------------	---------	-----	--	----------

TRI-NORINYL 28-DAY

>D> AB	+ ACTAVIS LABS UT INC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	002	Apr 13, 1984	Aug CAHN
--------	-----------------------	--	---------	-----	--------------	----------

>A> AB	+ MAYNE PHARMA	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	002	Apr 13, 1984	Aug CAHN
--------	----------------	--	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

FEMCON FE

AB	+ APIL	0.035MG; 0.4MG	N021490	001	Nov 14, 2003	Jan CAHN
----	--------	----------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+ APIL	0.025MG; 0.8MG	N022573	001	Dec 22, 2010	Jan CAHN
----	--------	----------------	---------	-----	--------------	----------

AB	LUPIN LTD	0.035MG; 0.4MG	A091332	001	Mar 23, 2016	Mar NEWA
----	-----------	----------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

>D>	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
>D>	@	APIL	0.02MG;1MG	N204426	001	Apr 19, 2013	Aug CTNA
	@		0.02MG;1MG	N204426	001	Apr 19, 2013	Apr CAHN
>A>	TAYTULLA						
>A>	+	APIL	0.02MG;1MG	N204426	001	Apr 19, 2013	Aug CTNA
	TABLET;ORAL						
	FEMHRT						
AB		APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan CAHN
	@		0.005MG;1MG	N021065	002	Oct 15, 1999	Jan CAHN
	LERIBANE						
AB		NOVAST LABS LTD	0.0025MG;0.5MG	A203435	002	Jun 03, 2016	May NEWA
AB			0.005MG;1MG	A203435	001	Jun 03, 2016	May NEWA
	LO LOESTRIN FE						
AB	+	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May CFTG
	+		0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan CAHN
	LOESTRIN 24 FE						
>A>	AB	APIL	0.02MG;1MG	N021871	001	Feb 17, 2006	Aug CAHN
>D>	AB	WARNER CHILCOTT	0.02MG;1MG	N021871	001	Feb 17, 2006	Aug CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB		JAI PHARMA LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May NEWA
	TABLET;ORAL-21						
	ESTROSTEP 21						
	@	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan CAHN
	LOESTRIN 21 1.5/30						
AB		APIL	0.03MG;1.5MG	N017875	001		Apr CAHN
	LOESTRIN 21 1/20						
AB		APIL	0.02MG;1MG	N017876	001		Apr CAHN
	MICROGESTIN 1.5/30						
>A>	AB	MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Aug CAHN
>D>	AB	WATSON LABS	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Aug CAHN
	MICROGESTIN 1/20						
>A>	AB	MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Aug CAHN
>D>	AB	WATSON LABS	0.02MG;1MG	A075647	002	Jul 30, 2003	Aug CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB		GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan NEWA
	TABLET;ORAL-28						
	ESTROSTEP FE						
AB	+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan CAHN
	LOESTRIN FE 1.5/30						
AB	+	APIL	0.03MG;1.5MG	N017355	001		Apr CAHN
	LOESTRIN FE 1/20						
AB		APIL	0.02MG;1MG	N017354	001		Apr CAHN
	MICROGESTIN FE 1.5/30						
>A>	AB	MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Aug CAHN
>D>	AB	WATSON LABS	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Aug CAHN
	MICROGESTIN FE 1/20						
>A>	AB	MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Aug CAHN
>D>	AB	WATSON LABS	0.02MG;1MG	A075647	001	Feb 05, 2001	Aug CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
>A>	AB	MAYNE PHARMA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Aug CAHN
>D>	AB	WATSON LABS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Aug CAHN
	TABLET, CHEWABLE;ORAL						
	MIBELAS 24 FE						
AB		LUPIN ATLANTIS	0.02MG;1MG	A206287	001	May 24, 2016	May NEWA
	MINASTRIN 24 FE						
AB	+	APIL	0.02MG;1MG	N203667	001	May 08, 2013	May CFTG
	+		0.02MG;1MG	N203667	001	May 08, 2013	Jan CAHN
	TABLET, CHEWABLE, TABLET;ORAL						
	LO MINASTRIN FE						
	+	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

	MILI					
AB	AUROBINDO PHARMA LTD	0.035MG; 0.25MG	A205449	001	Jul 07, 2016	Jun NEWA
	NORGESTIMATE AND ETHINYL ESTRADIOL					
AB	AMNEAL PHARMS	0.035MG; 0.25MG	A203865	001	Oct 27, 2015	May CAHN
AB	GLENMARK PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG,	A204057	001	Feb 23, 2016	Jun CAHN

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

		0.215MG,0.25MG						
AB	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A204057	001	Feb 23, 2016	Feb	NEWA	
AB	HAUPT PHARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A203873	001	May 12, 2016	May	NEWA	
AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG	A201897	001	Jan 27, 2016	Jan	NEWA	
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan	NEWA	
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205588	001	Apr 26, 2016	Apr	NEWA	
	TRI-MILI							
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205441	001	Jul 06, 2016	Jun	NEWA	

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LO/OVRAL

	@ PELAGIUS	0.03MG;0.3MG	N017612	001		Jun	CAHN	
	LOW-OGESTREL-21							
>A>	@ MAYNE PHARMA	0.03MG;0.3MG	A075288	001	Jul 28, 1999	Aug	CAHN	
>D>	@ WATSON LABS	0.03MG;0.3MG	A075288	001	Jul 28, 1999	Aug	CAHN	
	TABLET;ORAL-28							
	LO/OVRAL-28							
	@ WYETH PHARMS	0.03MG;0.3MG	N017802	001		Jun	DISC	
	LOW-OGESTREL-28							
>A>	AB MAYNE PHARMA	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Aug	CAHN	
>D>	AB WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Aug	CAHN	
	NORGESTREL AND ETHINYL ESTRADIOL							
AB	JAI PHARMA LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Jun	NEWA	

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

>D>	+ GUERBET	99%	N009190	001		Aug	CPOT	
>A>	+	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001		Aug	CPOT	

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan	CAHN	
----	----------------	-------	---------	-----	--------------	-----	------	--

ETIDRONATE DISODIUM

TABLET;ORAL

DIDRONEL

AB	APIL	200MG	N017831	001		Apr	CAHN	
AB	+	400MG	N017831	002		Apr	CAHN	

ETODOLAC

CAPSULE;ORAL

ETODOLAC

	@ IDT AUSTRALIA LTD	200MG	A074840	001	Aug 29, 1997	May	CAHN	
	@	300MG	A074840	002	Aug 29, 1997	May	CAHN	
	@ LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb	CAHN	
	TABLET, EXTENDED RELEASE;ORAL							
	ETODOLAC							
>A>	@ IDT AUSTRALIA LTD	400MG	A075943	001	Jul 26, 2002	Aug	CAHN	
>A>	@	500MG	A075943	002	Jul 26, 2002	Aug	CAHN	
>A>	@	600MG	A075943	003	Jul 26, 2002	Aug	CAHN	
>D>	@ SANDOZ	400MG	A075943	001	Jul 26, 2002	Aug	CAHN	
>D>	@	500MG	A075943	002	Jul 26, 2002	Aug	CAHN	
>D>	@	600MG	A075943	003	Jul 26, 2002	Aug	CAHN	

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996	Apr	CAHN	
AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb	NEWA	

EXEMESTANETABLET;ORAL
EXEMESTANE

AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan CAHN
----	---------------	------	---------	-----	--------------	----------

EXENATIDE SYNTHETICFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON PEN

+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb NEWA
---	----------------	-----	---------	-----	--------------	----------

FAMOTIDINEINJECTABLE;INJECTION
FAMOTIDINE

AP	AMPHASTAR PHARMS INC	10MG/ML	A075651	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Apr CAHN

FAMOTIDINE PRESERVATIVE FREE

AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN

TABLET;ORAL
FAMOTIDINE

@	SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar CAHN
@		40MG	A075639	001	Dec 12, 2001	Mar CAHN

FELBAMATETABLET;ORAL
FELBAMATE

>A>	AB	ALVOGEN MALTA	400MG	A204595	001	Jan 11, 2016	Aug CAHN
>A>	AB		600MG	A204595	002	Jan 11, 2016	Aug CAHN
>D>	AB	MYLAN PHARMS INC	400MG	A204595	001	Jan 11, 2016	Aug CAHN
>D>	AB		600MG	A204595	002	Jan 11, 2016	Aug CAHN

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

>A>	AB	JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Aug NEWA
>A>	AB		5MG	A203983	002	Aug 19, 2016	Aug NEWA
>A>	AB		10MG	A203983	003	Aug 19, 2016	Aug NEWA
	AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
	AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
	AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATETABLET;ORAL
FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA
AB		145MG	A205118	002	May 05, 2016	Apr NEWA
AB	HETERO LABS LTD III	48MG	A204598	001	Jul 12, 2016	Jun NEWA
AB		145MG	A204598	002	Jul 12, 2016	Jun NEWA
AB	MYLAN	40MG	A204475	001	Jun 23, 2016	Jun NEWA
AB		120MG	A204475	002	Jun 23, 2016	Jun NEWA

FENOGLIDE

AB	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Jun CFTG
AB	+	120MG	N022118	002	Aug 10, 2007	Jun CFTG

FENOFIBRIC ACIDTABLET;ORAL
FIBRICOR

	ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Apr CAHN
+		105MG	N022418	002	Aug 14, 2009	Apr CAHN
	ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009	Jun CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

@ AUROLIFE PHARMA LLC EQ 200MG BASE

A072394 001 Oct 17, 1988 Mar CAHN

@ EQ 300MG BASE

A072395 001 Oct 17, 1988 Feb CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

@ AUROLIFE PHARMA LLC EQ 600MG BASE

A072396 001 Oct 17, 1988 Feb CAHN

@ SUN PHARM INDS EQ 600MG BASE

A072902 001 Dec 21, 1990 Mar CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-12

AB AVEVA 12.5MCG/HR

A077449 005 Sep 11, 2015 Jan NEWA

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS

TRIFERIC

+ ROCKWELL MEDICAL INC 272MG IRON/PACKET

N208551 001 Apr 25, 2016 Apr NEWA

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

@ ALKEM LABS LTD 4MG

A204827 001 Dec 10, 2015 Jan DISC

@ 8MG

A204827 002 Dec 10, 2015 Jan DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ BARR 60MG;120MG

A076236 001 Apr 14, 2005 Mar DISC

@ IMPAX PHARMS 60MG;120MG

A076298 001 Nov 12, 2010 Mar DISC

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

SMOFLIPID 20%

+ FRESENIUS KABI USA 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)

N207648 001 Jul 13, 2016 Jul NEWA

+ 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)

N207648 002 Jul 13, 2016 Jul NEWA

+ 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)

N207648 003 Jul 13, 2016 Jul NEWA

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS 100MG

A076234 001 Aug 28, 2003 Mar DISC

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

@ IDT AUSTRALIA LTD 50MG

A076030 001 Oct 28, 2002 May CAHN

@ 100MG

A076030 002 Oct 28, 2002 May CAHN

@ 150MG

A076030 003 Oct 28, 2002 May CAHN

FLUCICLOVINE F-18

SOLUTION;INTRAVENOUS

AXUMIN

+ BLUE EARTH 9-221mCi/ML

N208054 001 May 27, 2016 May NEWA

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

@ SUN PHARM INDS LTD 50MG/5ML

A076332 001 Jul 29, 2004 Feb DISC

@ 200MG/5ML

A076332 002 Jul 29, 2004 Feb DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP EUROHLTH INTL SARL 100MG/50ML (2MG/ML)

A076087 002 Sep 26, 2008 Apr CAHN

AP 200MG/100ML (2MG/ML)

A076087 001 Jul 29, 2004 Apr CAHN

400MG/200ML (2MG/ML)

A076087 003 Jul 29, 2004 Apr CAHN

@ TEVA PHARMS USA 200MG/100ML (2MG/ML)

A076653 001 Jul 29, 2004 Jan DISC

@ 400MG/200ML (2MG/ML)

A076653 002 Jul 29, 2004 Jan DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CMS1
AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CMS1
AP	EUROHLTH INTL SARL	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun CAHN
AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun CAHN

TABLET;ORAL

FLUCONAZOLE

@	IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May CAHN
@		100MG	A076086	002	Jul 29, 2004	May CAHN
@		150MG	A076086	003	Jul 29, 2004	May CAHN
@		200MG	A076086	004	Jul 29, 2004	May CAHN

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

>A>	AP	SAGENT PHARMS	50MG/VIAL	A076349	001	Aug 28, 2003	Aug CAHN
>A>	AP		50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Aug CAHN
>D>	AP	TEVA PHARMS USA	50MG/VIAL	A076349	001	Aug 28, 2003	Aug CAHN
>D>	AP		50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Aug CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May NEWA
AT		0.01%	A209336	001	May 19, 2016	May NEWA

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr NEWA
>A> AT	VERSAPHARM INC	0.01%	A202705	001	Sep 09, 2016	Aug NEWA

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

@	SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002	Mar CAHN
@		EQ 20MG BASE	A075787	002	Jan 29, 2002	Mar CAHN

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AA	LANNETT	EQ 20MG BASE/5ML	A076458	001	May 14, 2004	Aug DISC
>A>		@	EQ 20MG BASE/5ML	A076458	001	May 14, 2004	Aug DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

>D>		+ EDMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar CRLD
>A>	AB	+ MYLAN	EQ 20MG BASE	A075755	002	Aug 02, 2001	Aug CTEC
>A>	AB		EQ 20MG BASE	A075755	002	Aug 02, 2001	Aug CTEC
>A>	AB	PAR FORM	EQ 10MG BASE	A203836	001	Aug 19, 2016	Aug NEWA
>A>	AB		EQ 20MG BASE	A203836	002	Aug 19, 2016	Aug NEWA
		SARAFEM					
	AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
	AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN

TABLET; ORAL							
SARAFEM							
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CAHN
<u>FLURANDRENOLIDE</u>							
CREAM; TOPICAL							
CORDRAN SP							
AT	+	AQUA PHARMS 0.05%	N012806	002		Mar	CFTG
FLURANDRENOLIDE							
AT		TELIGENT PHARMA INC 0.05%	A205342	001	Apr 13, 2016	Mar	NEWA
LOTION; TOPICAL							
CORDRAN							
>D>	+	AQUA PHARMS 0.05%	N013790	001		Aug	CTEC
>A>	AT	+	N013790	001		Aug	CTEC
FLURANDRENOLIDE							
>A>	AT	PERRIGO UK FINCO 0.05%	A207133	001	Aug 30, 2016	Aug	NEWA
TAPE; TOPICAL							
CORDRAN							
	+	ALLERGAN SALES LLC 0.004MG/SQ CM	N016455	001		Apr	CAHN
<u>FLURANDRENOLIDE; NEOMYCIN SULFATE</u>							
CREAM; TOPICAL							
CORDRAN N							
	@	LILLY 0.05%;EQ 3.5MG BASE/GM	N050346	001		Mar	CMS1
OINTMENT; TOPICAL							
CORDRAN N							
	@	LILLY 0.05%;EQ 3.5MG BASE/GM	N050345	001		Mar	CMS1
<u>FLURAZEPAM HYDROCHLORIDE</u>							
CAPSULE; ORAL							
FLURAZEPAM HYDROCHLORIDE							
	@	AUROLIFE PHARMA LLC 15MG	A071716	001	Jul 31, 1991	Feb	CAHN
	@	30MG	A071717	001	Jul 31, 1991	Feb	CAHN
	@	HIKMA INTL PHARMS 15MG	A071107	001	Dec 08, 1986	May	CAHN
	@	SUN PHARM INDS 15MG	A070454	001	Aug 04, 1986	Mar	CAHN
	@	30MG	A070455	001	Aug 04, 1986	Mar	CAHN
<u>FLURBIPROFEN</u>							
TABLET; ORAL							
FLURBIPROFEN							
	@	AUROLIFE PHARMA LLC 50MG	A074448	001	Jul 28, 1995	Feb	CAHN
	@	100MG	A074448	002	Jul 28, 1995	Feb	CAHN
<u>FLUTICASONE FUROATE</u>							
POWDER; INHALATION							
ARNUIITY ELLIPTA							
	+	GLAXOSMITHKLINE 0.1MG/INH	N205625	001	Aug 20, 2014	Mar	CRLD
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE</u>							
POWDER; INHALATION							
BREO ELLIPTA							
	+	GLAXO GRP LTD 0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Mar	CRLD
<u>FLUTICASONE PROPIONATE</u>							
SPRAY, METERED; NASAL							
FLONASE							
	@	GLAXOSMITHKLINE 0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jun	DISC
<u>FLUVASTATIN SODIUM</u>							
TABLET, EXTENDED RELEASE; ORAL							
FLUVASTATIN SODIUM							
AB		MYLAN PHARMS INC EQ 80MG BASE	A202458	001	Sep 11, 2015	May	CPOT
AB		TEVA PHARMS USA EQ 80MG BASE	A079011	001	Jan 27, 2016	May	CPOT
AB		80MG	A079011	001	Jan 27, 2016	Jan	NEWA
LESCOL XL							
AB	+	NOVARTIS EQ 80MG BASE	N021192	001	Oct 06, 2000	May	CPOT

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@	NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb CAHN
@		50MG	A075900	002	Feb 23, 2006	Feb CAHN
@		100MG	A075900	003	Feb 23, 2006	Feb CAHN
@	SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002	Mar CAHN
@		50MG	A076125	002	Apr 29, 2002	Mar CAHN
@		100MG	A076125	003	Apr 29, 2002	Mar CAHN

FOLIC ACID

INJECTABLE; INJECTION

FOLVITE

@	WYETH PHARMS INC	5MG/ML	N005897	008		May CAHN
---	------------------	--------	---------	-----	--	----------

TABLET; ORAL

FOLIC ACID

@	SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005	Mar CAHN
	FOLVITE					
@	WYETH PHARMS INC	1MG	N005897	004		May CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

@	ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005	Jun DISC
@		150 IU/0.5ML	N021273	002	Aug 26, 2005	Jun DISC

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+	PEARL THERAPS INC	0.0048MG/INH; 0.0090MG/INH	N208294	001	Apr 25, 2016	Apr NEWA
---	-------------------	----------------------------	---------	-----	--------------	----------

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB	MYLAN PHARMS INC	EQ 700MG BASE	A204060	001	Apr 15, 2016	Apr NEWA
	LEXIVA					
AB	+ VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr CFTG

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

AP	+ MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010	May CFTG
	FOSAPREPITANT DIMEGLUMINE					
AP	FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016	May NEWA

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

	@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan DISC
	@		20MG	A076620	002	Oct 15, 2004	Jan DISC
	@		40MG	A076620	003	Oct 15, 2004	Jan DISC
>A>	AB	PRINSTON INC	10MG	A205670	001	Aug 29, 2016	Aug NEWA
>A>	AB		20MG	A205670	002	Aug 29, 2016	Aug NEWA
>A>	AB		40MG	A205670	003	Aug 29, 2016	Aug NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	10MG; 12.5MG	A076608	001	Dec 03, 2004	Jan DISC
@		20MG; 12.5MG	A076608	002	Dec 03, 2004	Jan DISC
@	SUN PHARM INDS LTD	10MG; 12.5MG	A076739	001	Dec 17, 2004	Feb DISC
@		20MG; 12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

>D>	AP	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Aug CRLD
>A>	AP	+	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Aug CRLD
		FOSPHENYTOIN SODIUM					
	AP	EUROHLTH INTL SARL	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jun CAHN
>D>	AP	+	FRESENIUS KABI USA	A078052	001	Aug 06, 2007	Aug DISC

INJECTABLE; INJECTION								
FOSPHENYTOIN SODIUM								
>A>	@	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Aug	DISC	
<u>FROVATRIPTAN SUCCINATE</u>								
TABLET; ORAL								
FROVATRIPTAN SUCCINATE								
AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb	NEWA	
<u>FUROSEMIDE</u>								
INJECTABLE; INJECTION								
FUROSEMIDE								
AP	AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul	NEWA	
AP	CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May	CAHN	
	@ EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan	CAHN	
TABLET; ORAL								
FUROSEMIDE								
	@ SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar	CAHN	
	@	80MG	A070100	001	Jan 26, 1988	Mar	CAHN	
LASIX								
AB	US PHARM HOLDINGS	20MG	N016273	002		Jan	CAHN	
AB		40MG	N016273	001		Jan	CAHN	
AB	+	80MG	N016273	003		Jan	CAHN	
<u>GABAPENTIN</u>								
CAPSULE; ORAL								
GABAPENTIN								
AB	SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb	NEWA	
AB		300MG	A204989	002	Feb 18, 2016	Feb	NEWA	
AB		400MG	A204989	003	Feb 18, 2016	Feb	NEWA	
	@ SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar	CAHN	
	@	300MG	A076537	002	Jun 30, 2005	Mar	CAHN	
	@	400MG	A076537	003	Jun 30, 2005	Mar	CAHN	
SOLUTION; ORAL								
GABAPENTIN								
AA	TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb	NEWA	
TABLET; ORAL								
GABAPENTIN								
AB	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan	NEWA	
AB		800MG	A205101	002	Feb 04, 2016	Jan	NEWA	
<u>GABAPENTIN ENACARBIL</u>								
TABLET, EXTENDED RELEASE; ORAL								
HORIZANT								
	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011	Jul	CAHN	
	+	600MG	N022399	001	Apr 06, 2011	Jul	CAHN	
<u>GALANTAMINE HYDROBROMIDE</u>								
CAPSULE, EXTENDED RELEASE; ORAL								
GALANTAMINE HYDROBROMIDE								
AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895	001	Aug 05, 2016	Jul	NEWA	
AB		EQ 16MG BASE	A204895	002	Aug 05, 2016	Jul	NEWA	
AB		EQ 24MG BASE	A204895	003	Aug 05, 2016	Jul	NEWA	
	@ IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC	
	@	EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC	
	@	EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC	
SOLUTION; ORAL								
GALANTAMINE HYDROBROMIDE								
	+ ROXANE	4MG/ML	A078185	001	Jan 30, 2009	May	CRLD	
	RAZADYNE							
	@ JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May	DISC	
>A>	<u>GALLIUM DOTATATE GA-68</u>							
>A>	POWDER; INTRAVENOUS							
>A>	NETSPOT							
>A>	+	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016	Aug	NEWA

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun NEWA
----	---------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar NEWA
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar NEWA
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar NEWA
AP	+ HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar CFTG
AP	+	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar CFTG
AP	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar CFTG

GEMFIBROZILTABLET;ORAL
GEMFIBROZIL

AB	CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun NEWA
----	-------------------	-------	---------	-----	--------------	----------

GLIMEPIRIDETABLET;ORAL
GLIMEPIRIDE

@	ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
@		2MG	A076995	002	Apr 27, 2010	Jan DISC
@		4MG	A076995	003	Apr 27, 2010	Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATETABLET;ORAL
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG;4MG	A078709	001	Apr 01, 2016	Mar NEWA
		2MG;4MG	A078709	002	Apr 01, 2016	Mar NEWA
		2MG;8MG	A078709	004	Apr 01, 2016	Mar NEWA
		4MG;4MG	A078709	003	Apr 01, 2016	Mar NEWA
		4MG;8MG	A078709	005	Apr 01, 2016	Mar NEWA

GLYBURIDETABLET;ORAL
GLYBURIDE

AB1	PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr NEWA
AB1		2.5MG	A203581	002	Apr 14, 2016	Apr NEWA
AB1		5MG	A203581	003	Apr 14, 2016	Apr NEWA
AB1	ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr NEWA
AB1		2.5mg	A206749	002	May 10, 2016	Apr NEWA
AB1		5MG	A206749	003	May 10, 2016	Apr NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET;ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	COREPHARMA	1.25MG;250MG	A076731	001	Nov 19, 2004	Jan DISC
@		2.5MG;500MG	A076731	002	Nov 19, 2004	Jan DISC
@		5MG;500MG	A076731	003	Nov 19, 2004	Jan DISC
>A> AB	IMPAX LABS INC	1.25MG;250MG	A076345	001	Feb 18, 2004	Aug CAHN
>A> AB		2.5MG;500MG	A076345	002	Feb 18, 2004	Aug CAHN
>A> AB		5MG;500MG	A076345	003	Feb 18, 2004	Aug CAHN
>D> AB	IVAX SUB TEVA PHARMS	1.25MG;250MG	A076345	001	Feb 18, 2004	Aug CAHN
>D> AB		2.5MG;500MG	A076345	002	Feb 18, 2004	Aug CAHN
>D> AB		5MG;500MG	A076345	003	Feb 18, 2004	Aug CAHN
AB	ZYDUS PHARMS USA INC	1.25MG;250MG	A206748	001	Feb 29, 2016	Feb NEWA
AB		2.5MG;500MG	A206748	002	Feb 29, 2016	Feb NEWA
AB		5MG;500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATEINJECTABLE;INJECTION
GLYCOPYRROLATE

AP	+ HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
----	----------------------	----------	---------	-----	--------------	----------

TABLET;ORAL
GLYCOPYRROLATE

@	HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009	May CAHN
@		2MG	A040836	002	Mar 05, 2009	May CAHN
AA	NATCO PHARMA LTD	1MG	A091413	001	Jun 20, 2016	Jun NEWA

TABLET;ORAL
GLYCOPYRROLATE

AA		2MG	A091413	002	Jun 20, 2016	Jun NEWA
AA	RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN
AA		2MG	A040821	002	Dec 29, 2008	Jan CAHN
	ROBINUL					
AA	+ CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN
	ROBINUL FORTE					
AA	+ CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL
SANCUSO

>A>	+ KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008	Aug CAHN
>D>	+ PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008	Aug CAHN
>A>	INJECTION, EXTENDED RELEASE;SUBCUTANEOUS					
>A>	SUSTOL					
>A>	+ HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun NEWA
AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@ CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	May CAHN
AP	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun CAHN
AP	HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

TABLET;ORAL
GRANISETRON HYDROCHLORIDE

@ COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
--------------	-------------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
HYCOFENIX

+ MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
------------------------	------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

@ IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
@	EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
@	EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
@	EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL
ULTRAVATE

+ SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun CAHN
------------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

@ CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
@ FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Jul CAHN
@	1MG	A071157	001	Jan 02, 1987	Jul CAHN
@	2MG	A071172	001	Jan 02, 1987	Jul CAHN
@	5MG	A071212	001	Jan 07, 1988	Jul CAHN
@	10MG	A071173	001	Jan 07, 1988	Jul CAHN
@ SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
@	1MG	A071157	001	Jan 02, 1987	Jun CAHN
@	2MG	A071172	001	Jan 02, 1987	Mar CAHN
@	5MG	A071212	001	Jan 07, 1988	Mar CAHN
@	10MG	A071173	001	Jan 07, 1988	Mar CAHN

TABLET;ORAL
HALOPERIDOL

@	20MG	A071177	001	Jan 07, 1988	Mar CAHN
@ VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
@	1MG	A071235	003	Nov 03, 1986	Jan CMS1
@	5MG	A071235	004	Nov 03, 1986	Jan CMS1
@	10MG	A071235	005	Jul 20, 1987	Jan CMS1

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

AP	FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May NEWA
----	--------------------	----------------	---------	-----	--------------	----------

HEXACHLOROPHENE

EMULSION;TOPICAL
PHISOHEX

@ SANOFI AVENTIS US	3%	N006882	001		May DISC
---------------------	----	---------	-----	--	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
@ ACTAVIS ELIZABETH 1.5MG;5MG

A040295	001	Dec 01, 2000	Jan CMS1
---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
----	---------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

@ ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC
@	25MG	A091679	002	Mar 04, 2013	Apr DISC
@	50MG	A091679	003	Mar 04, 2013	Apr DISC
@	100MG	A091679	004	Mar 04, 2013	Apr DISC
@ FRONTIDA BIOPHARM	10MG	A089359	001	Jul 25, 1986	Jul CAHN
@	25MG	A089258	001	May 05, 1986	Jul CAHN
@	50MG	A089259	001	May 05, 1986	Jul CAHN
@	100MG	A088729	001	Apr 11, 1985	Jul CAHN
@ SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar CAHN
@	25MG	A089258	001	May 05, 1986	Mar CAHN
@	50MG	A089259	001	May 05, 1986	Mar CAHN
@	100MG	A088729	001	Apr 11, 1985	Jun CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
HYDRALAZINE AND HYDROCHLOROTHIAZIDE
@ WATSON LABS 25MG;15MG

A085827	001		Feb CMS1
---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
@ SUN PHARM INDS 25MG;15MG;0.1MG

A088570	001	Apr 10, 1984	Mar CAHN
---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL
HYDROCHLOROTHIAZIDE

>D> AB	LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Aug DISC
>A>	@	12.5MG	A091662	001	Jan 27, 2012	Aug DISC
AB	+ ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN
	TABLET;ORAL					
	HYDROCHLOROTHIAZIDE					
	@ AUROLIFE PHARMA LLC	25MG	A083899	001		Feb CAHN
	@	50MG	A085219	001		Feb CAHN
	@ HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006	May CAHN
AB		50MG	A084878	001		May CAHN
>D> AB	LANNETT	25MG	A084325	001		Aug DISC
>A>	@	25MG	A084325	001		Aug DISC
>D> AB		50MG	A084324	001		Aug DISC
>A>	@	50MG	A084324	001		Aug DISC
	@ SUN PHARM INDS	25MG	A083972	001		Mar CAHN
	@	50MG	A083972	002		Mar CAHN
	@	100MG	A083972	003		Mar CAHN

TABLET;ORAL
ORETIC

@ ABBVIE 50MG N011971 002 Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	25MG;300MG	A203630	003	Mar 31, 2016	Mar NEWA
AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016	Jan NEWA
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Jan NEWA
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar CTEC
		25MG;300MG	A203036	003	Jan 15, 2016	Jan NEWA
AB	MYLAN PHARMS INC	25MG;300MG	A077969	003	Jul 20, 2016	Jul NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

ZESTORETIC

AB	ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan CAHN
AB	+	12.5MG;20MG	N019888	001	Sep 20, 1990	Jan CAHN
AB	+	25MG;20MG	N019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	TEVA	25MG;15MG	A076980	002	Mar 07, 2007	Aug CRLD
>A>	AB	+	25MG;15MG	A076980	002	Mar 07, 2007	Aug CRLD
>D>		UNIRETIC					
>D>	AB	UCB INC	12.5MG;7.5MG	N020729	001	Jun 27, 1997	Aug DISC
>A>		@	12.5MG;7.5MG	N020729	001	Jun 27, 1997	Aug DISC
>D>	AB		12.5MG;15MG	N020729	003	Feb 14, 2002	Aug DISC
>A>		@	12.5MG;15MG	N020729	003	Feb 14, 2002	Aug DISC
>D>	AB	+	25MG;15MG	N020729	002	Jun 27, 1997	Aug DISC
>A>		@	25MG;15MG	N020729	002	Jun 27, 1997	Aug DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS	25MG;25MG	A089534	001	Jul 02, 1987	Mar CAHN
----	----------------	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016	Jan NEWA
AB		12.5MG;160MG	A206083	002	Feb 08, 2016	Jan NEWA
AB		12.5MG;320MG	A206083	003	Feb 08, 2016	Jan NEWA
AB		25MG;160MG	A206083	004	Feb 08, 2016	Jan NEWA
AB		25MG;320MG	A206083	005	Feb 08, 2016	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

	@	ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010	Jan DISC
AB		AUROLIFE PHARMA LLC	7.5MG;200MG	A204575	001	Jun 02, 2016	May NEWA

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

AB	PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr NEWA
AB		10MG	A207029	002	Apr 26, 2016	Apr NEWA
AB		20MG	A207029	003	Apr 26, 2016	Apr NEWA

HYDROCORTISONE VALERATE

CREAM;TOPICAL

WESTCORT

	@	RANBAXY LABS LTD	0.2%	N017950	001		Jul CAHN
	@	SUN PHARM INDS LTD	0.2%	N017950	001		Jun CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OTIC
PEDIOTIC

@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Jan DISC
------------------	--	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016	May NEWA
AB		4MG	A205814	002	May 13, 2016	May NEWA
AB		8MG	A205814	003	May 13, 2016	May NEWA
>A> AB	MALLINCKRODT	2MG	A076855	002	Sep 19, 2007	Aug NEWA
>A> AB		4MG	A076855	003	Sep 19, 2007	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL
EXALGO

AB	+ MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Jun CFTG
HYDROMORPHONE HYDROCHLORIDE						
AB	ACTAVIS LABS FL INC	32MG	A202144	004	Jun 30, 2016	Jun NEWA
AB	OSMOTICA	8MG	A205629	001	Jul 07, 2016	Jun NEWA
AB		12MG	A205629	002	Jul 07, 2016	Jun NEWA
AB		16MG	A205629	003	Jul 07, 2016	Jun NEWA
AB		32MG	A205629	004	Jul 07, 2016	Jun NEWA

HYDROXOCOBALAMININJECTABLE;INJECTION
CYANOKIT

@ SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Jan CAHN
+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Jan CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb CMFD
----	-------------	-------	---------	-----	--------------	----------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION

HYDROXYPROGESTERONE CAPROATE

@ ALLERGAN SALES LLC	125MG/ML	N017439	001		Jul CAHN	
@	250MG/ML	N017439	002		Jul CAHN	
+ ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015	Jan CAHN	
SOLUTION;INTRAMUSCULAR						
MAKENA						
+ AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun CAHN	
+	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Jun CAHN	
+ LUMARA HEALTH INC	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Feb NEWA	
MAKENA PRESERVATIVE FREE						
+ AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	003	Jul 15, 2016	Jul NEWA	

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	10MG	A087869	001	Dec 20, 1982	Feb CAHN	
@	25MG	A087870	001	Dec 20, 1982	Feb CAHN	
@	50MG	A087871	001	Dec 20, 1982	Feb CAHN	
AB	ECI PHARMS LLC	10MG	A040804	001	Jun 30, 2008	May CAHN
AB		25MG	A040804	002	Jun 30, 2008	May CAHN
AB		50MG	A040804	003	Jun 30, 2008	May CAHN
AB	ELITE LABS INC	10MG	A040604	002	Dec 28, 2004	Jun NEWA
AB		25MG	A040604	003	Dec 28, 2004	Jun NEWA
@ SUN PHARM INDS	10MG	A089381	001	May 19, 1986	Mar CAHN	
@	25MG	A089382	001	May 19, 1986	Mar CAHN	
@	50MG	A089383	001	May 19, 1986	Mar CAHN	
@	100MG	A087862	001	Apr 18, 1983	Mar CAHN	

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

>A> AB	IMPAX LABS INC	EQ 25MG HCL	A040156	001	Jul 15, 1996	Aug CAHN
>A> AB		EQ 50MG HCL	A040156	002	Jul 15, 1996	Aug CAHN
>D> AB	WATSON LABS	EQ 25MG HCL	A040156	001	Jul 15, 1996	Aug CAHN

CAPSULE;ORAL					
HYDROXYZINE PAMOATE					
>D>	AB	EQ 50MG HCL	A040156	002	Jul 15, 1996 Aug CAHN
<u>IBANDRONATE SODIUM</u>					
INJECTABLE;INTRAVENOUS					
IBANDRONATE SODIUM					
AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016 Jan NEWA
TABLET;ORAL					
IBANDRONATE SODIUM					
AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016 Feb NEWA
AB	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012 Mar CAHN
<u>IBUPROFEN</u>					
TABLET;ORAL					
IBUPROFEN					
	@ AUROLIFE PHARMA LLC	300MG	A070734	001	Jun 12, 1986 Feb CAHN
	@	400MG	A070735	001	Jun 12, 1986 Feb CAHN
	@	600MG	A070736	001	Jun 12, 1986 Feb CAHN
	@	800MG	A071938	001	Jan 14, 1988 Mar CAHN
	@ J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986 Jul CAHN
AB	STRIDES PHARMA	400MG	A078329	001	Feb 05, 2009 May CAHN
AB		600MG	A078329	002	Feb 05, 2009 May CAHN
AB		800MG	A078329	003	Feb 05, 2009 May CAHN
	@ SUN PHARM INDS	400MG	A070079	001	Jul 24, 1985 Mar CAHN
	@	600MG	A070080	001	Jul 24, 1985 Mar CAHN
	@	800MG	A071448	001	Feb 18, 1987 Mar CAHN
<u>IBUPROFEN LYSINE</u>					
INJECTABLE;INTRAVENOUS					
IBUPROFEN LYSINE					
AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016 Mar NEWA
AP	+ NEOPROFEN				
AP	+ RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006 Mar CFTG
<u>IDOXURIDINE</u>					
SOLUTION/DROPS;OPHTHALMIC					
DENDRID					
>D>	+ ALCON	0.1%	N014169	001	Aug CTEC
>A>	+	0.1%	N014169	001	Aug CTEC
>D>	HERPLEX				
>D>	+ ALLERGAN	0.1%	N013935	002	Aug DISC
>A>	@	0.1%	N013935	002	Aug DISC
<u>IMATINIB MESYLATE</u>					
TABLET;ORAL					
IMATINIB MESYLATE					
AB	APOTEX INC	EQ 100MG BASE	A079179	001	Aug 05, 2016 Jul NEWA
AB		EQ 400MG BASE	A079179	002	Aug 05, 2016 Jul NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A204285	001	Aug 04, 2016 Jul NEWA
AB		EQ 400MG BASE	A204285	002	Aug 04, 2016 Jul NEWA
<u>IMIPRAMINE HYDROCHLORIDE</u>					
TABLET;ORAL					
IMIPRAMINE HYDROCHLORIDE					
AB	SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990 Mar CAHN
AB		25MG	A081049	001	Jun 05, 1990 Mar CAHN
AB		50MG	A081050	001	Jun 05, 1990 Mar CAHN
<u>IMIPRAMINE PAMOATE</u>					
CAPSULE;ORAL					
IMIPRAMINE PAMOATE					
AB	+ ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010 Feb CRLD
<u>INDIUM IN-111 CHLORIDE</u>					
INJECTABLE;INJECTION					
INDIUM IN 111 CHLORIDE					
	+ MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994 Jan CAHN

<u>INDIUM IN-111 OXYQUINOLINE</u>							
INJECTABLE; INJECTION							
INDIUM IN 111 OXYQUINOLINE							
	+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar CMS1
<u>INDIUM IN-111 PENTETREOTIDE KIT</u>							
INJECTABLE; INJECTION							
OCTREOSCAN							
	+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
<u>INDOCYANINE GREEN</u>							
INJECTABLE; INJECTION							
INDOCYANINE GREEN							
AP		DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan CAHN
<u>INDOMETHACIN SODIUM</u>							
INJECTABLE; INJECTION							
INDOMETHACIN SODIUM							
AP		HOSPIRA INC	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Apr NEWA
<u>INSULIN DETEMIR RECOMBINANT</u>							
INJECTABLE; SUBCUTANEOUS							
LEVEMIR FLEXPEN							
	@	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb DISC
<u>INSULIN HUMAN</u>							
SOLUTION; SUBCUTANEOUS							
HUMULIN R							
	+	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan CAIN
HUMULIN R KWIKPEN							
	+	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan NEWA
<u>INSULIN RECOMBINANT HUMAN</u>							
POWDER; INHALATION							
AFREZZA							
		MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar CAHN
	+		8 UNITS/INH	N022472	002	Jun 27, 2014	Mar CAHN
			12 UNITS/INH	N022472	003	Apr 17, 2015	Mar CAHN
<u>IOXILAN</u>							
INJECTABLE; INJECTION							
OXILAN-300							
	@	GUERBET	62%	N020316	001	Dec 21, 1995	Jun DISC
OXILAN-350							
	@	GUERBET	73%	N020316	002	Dec 21, 1995	Jun DISC
<u>IPRATROPIUM BROMIDE</u>							
SOLUTION; INHALATION							
IPRATROPIUM BROMIDE							
	@	MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Jul DISC
AN	+	RTEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul CRLD
<u>IRBESARTAN</u>							
TABLET; ORAL							
IRBESARTAN							
AB		HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May NEWA
AB			150MG	A206194	002	Jun 14, 2016	May NEWA
AB			300MG	A206194	003	Jun 14, 2016	May NEWA
<u>IRINOTECAN HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
CAMPTOSAR							
AP	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr CTEC
IRINOTECAN HYDROCHLORIDE							
AP		EUROHLTH INTL SARL	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun CAHN
AP			100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun CAHN
AP		QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr NEWA
AP			100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr NEWA
AP			300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr NEWA
AP		SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan CAHN
AP			100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan CAHN

IRON DEXTRANINJECTABLE;INJECTION
INFED

BP + ALLERGAN SALES LLC EQ 50MG IRON/ML N017441 001 Apr CAHN

ISONIAZIDTABLET;ORAL
ISONIAZID

AA	MIKART	100MG	A040090	001	Jun 26, 1997	Jun	CMFD
AA		300MG	A040090	002	Jun 26, 1997	Jun	CMFD
	@ SUN PHARM INDS	100MG	A080136	001		Mar	CAHN
	@	300MG	A083633	001		Mar	CAHN

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE;ORAL
DILATRATE-SR

+	AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Mar	CAHN
+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Jul	CAHN

TABLET;ORAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar	CAHN
@		10MG	A086169	001	Sep 19, 1986	Jun	CAHN
@		20MG	A086167	001	Sep 19, 1986	Jun	CAHN
@		30MG	A087564	001	Sep 18, 1986	Jun	CAHN

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun	CAHN
@		5MG	A086168	001	Sep 18, 1986	Jun	CAHN
@		10MG	A087545	001	Sep 18, 1986	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

@	COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar	DISC
+	SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar	CTEC

ISOSULFAN BLUEINJECTABLE;INJECTION
ISOSULFAN BLUE

AP	AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan	NEWA
AP	+ MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan	CTEC

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA

>A> BX	RANBAXY	10MG	N021951	001	May 25, 2012	Aug	CAHN
>A> BX		20MG	N021951	002	May 25, 2012	Aug	CAHN
>A>		25MG	N021951	005	Aug 15, 2014	Aug	CAHN
>A> BX		30MG	N021951	003	May 25, 2012	Aug	CAHN
>A>		35MG	N021951	006	Aug 15, 2014	Aug	CAHN
>A> BX	+	40MG	N021951	004	May 25, 2012	Aug	CAHN
>D> BX	RANBAXY LABS LTD	10MG	N021951	001	May 25, 2012	Aug	CAHN
BX		10MG	N021951	001	May 25, 2012	Jul	CAHN
>D> BX		20MG	N021951	002	May 25, 2012	Aug	CAHN
BX		20MG	N021951	002	May 25, 2012	Jul	CAHN
>D>		25MG	N021951	005	Aug 15, 2014	Aug	CAHN
>A>		25MG	N021951	005	Aug 15, 2014	Aug	CAHN
		25MG	N021951	005	Aug 15, 2014	Jul	CAHN
>D> BX		30MG	N021951	003	May 25, 2012	Aug	CAHN
BX		30MG	N021951	003	May 25, 2012	Jul	CAHN
>D>		35MG	N021951	006	Aug 15, 2014	Aug	CAHN
>A>		35MG	N021951	006	Aug 15, 2014	Aug	CAHN
		35MG	N021951	006	Aug 15, 2014	Jul	CAHN
>D> BX	+	40MG	N021951	004	May 25, 2012	Aug	CAHN
BX	+	40MG	N021951	004	May 25, 2012	Jul	CAHN

ITRACONAZOLECAPSULE;ORAL
ITRACONAZOLE

AB ACCORD HLTHCARE 100MG A205991 001 May 26, 2016 May NEWA

SOLUTION;ORAL

ITRACONAZOLE

@ AMNEAL PHARMS 10MG/ML A205573 001 Oct 30, 2015 Apr DISC

SOLUTION;ORAL									
SPORANOX									
	+ JANSSEN PHARMS	10MG/ML		N020657	001	Feb 21, 1997	Apr	CTEC	
<u>IVERMECTIN</u>									
LOTION;TOPICAL									
SKLICE									
	+ ARBOR PHARMS LLC	0.5%		N202736	001	Feb 07, 2012	May	CAHN	
<u>KETOCONAZOLE</u>									
TABLET;ORAL									
KETOCONAZOLE									
	@ SUN PHARM INDS	200MG		A075314	001	Jun 15, 1999	Jan	CAHN	
<u>KETOPROFEN</u>									
CAPSULE;ORAL									
KETOPROFEN									
	@ AUROLIFE PHARMA LLC	50MG		A074024	001	Dec 29, 1995	Feb	CAHN	
	@	75MG		A074024	002	Dec 29, 1995	Feb	CAHN	
<u>KETOROLAC TROMETHAMINE</u>									
INJECTABLE;INJECTION									
KETOROLAC TROMETHAMINE									
	@ EUROHLTH INTL SARL	15MG/ML		A075222	001	Apr 26, 1999	Apr	CAHN	
	@	30MG/ML		A075222	002	Apr 26, 1999	Apr	CAHN	
	@	30MG/ML		A075228	001	Apr 26, 1999	May	CAHN	
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE</u>									
SOLUTION;IRRIGATION									
OMIDRIA									
>A>	+ OMEROS	EQ 0.3% BASE;EQ 1% BASE		N205388	001	May 30, 2014	Aug	CPOT	
>D>	+	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML		N205388	001	May 30, 2014	Aug	CPOT	
<u>LABETALOL HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
LABETALOL HYDROCHLORIDE									
AP	SAGENT STRIDES	5MG/ML		A079134	001	Feb 03, 2010	Jan	CTNA	
TRANDATE									
	@ SEBELA IRELAND LTD	5MG/ML		N019425	001	Dec 31, 1985	Jan	CAHN	
TABLET;ORAL									
LABETALOL HYDROCHLORIDE									
AB	NOSTRUM LABS INC	100MG		A075215	001	Jul 29, 1999	Jan	CAHN	
AB		200MG		A075215	002	Jul 29, 1999	Jan	CAHN	
AB		300MG		A075215	003	Jul 29, 1999	Jan	CAHN	
<u>LACOSAMIDE</u>									
SOLUTION;ORAL									
LACOSAMIDE									
AA	AMNEAL PHARMS	10MG/ML		A204839	001	Apr 28, 2016	Apr	NEWA	
VIMPAT									
AA	+ UCB INC	10MG/ML		N022255	001	Apr 20, 2010	Apr	CFTG	
TABLET;ORAL									
LACOSAMIDE									
AB	ACTAVIS LABS FL INC	50MG		A204855	001	Apr 28, 2016	Apr	NEWA	
AB		100MG		A204855	002	Apr 28, 2016	Apr	NEWA	
AB		150MG		A204855	003	Apr 28, 2016	Apr	NEWA	
AB		200MG		A204855	004	Apr 28, 2016	Apr	NEWA	
AB	ALEMBIC PHARMS LTD	50MG		A204974	001	Apr 28, 2016	Apr	NEWA	
AB		100MG		A204974	002	Apr 28, 2016	Apr	NEWA	
AB		150MG		A204974	003	Apr 28, 2016	Apr	NEWA	
AB		200MG		A204974	004	Apr 28, 2016	Apr	NEWA	
>A>	AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	Aug	NEWA	
>A>	AB		100MG	A204857	002	Sep 09, 2016	Aug	NEWA	
>A>	AB		150MG	A204857	003	Sep 09, 2016	Aug	NEWA	
>A>	AB		200MG	A204857	004	Sep 09, 2016	Aug	NEWA	
AB	AUROBINDO PHARMA LTD	50MG		A204994	001	Apr 28, 2016	Apr	NEWA	
AB		100MG		A204994	002	Apr 28, 2016	Apr	NEWA	
AB		150MG		A204994	003	Apr 28, 2016	Apr	NEWA	
AB		200MG		A204994	004	Apr 28, 2016	Apr	NEWA	
AB	MSN LABS PVT LTD	50MG		A204921	001	Apr 28, 2016	Apr	NEWA	
AB		100MG		A204921	002	Apr 28, 2016	Apr	NEWA	

TABLET;ORAL
LACOSAMIDE

AB		150MG	A204921	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204921	004	Apr 28, 2016	Apr NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205026	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205026	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205026	004	Apr 28, 2016	Apr NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr NEWA
	VIMPAT					
AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr CFTG

LACTULOSE

SOLUTION;ORAL
CONSTULOSE

>D>		CONSTULOSE						
>D>	AA	+	ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988	Aug DISC
>A>			@	10GM/15ML	A070288	001	Aug 15, 1988	Aug DISC
			LACTULOSE					
>D>	AA		HI TECH PHARMA	10GM/15ML	A074076	001	Jul 03, 1995	Aug CRLD
>A>	AA	+		10GM/15ML	A074076	001	Jul 03, 1995	Aug CRLD

LAMIVUDINE

TABLET;ORAL
LAMIVUDINE

AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb NEWA
AB		300MG	A204528	002	Mar 04, 2016	Feb NEWA

LAMOTRIGINE

TABLET;ORAL
LAMOTRIGINE

AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009	Jun CAHN
AB		100MG	A079132	002	Jan 27, 2009	Jun CAHN
AB		150MG	A079132	003	Jan 27, 2009	Jun CAHN
AB		200MG	A079132	004	Jan 27, 2009	Jun CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	LAMICTAL XR					
AB	+ GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan CRLD
	TABLET, ORALLY DISINTEGRATING;ORAL					
	LAMOTRIGINE					
AB	SCIEGEN PHARMS INC	25MG	A206382	001	Jun 17, 2016	Jun NEWA
AB		50MG	A206382	002	Jun 17, 2016	Jun NEWA
AB		100MG	A206382	003	Jun 17, 2016	Jun NEWA
AB		200MG	A206382	004	Jun 17, 2016	Jun NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	ANCHEN PHARMS	15MG	A203203	001	Jul 25, 2016	Jul NEWA
AB		30MG	A203203	002	Jul 25, 2016	Jul NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT	FDC LTD	0.005%	A202442	001	Apr 22, 2016	Apr NEWA
----	---------	--------	---------	-----	--------------	----------

LESINURAD

TABLET;ORAL
ZURAMPIC

>D>		+ ARDEA BIOSCIENCES	200MG	N207988	001	Dec 22, 2015	Aug CAHN
>A>		+ IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Aug CAHN

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016	May NEWA
AB	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan CAHN

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

@	IDT AUSTRALIA LTD	EQ 15MG BASE	A075327	001	Mar 24, 1999	May CAHN
	ROXANE	EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun CTEC

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>A>	AN	IMPAX LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug CAHN
>A>	AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug CAHN
>A>	AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug CAHN
	AN	RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar NEWA
	AN		EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar NEWA
	AN		EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar NEWA
>D>	AN	WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug CAHN
>D>	AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug CAHN
>D>	AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan NEWA
AP	JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb NEWA	
AB		750MG	A204511	002	Feb 23, 2016	Feb NEWA	
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May NEWA	
AB		750MG	A202095	001	Jun 06, 2016	May NEWA	
>A>	AB	NOSTRUM LABS INC	500MG	A204754	001	Aug 26, 2016	Aug NEWA
>A>	AB		750MG	A204754	002	Aug 26, 2016	Aug NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar CAHN	
AB		750MG	A091285	002	Sep 12, 2011	Mar CAHN	

TABLET, FOR SUSPENSION; ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb CDFR
		500MG	N207958	002	Jul 31, 2015	Feb CDFR
		750MG	N207958	003	Jul 31, 2015	Feb CDFR
+		1GM	N207958	004	Jul 31, 2015	Mar CRLD
		1GM	N207958	004	Jul 31, 2015	Feb CDFR

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

AT	ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Jul CAHN
----	----------------	-------	---------	-----	--------------	----------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	JANSSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun DISC
@		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun DISC
@		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT	+	RIISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan CAHN
----	---	--------------------	------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUMPOWDER; IV (INFUSION)
FUSILEV

AP	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun CFTG
		LEVOLEUCOVORIN CALCIUM					
AP		EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jun NEWA

LEVONORGESTRELTABLET; ORAL
LEVONORGESTREL

>A>	AB	JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016	Aug NEWA
>A>	AB	LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Aug NEWA
>D>	+	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Aug CTEC
>A>	AB	+	0.75MG	A090740	001	Dec 30, 2010	Aug CTEC
		+	0.75MG	A090740	001	Dec 30, 2010	Apr CRLD

LEVOTHYROXINE SODIUMPOWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

AP		FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun NEWA
AP			500MCG/VIAL	A206163	002	Jun 29, 2016	Jun NEWA
AP	+	FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun CFTG
AP	+		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun CFTG

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOLET

@	LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Jul CAHN
@		0.05MG	N021137	002	Jun 06, 2003	Jul CAHN
@		0.075MG	N021137	003	Jun 06, 2003	Jul CAHN
@		0.088MG	N021137	004	Jun 06, 2003	Jul CAHN
@		0.1MG	N021137	005	Jun 06, 2003	Jul CAHN
@		0.112MG	N021137	006	Jun 06, 2003	Jul CAHN
@		0.125MG	N021137	007	Jun 06, 2003	Jul CAHN
@		0.137MG	N021137	008	Jun 06, 2003	Jul CAHN
@		0.15MG	N021137	009	Jun 06, 2003	Jul CAHN
@		0.175MG	N021137	010	Jun 06, 2003	Jul CAHN
@		0.2MG	N021137	011	Jun 06, 2003	Jul CAHN
@		0.3MG	N021137	012	Jun 06, 2003	Jul CAHN

LEVOTHROID

@	LLOYD	0.025MG	N021116	001	Oct 24, 2002	May DISC
@		0.05MG	N021116	002	Oct 24, 2002	May DISC
@		0.075MG	N021116	003	Oct 24, 2002	May DISC
@		0.088MG	N021116	010	Oct 24, 2002	May DISC
@		0.1MG	N021116	004	Oct 24, 2002	May DISC
@		0.112MG	N021116	011	Oct 24, 2002	May DISC
@		0.125MG	N021116	005	Oct 24, 2002	May DISC
@		0.137MG	N021116	012	Dec 07, 2004	May DISC
@		0.15MG	N021116	006	Oct 24, 2002	May DISC
@		0.175MG	N021116	007	Oct 24, 2002	May DISC
@		0.2MG	N021116	008	Oct 24, 2002	May DISC
@		0.3MG	N021116	009	Oct 24, 2002	May DISC

LEVOTHYROXINE SODIUM

AB1,		MYLAN	0.3MG	A076187	011	Jun 05, 2002	May CRLD
AB2,							
AB3,							
AB4,	+						

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

>A>	AT	GLENMARK PHARMS LTD	5%	A206498	001	Sep 09, 2016	Aug NEWA
	AT	SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun CAHN
	AT	TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	400MG/100ML	N018388	002			Feb DISC
---	---------	-------------	---------	-----	--	--	----------

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 800MG/100ML N018388 003 Nov 05, 1982 Feb DISC

JELLY;TOPICAL

ANESTACON

@ BIONPHARMA INC 2% A080429 001 Jan CAHN

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

>D> AT VINTAGE 2% A040708 001 Feb 27, 2007 Aug CRLD

>A> AT + 2% A040708 001 Feb 27, 2007 Aug CRLD

>D> XYLOCAINE VISCOUS

>D> AT + FRESENIUS KABI USA 2% N009470 001 Aug DISC

>A> @ 2% N009470 001 Aug DISC

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT TELIGENT PHARMA INC 4% A204494 001 Mar 12, 2014 May CAHN

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

XIIDRA

+ SHIRE DEV LLC 5% N208073 001 Jul 11, 2016 Jul NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

JENTADUETO XR

BOEHRINGER INGELHEIM 2.5MG;1GM N208026 001 May 27, 2016 May NEWA

+ 5MG;1GM N208026 002 May 27, 2016 May NEWA

LINEZOLID

SOLUTION;IV (INFUSION)

LINEZOLID

AP AUROBINDO PHARMA LTD 600MG/300ML (2MG/ML) A206917 001 Aug 04, 2016 Jul NEWA

AP FRESENIUS KABI USA 600MG/300ML (2MG/ML) A204764 001 Mar 15, 2016 Feb NEWA

TABLET;ORAL

LINEZOLID

AB GATE PHARMS 600MG A091210 001 Feb 05, 2016 Jan NEWA

AB GLENMARK PHARMS 600MG A078987 001 Dec 21, 2015 Mar CAHN

>A> AB NOVEL LABS INC 600MG A207526 001 Aug 22, 2016 Aug NEWA

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

AB MAYNE PHARMA INC EQ 0.005MG BASE A090097 001 Mar 20, 2009 Mar CAHN

AB EQ 0.025MG BASE A090097 002 Mar 20, 2009 Mar CAHN

AB EQ 0.05MG BASE A090097 003 Mar 20, 2009 Mar CAHN

AB SUN PHARM INDS LTD EQ 0.005MG BASE A091382 001 Apr 20, 2016 Apr NEWA

AB EQ 0.025MG BASE A091382 002 Apr 20, 2016 Apr NEWA

AB EQ 0.05MG BASE A091382 003 Apr 20, 2016 Apr NEWA

LISINOPRIL

SOLUTION;ORAL

QBRELIS

+ SILVERGATE PHARMS 1MG/ML N208401 001 Jul 29, 2016 Jul NEWA

TABLET;ORAL

ZESTRIL

AB ALVOGEN MALTA 2.5MG N019777 005 Apr 29, 1993 Jan CAHN

AB 5MG N019777 001 May 19, 1988 Jan CAHN

AB 10MG N019777 002 May 19, 1988 Jan CAHN

AB 20MG N019777 003 May 19, 1988 Jan CAHN

AB 30MG N019777 006 Jan 20, 1999 Jan CAHN

AB + 40MG N019777 004 May 19, 1988 Jan CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB DELCOR ASSET CORP 150MG A076243 002 Feb 24, 2003 Feb CAHN

AB 300MG A076243 001 Jun 27, 2002 Feb CAHN

AB 600MG A078763 001 Apr 15, 2008 Feb CAHN

AB HIKMA PHARMS 600MG A078763 001 Apr 15, 2008 Jan CMFD

LIXISENATIDESOLUTION; SUBCUTANEOUS
ADLYXIN

>D>	+	SANOFI-AVENTIS US	0.05MG/ML	N208471	001	Jul 27, 2016	Aug CPOT
>A>	+		0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016	Aug CPOT
	+		0.05MG/ML	N208471	001	Jul 27, 2016	Jul NEWA
>D>	+		0.1MG/ML	N208471	002	Jul 27, 2016	Aug CPOT
	+		0.1MG/ML	N208471	002	Jul 27, 2016	Jul NEWA
>A>	+		0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016	Aug CPOT

LOMITAPIDE MESYLATECAPSULE; ORAL
JUXTAPID

AEGERION

+

EQ 20MG BASE
EQ 60MG BASE

N203858	003	Dec 21, 2012	Jan CRLD
N203858	006	Apr 23, 2015	Jan CRLD

LOPERAMIDE HYDROCHLORIDECAPSULE; ORAL
IMODIUM

@ J AND J CONSUMER INC 2MG

N017694	001		Feb DISC
---------	-----	--	----------

LOPERAMIDE HYDROCHLORIDE

AB + MYLAN 2MG

A072741	001	Sep 18, 1991	Feb CRLD
---------	-----	--------------	----------

LORAZEPAMTABLET; ORAL
LORAZEPAM

@ FRONTIDA BIOPHARM 2MG

A072555	001	Mar 29, 1991	Jul CAHN
---------	-----	--------------	----------

LORCASERIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
BELVIQ XR

+ EISAI INC 20MG

N208524	001	Jul 15, 2016	Jul NEWA
---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

BX		HETERO LABS LTD V	25MG
BX			50MG
BX			100MG
BX		LUPIN LTD	25MG
BX			50MG
BX			100MG

A203835	001	Aug 12, 2015	Apr CTEC
A203835	002	Aug 12, 2015	Apr CTEC
A203835	003	Aug 12, 2015	Apr CTEC
A078232	001	Oct 06, 2010	Apr CTEC
A078232	002	Oct 06, 2010	Apr CTEC
A078232	003	Oct 06, 2010	Apr CTEC

LOVASTATINTABLET; ORAL
LOVASTATIN

AB		SUN PHARM INDS	10MG
AB			20MG
AB			40MG

A077520	001	Apr 14, 2006	Mar CAHN
A077520	002	Apr 14, 2006	Mar CAHN
A077520	003	Apr 14, 2006	Mar CAHN

LOXAPINEPOWDER; INHALATION
ADASUVE

+ ALEXZA PHARMS 10MG

N022549	001	Dec 21, 2012	Feb CAHN
---------	-----	--------------	----------

LUCINACTANTSUSPENSION; INTRATRACHEAL
SURFAXIN

>D>		@ DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	Aug CAHN
>A>		@ WINDTREE THERAP	8.5ML	N021746	001	Mar 06, 2012	Aug CAHN

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	1GM/100ML
AP	+	HOSPIRA	1GM/100ML
AP		HQ SPCLT PHARMA	1GM/100ML

A206486	001	Mar 07, 2016	Feb NEWA
N020488	001	Jul 11, 1995	Feb CFTG
A207349	001	Mar 02, 2016	Feb NEWA

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	4GM/100ML (40MG/ML)
AP			4GM/50ML (80MG/ML)
AP			2GM/50ML (40MG/ML)

A206485	001	Mar 15, 2016	Feb NEWA
A206485	002	Mar 15, 2016	Feb NEWA
A206485	003	Mar 15, 2016	Mar NEWA

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar NEWA
AP		40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar NEWA
AP	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar CFTG
AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar CFTG

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

>A>		EMVERM				
>A>	+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995 Aug CTNA
>D>		MEBENDAZOLE				
>D>	+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995 Aug CTNA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@	RIISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan CAHN
@		25MG	A040179	002	Jan 30, 1997	Jan CAHN

TABLET, CHEWABLE;ORAL

ANTIVERT

@	CASPER PHARMA LLC	25MG	N010721	005		Jun DISC
---	-------------------	------	---------	-----	--	----------

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

@	HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010	May CAHN
---	-------------------	-------	---------	-----	--------------	----------

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005 Feb CAHN
----	---	-----------------	----------	---------	-----	-----------------------

MELOXICAM

TABLET;ORAL

MELOXICAM

@	FRONTIDA BIOPHARM	7.5MG	A077935	001	Jul 19, 2006	Jul CAHN
@		15MG	A077935	002	Jul 19, 2006	Jul CAHN
@	SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jan CAHN
@		15MG	A077935	002	Jul 19, 2006	Jan CAHN

MELPHALAN

TABLET;ORAL

ALKERAN

+	APOTEX INC	2MG	N014691	002		Jan CAHN
---	------------	-----	---------	-----	--	----------

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992 Jan CAHN
----	---	------------	-------------------	---------	-----	-----------------------

MELPHALAN HYDROCHLORIDE

>A>	AP	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016 Aug NEWA
-----	----	----------------------	-------------------	---------	-----	-----------------------

POWDER;IV (INFUSION)

EVOMELA

		SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016 Mar NEWA
--	--	-----------------	-------------------	---------	-----	-----------------------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

@	US PHARM HOLDINGS	25MG/ML	N005010	007		Jan CAHN
@		50MG/ML	N005010	002		Jan CAHN
@		75MG/ML	N005010	009		Jan CAHN
@		100MG/ML	N005010	003		Jan CAHN

SYRUP; ORAL

DEMEROL

@ US PHARM HOLDINGS

50MG/5ML

N005010 005

Jan CAHN

TABLET; ORAL

DEMEROL

AA + US PHARM HOLDINGS

50MG

N005010 001

Jan CAHN

AA +

100MG

N005010 004

Jan CAHN

MEPERIDINE HYDROCHLORIDE

@ SUN PHARM INDS

50MG

A080448 001

Mar CAHN

@

100MG

A080448 002

Mar CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ AUROLIFE PHARMA LLC

400MG

A080655 001

Feb CAHN

@ SUN PHARM INDS

200MG

A080699 001

Mar CAHN

@

400MG

A080699 002

Mar CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB DR REDDYS LABS INTL

50MG

A040461 001 Feb 11, 2004

Apr CAHN

PURINETHOL

>D> @ STASON PHARMS

50MG

N009053 002

Aug CMFD

>A> AB

50MG

N009053 002

Aug CMFD

@

50MG

N009053 002

Jan CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP AMNEAL PHARMS

500MG/VIAL

A205883 001 Apr 12, 2016 Mar NEWA

AP

1GM/VIAL

A205883 002 Apr 12, 2016 Mar NEWA

AP GLAND PHARMA LTD

500MG/VIAL

A206141 001 Jun 08, 2016 May NEWA

AP

1GM/VIAL

A206141 002 Jun 08, 2016 May NEWA

AP PAR STERILE PRODUCTS

500MG/VIAL

A204139 001 Jun 09, 2016 May NEWA

AP

1GM/VIAL

A204139 002 Jun 09, 2016 May NEWA

AP SAVIOR LIFETEC CORP

500MG/VIAL

A206086 001 Apr 19, 2016 Apr NEWA

AP

1GM/VIAL

A206086 002 Apr 19, 2016 Apr NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+ APIL

400MG

N204412 001 Feb 01, 2013 Jan CAHN

TABLET, DELAYED RELEASE; ORAL

ASACOL

@ APIL

400MG

N019651 001 Jan 31, 1992 Jan CAHN

ASACOL HD

+ APIL

800MG

N021830 001 May 29, 2008 Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB CSPC OUYI PHARM CO

500MG

A205096 001 Jul 11, 2016 Jun NEWA

AB

850MG

A205096 002 Jul 11, 2016 Jun NEWA

AB

1GM

A205096 003 Jul 11, 2016 Jun NEWA

AB SUN PHARM INDS

500MG

A076038 001 Feb 21, 2002 Mar CAHN

AB

850MG

A076038 002 Feb 21, 2002 Mar CAHN

AB

1GM

A076038 003 Feb 21, 2002 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

AB3 SANTARUS INC

500MG

N021748 001 Jun 03, 2005 Jan CTEC

AB3 +

1GM

N021748 002 Jun 03, 2005 Jan CTEC

METFORMIN HYDROCHLORIDE

AB3 ACTAVIS LABS FL INC

500MG

A203755 001 Aug 01, 2016 Jul NEWA

AB3

1GM

A203755 002 Aug 01, 2016 Jul NEWA

@ IMPAX LABS

500MG

A076249 001 Jul 30, 2004 Mar DISC

@

750MG

A076985 001 Sep 13, 2005 Mar DISC

AB1 MARKSANS PHARMA

500MG

A090295 001 Apr 29, 2016 Apr NEWA

AB

750MG

A090295 002 Apr 29, 2016 Apr NEWA

@ SUN PHARM INDS

500MG

A077124 001 Dec 21, 2005 Mar CAHN

AB3 SUN PHARMA GLOBAL

500MG

A202917 001 Aug 01, 2016 Jul NEWA

AB3

1GM

A202917 002 Aug 01, 2016 Jul NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL
METHADOSE

>D>	AA	MALLINCKRODT	40MG	A074184	001	Apr 29, 1993	Aug CAHN
>A>	AA	MALLINCKRODT INC	40MG	A074184	001	Apr 29, 1993	Aug CAHN

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
METHAMPHETAMINE HYDROCHLORIDE

>D>	AA	COASTAL PHARMS	5MG	A091189	001	Apr 21, 2010	Aug CAHN
>A>	AA	MAYNE PHARMA INC	5MG	A091189	001	Apr 21, 2010	Aug CAHN

METHENAMINE HIPPURATE

TABLET; ORAL
HIPREX

AB	+	US PHARM HOLDINGS	1GM	N017681	001		Jan CAHN
METHENAMINE HIPPURATE							
AB		AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun NEWA

METHIMAZOLE

TABLET; ORAL
METHIMAZOLE

AB		ECI PHARMS LLC	5MG	A040547	001	Feb 18, 2005	Jul CAHN
AB			10MG	A040547	002	Feb 18, 2005	Jul CAHN
		@	20MG	A040547	004	Feb 18, 2005	Jul CAHN
AB		RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan CAHN
AB			10MG	A202068	002	Mar 07, 2012	Jan CAHN

METHOCARBAMOL

SOLUTION; IM-IV
METHOCARBAMOL

AP		AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May NEWA
----	--	----------------------	---------------------	---------	-----	--------------	----------

TABLET; ORAL
METHOCARBAMOL

>D>	AA	LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Aug DISC
>A>		@	500MG	A084756	002	Mar 31, 2003	Aug DISC
>D>	AA		750MG	A084756	001		Aug DISC
>A>		@	750MG	A084756	001		Aug DISC
		@ SANDOZ	500MG	A084616	001		Feb DISC
		@	750MG	A084615	001		Feb DISC
		@ SUN PHARM INDS	500MG	A084488	001		Mar CAHN
		@	750MG	A084486	001		Mar CAHN
ROBAXIN							
AA	+	AUXILIUM PHARMS INC	500MG	N011011	004		Mar CAHN
AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004		Jul CAHN
ROBAXIN-750							
AA	+	AUXILIUM PHARMS INC	750MG	N011011	006		Mar CAHN
AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Jul CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION
BREVITAL SODIUM

@	PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC
---	----------------------	------------	---------	-----	--------------	----------

METHOTREXATE

SOLUTION; SUBCUTANEOUS
OTREXUP

	ANTARES PHARMA INC	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May NEWA
		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May NEWA
		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP		SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan CAHN
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan CAHN
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan CAHN

METHOXSALLENCAPSULE; ORAL
METHOXSALLEN

>A>	@ IDT AUSTRALIA LTD	10MG	A087781	001	Jun 08, 1982	Aug CAHN
>D>	@ SANDOZ	10MG	A087781	001	Jun 08, 1982	Aug CAHN

INJECTABLE; INJECTION
UVADEX

+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr CAHN
---	-------------------	-----------	---------	-----	--------------	----------

METHYLDOPATABLET; ORAL
METHYLDOPA

@	SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986	Mar CAHN
@		250MG	A070060	001	Oct 09, 1986	Mar CAHN
@		500MG	A070074	001	Oct 09, 1986	Mar CAHN

METHYLENE BLUESOLUTION; INTRAVENOUS
PROVAYBLUE

+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr NEWA
---	----------------	--------------------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATETABLET; ORAL
METHERGINE

@	EDISON THERAPS LLC	0.2MG	N006035	003		Jan DISC
---	--------------------	-------	---------	-----	--	----------

METHYLERGONOVINE MALEATE

+	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan CRLD
---	----------------	-------	---------	-----	--------------	----------

METHYLNALTREXONE BROMIDESOLUTION; SUBCUTANEOUS
RELISTOR

+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Jul CRLD
---	--------------	-----------------------	---------	-----	--------------	----------

TABLET; ORAL
RELISTOR

+	SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016	Jul NEWA
---	------------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB2	COREPHARMA	10MG	A205105	001	Jul 28, 2016	Jul NEWA
AB2		20MG	A205105	002	Jul 28, 2016	Jul NEWA
AB2		30MG	A205105	003	Jul 28, 2016	Jul NEWA
AB2		40MG	A205105	004	Jul 28, 2016	Jul NEWA
AB2		50MG	A205105	005	Jul 28, 2016	Jul NEWA
AB2		60MG	A205105	006	Jul 28, 2016	Jul NEWA
>A> AB1	MAYNE PHARMA	20MG	A078458	001	Dec 01, 2011	Aug CAHN
>A> AB1		30MG	A078458	002	Dec 01, 2011	Aug CAHN
>A> AB1		40MG	A078458	003	Dec 01, 2011	Aug CAHN
>A> AB1		60MG	A078458	004	Jun 23, 2016	Aug CAHN
>D> AB1	WATSON LABS INC	20MG	A078458	001	Dec 01, 2011	Aug CAHN
>D> AB1		30MG	A078458	002	Dec 01, 2011	Aug CAHN
>D> AB1		40MG	A078458	003	Dec 01, 2011	Aug CAHN
>D> AB1		60MG	A078458	004	Jun 23, 2016	Aug CAHN
AB1		60MG	A078458	004	Jun 23, 2016	Jun NEWA

RITALIN LA

AB1	+	NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun CFTG
-----	---	----------	------	---------	-----	--------------	----------

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A> AB	CNTY LINE PHARMS	10MG	A204772	001	Feb 29, 2016	Aug CAHN
>A> AB		20MG	A204772	002	Feb 29, 2016	Aug CAHN
>D> AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Aug CAHN
AB		10MG	A204772	001	Feb 29, 2016	Feb NEWA
>D> AB		20MG	A204772	002	Feb 29, 2016	Aug CAHN
AB		20MG	A204772	002	Feb 29, 2016	Feb NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb NEWA
AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb NEWA
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan CAHN
AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan CAHN
AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan CAHN
AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan CAHN
AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan CAHN

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 10

	@ VALEANT PHARM INTL	10MG	A086450	001		Apr DISC
	METHYLTESTOSTERONE					
	@ IMPAX LABS	25MG	A084310	001		Mar DISC

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D> AA	SILARX	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992	Aug DISC
>A>	@	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992	Aug DISC

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A> AB	IMPAX LABS INC	EQ 5MG BASE	A072750	001	Dec 28, 1995	Aug CAHN
>A> AB		EQ 10MG BASE	A071250	001	Feb 03, 1988	Aug CAHN
AB	SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar CAHN
	@	EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar CAHN
>D> AB	WATSON LABS	EQ 5MG BASE	A072750	001	Dec 28, 1995	Aug CAHN
>D> AB		EQ 10MG BASE	A071250	001	Feb 03, 1988	Aug CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP	EUROHLTH INTL SARL	1MG/ML	A076495	001	Jul 07, 2003	Apr CAHN
	TABLET;ORAL					
	METOPROLOL TARTRATE					
	@ SANDOZ	50MG	A073288	001	Mar 25, 1994	May DISC
	@	100MG	A073289	001	Mar 25, 1994	May DISC
AB	SUN PHARM INDS	25MG	A073654	002	Jul 15, 2009	Mar CAHN
AB		100MG	A073654	001	Dec 21, 1993	Mar CAHN

METRONIDAZOLE

GEL;VAGINAL

NUVESSA

+	ALLERGAN SALES LLC	1.3%	N205223	001	Mar 24, 2014	Apr CAHN
---	--------------------	------	---------	-----	--------------	----------

TABLET;ORAL

METRONIDAZOLE

AB	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	May NEWA
AB		500MG	A207309	002	May 16, 2016	May NEWA
AB	NOSTRUM LABS INC	250MG	A070772	001	Jul 16, 1986	Jan CAHN
AB		500MG	A070773	001	Jul 16, 1986	Jan CAHN
AB	STRIDES PHARMA	250MG	A208162	001	May 25, 2016	May NEWA
AB		500MG	A208162	002	May 25, 2016	May NEWA
AB	VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	May CMFD
AB		500MG	A070039	001	Jan 29, 1985	May CMFD

MICONAZOLE

TABLET;BUCCAL

ORAVIG

+	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan CAHN
---	--------------------	------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	May CAHN
AP		EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr CAHN
AP		EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	May CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr CAHN

MIGLITOLTABLET; ORAL
GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb CRLD
AB			100MG	N020682	003	Dec 18, 1996	Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Apr NEWA
AB			25MG	A205081	002	Apr 22, 2016	Apr NEWA
AB			50MG	A205081	003	Apr 22, 2016	Apr NEWA
AB			100MG	A205081	004	Apr 22, 2016	Apr NEWA
	@	LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan DISC
			12.5MG	A205071	001	Jan 27, 2016	Jan NEWA
	@		25MG	A205071	002	Jan 27, 2016	Jan DISC
			25MG	A205071	002	Jan 27, 2016	Jan NEWA
	@		50MG	A205071	003	Jan 27, 2016	Jan DISC
			50MG	A205071	003	Jan 27, 2016	Jan NEWA
	@		100MG	A205071	004	Jan 27, 2016	Jan DISC
			100MG	A205071	004	Jan 27, 2016	Jan NEWA
		SAVELLA					
AB		CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr CFTG
AB			25MG	N022256	002	Jan 14, 2009	Apr CFTG
AB	+		50MG	N022256	003	Jan 14, 2009	Apr CFTG
AB			100MG	N022256	004	Jan 14, 2009	Apr CFTG

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Apr CAHN
		MILRINONE LACTATE IN DEXTROSE 5%					
AP		CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@	CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar CAHN
AP		EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun CAHN
AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	TEVA	EQ 50MG BASE	A063011	001	Mar 02, 1992	Aug CAHN
>D>	AB		EQ 75MG BASE	A063009	002	Aug 12, 2003	Aug CAHN
>D>	AB	+	EQ 100MG BASE	A063009	001	Mar 02, 1992	Aug CAHN
>A>	AB	ZYDUS WORLDWIDE	EQ 50MG BASE	A063011	001	Mar 02, 1992	Aug CAHN
>A>	AB		EQ 75MG BASE	A063009	002	Aug 12, 2003	Aug CAHN
>A>	AB	+	EQ 100MG BASE	A063009	001	Mar 02, 1992	Aug CAHN

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
AB			EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
AB			EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May NEWA
AB			EQ 105MG BASE	A202261	007	Jun 13, 2016	May NEWA
	@	IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar DISC
	@		EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar DISC
	@		EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar DISC

MINOXIDIL

TABLET; ORAL

MINOXIDIL

AB		SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar CAHN
----	--	----------------	------	---------	-----	--------------	----------

MIPOMERSEN SODIUMSOLUTION;SUBCUTANEOUS
KYNAMRO

+ KASTLE THERAPS LLC 200MG/ML (200MG/ML) N203568 001 Jan 29, 2013 Jun CAHN

MIRTAZAPINETABLET;ORAL
MIRTAZAPINE

@ ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan DISC
@	30MG	A076336	002	Jun 20, 2003	Jan DISC
@	45MG	A076336	003	Jun 20, 2003	Jan DISC

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

>A> AB	IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005	Aug CAHN
>A> AB		30MG	A076901	002	Jun 28, 2005	Aug CAHN
>A> AB		45MG	A076901	003	Jun 28, 2005	Aug CAHN
>D> AB	TEVA	15MG	A076901	001	Jun 28, 2005	Aug CAHN
>D> AB		30MG	A076901	002	Jun 28, 2005	Aug CAHN
>D> AB		45MG	A076901	003	Jun 28, 2005	Aug CAHN

MITOMYCININJECTABLE;INJECTION
MITOMYCIN

AP	EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MODAFINILTABLET;ORAL
MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOEXIPRIL HYDROCHLORIDETABLET;ORAL
MOEXIPRIL HYDROCHLORIDE

>D> AB	TEVA	15MG	A076204	002	May 08, 2003	Aug CRLD
>A> AB	+	15MG	A076204	002	May 08, 2003	Aug CRLD
>D>	UNIVASC					
>D> AB	UCB INC	7.5MG	N020312	001	Apr 19, 1995	Aug DISC
>A>	@	7.5MG	N020312	001	Apr 19, 1995	Aug DISC
>D> AB	+	15MG	N020312	002	Apr 19, 1995	Aug DISC
>A>	@	15MG	N020312	002	Apr 19, 1995	Aug DISC

MOMETASONE FUROATECREAM;TOPICAL
ELOCON

>D> AB	+	MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987	Aug DISC
>A>	@		0.1%	N019625	001	May 06, 1987	Aug DISC
>D> AB			0.1%	N019625	002	Apr 19, 2013	Aug CRLD
>A> AB	+		0.1%	N019625	002	Apr 19, 2013	Aug CRLD

SPRAY, METERED;NASAL
MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA	
AB	+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB			20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB			30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB			40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB			50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB			60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB			70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB			80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+		100MG	N020616	003	Jul 03, 1996	Feb CTEC
AB	+		200MG	N020616	007	Feb 27, 2007	Feb CTEC

CAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB	+	ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB			20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB			30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB			40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB			50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB			60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB			70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB			80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+		100MG	N020616	003	Jul 03, 1996	Apr CAHN
			130MG	N020616	011	Jul 09, 2012	Apr CAHN
			150MG	N020616	012	Jul 09, 2012	Apr CAHN
	+		200MG	N020616	007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB		IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB			30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB			50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB			60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB			80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB			100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
AB			30MG	A200812	002	Nov 10, 2011	Feb CTEC
AB			50MG	A200812	003	Nov 10, 2011	Feb CTEC
AB			60MG	A200812	004	Nov 10, 2011	Feb CTEC
AB			80MG	A200812	005	Nov 10, 2011	Feb CTEC
AB			100MG	A200812	006	Nov 10, 2011	Feb CTEC
AB		TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC
AB			30MG	A202718	002	Dec 29, 2014	Feb CTEC
AB			40MG	A202718	007	Jun 03, 2015	Feb CTEC
AB			50MG	A202718	003	Dec 29, 2014	Feb CTEC
AB			60MG	A202718	004	Dec 29, 2014	Feb CTEC
AB			70MG	A202718	008	Jun 03, 2015	Feb CTEC
AB			80MG	A202718	005	Dec 29, 2014	Feb CTEC
AB			100MG	A202718	006	Dec 29, 2014	Feb CTEC
AB		UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
AB			20MG	A202104	002	Jun 03, 2013	Feb CTEC
AB			30MG	A202104	003	Jun 03, 2013	Feb CTEC
AB			50MG	A202104	004	Jun 03, 2013	Feb CTEC
AB			60MG	A202104	005	Jun 03, 2013	Feb CTEC
AB			80MG	A202104	006	Jun 03, 2013	Feb CTEC
AB			100MG	A202104	007	Jun 03, 2013	Feb CTEC

SOLUTION;ORAL

MORPHINE SULFATE

AA		NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar CAHN
AA			20MG/5ML	A201011	002	Feb 05, 2014	Mar CAHN
AA		RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun NEWA
AA		TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun NEWA
AB			30MG	A091357	002	Jun 23, 2016	Jun NEWA
AB			60MG	A091357	003	Jun 23, 2016	Jun NEWA
AB			100MG	A091357	004	Jun 23, 2016	Jun NEWA
AB			200MG	A091357	005	Jun 23, 2016	Jun NEWA
>A>	AB	SUN PHARM INDS LTD	15MG	A205634	001	Aug 25, 2016	Aug NEWA
>A>	AB		30MG	A205634	002	Aug 25, 2016	Aug NEWA
>A>	AB		60MG	A205634	003	Aug 25, 2016	Aug NEWA
>A>	AB		100MG	A205634	004	Aug 25, 2016	Aug NEWA
>A>	AB		200MG	A205634	005	Aug 25, 2016	Aug NEWA

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan NEWA
----	--	----------------	---------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

AB		JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Jun CAHN
----	--	------------------	-------	---------	-----	--------------	----------

		TABLET;ORAL							
		MYCOPHENOLATE MOFETIL							
AB		JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Jun	CAHN	
<u>NABUMETONE</u>									
		TABLET;ORAL							
		NABUMETONE							
>A>	AB	IMPAX LABS INC	500MG	A075189	001	May 26, 2000	Aug	CAHN	
>A>	AB	+	750MG	A075189	002	Sep 24, 2001	Aug	CAHN	
>D>	AB	TEVA	500MG	A075189	001	May 26, 2000	Aug	CAHN	
>D>	AB	+	750MG	A075189	002	Sep 24, 2001	Aug	CAHN	
<u>NAFTIFINE HYDROCHLORIDE</u>									
		CREAM;TOPICAL							
		NAFTIFINE HYDROCHLORIDE							
>A>	AB	TARO	1%	A205975	001	Sep 08, 2016	Aug	NEWA	
		NAFTIN							
>D>		+	MERZ PHARMS	N019599	001	Feb 29, 1988	Aug	CFTG	
>A>	AB	+	1%	N019599	001	Feb 29, 1988	Aug	CFTG	
<u>NALBUPHINE HYDROCHLORIDE</u>									
		INJECTABLE;INJECTION							
		NUBAIN							
>D>		@	ENDO PHARMS	N018024	001		Aug	CAHN	
>D>		@	20MG/ML	N018024	002	May 27, 1982	Aug	CAHN	
>A>		@	PAR PHARM INC	N018024	001		Aug	CAHN	
>A>		@	20MG/ML	N018024	002	May 27, 1982	Aug	CAHN	
<u>NALIDIXIC ACID</u>									
		TABLET;ORAL							
		NALIDIXIC ACID							
		@	SUN PHARM INDS	A070270	001	Jun 29, 1988	Mar	CAHN	
		@	500MG	A070271	001	Jun 29, 1988	Jun	CAHN	
		@	1GM	A070272	001	Jun 29, 1988	Mar	CAHN	
<u>NALOXONE HYDROCHLORIDE</u>									
		INJECTABLE;INJECTION							
		NALOXONE HYDROCHLORIDE							
AP		MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016	Jun	NEWA	
>A>	<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE</u>								
>A>	CAPSULE, EXTENDED RELEASE;ORAL								
>A>	TROXYCA ER								
>A>		PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016	Aug	NEWA	
>A>			2.4MG;20MG	N207621	002	Aug 19, 2016	Aug	NEWA	
>A>			3.6MG;30MG	N207621	003	Aug 19, 2016	Aug	NEWA	
>A>			4.8MG;40MG	N207621	004	Aug 19, 2016	Aug	NEWA	
>A>			7.2MG;60MG	N207621	005	Aug 19, 2016	Aug	NEWA	
>A>			9.6MG;80MG	N207621	006	Aug 19, 2016	Aug	NEWA	
<u>NAPROXEN</u>									
		SUSPENSION;ORAL							
		NAPROSYN							
AB	+	ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun	CAHN	
		TABLET;ORAL							
		NAPROSYN							
AB		ATNAHS PHARMA US	250MG	N017581	002		Feb	CAHN	
AB			375MG	N017581	003		Feb	CAHN	
AB	+		500MG	N017581	004	Apr 15, 1982	Feb	CAHN	
		NAPROXEN							
		@	SANDOZ	A074140	001	Dec 21, 1993	Feb	DISC	
		@	375MG	A074140	002	Dec 21, 1993	Feb	DISC	
		@	500MG	A074140	003	Dec 21, 1993	Feb	DISC	
		TABLET, DELAYED RELEASE;ORAL							
		EC-NAPROSYN							
AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb	CAHN	
AB	+		500MG	N020067	003	Oct 14, 1994	Feb	CAHN	
		NAPROXEN							
		@	SANDOZ	A075061	001	Feb 18, 1998	Feb	DISC	
		@	500MG	A075061	002	Feb 18, 1998	Feb	DISC	

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

AB	ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb CAHN
----	------------------	---------------	---------	-----	--	----------

ANAPROX DS

AB	+ ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb CAHN
----	--------------------	---------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

>D>	+ ALVOGEN MALTA	EQ 750MG BASE	N020353	003	Jan 05, 1996	Aug CFTG
-----	-----------------	---------------	---------	-----	--------------	----------

>A> AB	+ ALVOGEN MALTA	EQ 750MG BASE	N020353	003	Jan 05, 1996	Aug CFTG
--------	-----------------	---------------	---------	-----	--------------	----------

NAPROXEN SODIUM

>A> AB	ACTAVIS LABS FL INC	EQ 750MG BASE	A075416	003	Aug 11, 2016	Aug NEWA
--------	---------------------	---------------	---------	-----	--------------	----------

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

AB	ZYDUS PHARMS USA INC	60MG	A205248	001	Jul 06, 2016	Jun NEWA
----	----------------------	------	---------	-----	--------------	----------

AB		120MG	A205248	002	Jul 06, 2016	Jun NEWA
----	--	-------	---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

	FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Jun NEWA
--	-----------------	------------------	---------	-----	--------------	----------

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

@	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Feb DISC
---	--------------------	------	---------	-----	--------------	----------

@		100MG	A076409	002	Sep 16, 2003	Feb DISC
---	--	-------	---------	-----	--------------	----------

@		150MG	A076409	003	Sep 16, 2003	Feb DISC
---	--	-------	---------	-----	--------------	----------

@		200MG	A076409	004	Sep 16, 2003	Feb DISC
---	--	-------	---------	-----	--------------	----------

@		250MG	A076409	005	Sep 16, 2003	Feb DISC
---	--	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA	LANNETT HOLDINGS INC	500MG	A204435	001	Jun 10, 2016	May NEWA
----	----------------------	-------	---------	-----	--------------	----------

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

CARDENE

@	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	May DISC
---	----------------	------	---------	-----	--------------	----------

@		30MG	N019488	002	Dec 21, 1988	May DISC
---	--	------	---------	-----	--------------	----------

NICARDIPINE HYDROCHLORIDE

AB	+ MYLAN	30MG	A074642	002	Jul 18, 1996	May CRLD
----	---------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jun CAHN
----	--------------------	----------------------	---------	-----	--------------	----------

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB	VALIDUS PHARMS	10MG	A073250	001	Oct 08, 1991	Jul CMFD
----	----------------	------	---------	-----	--------------	----------

@		10MG	A073250	001	Oct 08, 1991	Mar CAHN
---	--	------	---------	-----	--------------	----------

AB		20MG	A074045	001	Apr 30, 1992	Jul CMFD
----	--	------	---------	-----	--------------	----------

@		20MG	A074045	001	Apr 30, 1992	Mar CAHN
---	--	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

AB1	ALVOGEN	30MG	N020198	001	Apr 21, 1993	Feb CAHN
-----	---------	------	---------	-----	--------------	----------

AB1	+	60MG	N020198	002	Apr 21, 1993	Feb CAHN
-----	---	------	---------	-----	--------------	----------

AB1	+	90MG	N020198	003	Apr 21, 1993	Feb CAHN
-----	---	------	---------	-----	--------------	----------

NIFEDIPINE

>A> AB1	NOVAST LABS LTD	30MG	A202987	001	Aug 25, 2016	Aug NEWA
---------	-----------------	------	---------	-----	--------------	----------

>A> AB1		60MG	A202987	002	Aug 25, 2016	Aug NEWA
---------	--	------	---------	-----	--------------	----------

>A> AB1		90MG	A202987	003	Aug 25, 2016	Aug NEWA
---------	--	------	---------	-----	--------------	----------

AB2	OSMOTICA PHARM US	30MG	A077127	001	Nov 21, 2005	Jun CAHN
-----	-------------------	------	---------	-----	--------------	----------

AB2		60MG	A077127	002	Nov 21, 2005	Jun CAHN
-----	--	------	---------	-----	--------------	----------

AB1	VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000	Jan CAHN
-----	----------------------	------	---------	-----	--------------	----------

AB1		60MG	A075269	002	Dec 04, 2000	Jan CAHN
-----	--	------	---------	-----	--------------	----------

AB1		90MG	A076070	001	Aug 16, 2002	Jan CAHN
-----	--	------	---------	-----	--------------	----------

NILUTAMIDE

		TABLET; ORAL							
		NILANDRON							
AB	+	CONCORDIA PHARMS INC	150MG	N020169	002	Apr 30, 1999	Jul	CFTG	
		NILUTAMIDE							
AB		ANI PHARMS INC	150MG	A207631	001	Jul 15, 2016	Jul	NEWA	

NIMODIPINE

		CAPSULE; ORAL							
		NIMODIPINE							
>D>	AB	BARR LABS INC	30MG	A077811	001	May 02, 2007	Aug	CAHN	
	AB	+	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
>A>	AB	HERITAGE PHARMS INC	30MG	A077811	001	May 02, 2007	Aug	CAHN	

NITISINONE

		CAPSULE; ORAL							
		ORFADIN							
	+	SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Jun	NEWA	
		SUSPENSION; ORAL							
		ORFADIN							
	+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016	Apr	NEWA	

NITRIC OXIDE

		GAS; INHALATION							
		INOMAX							
	+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan	CAHN	

NITROFURANTOIN

		SUSPENSION; ORAL							
		FURADANTIN							
AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun	CAHN	
		NITROFURANTOIN							
AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr	NEWA	
AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb	CAHN	

NITROFURANTOIN, MACROCRYSTALLINE

		CAPSULE; ORAL							
		NITROFURANTOIN							
>A>	AB	IMPAX LABS INC	50MG	A073671	001	Jan 28, 1993	Aug	CAHN	
>A>	AB		100MG	A073652	001	Jan 28, 1993	Aug	CAHN	
>D>	AB	IVAX SUB TEVA PHARMS	50MG	A073671	001	Jan 28, 1993	Aug	CAHN	
>D>	AB		100MG	A073652	001	Jan 28, 1993	Aug	CAHN	
	AB	SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb	NEWA	
	AB		50MG	A201722	002	Feb 16, 2016	Feb	NEWA	
	AB		100MG	A201722	003	Feb 16, 2016	Feb	NEWA	

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

		CAPSULE; ORAL							
		MACROBID							
AB	+	ALVOGEN MALTA	75MG; 25MG	N020064	001	Dec 24, 1991	Jan	CAHN	

NITROGLYCERIN

		FILM, EXTENDED RELEASE; TRANSDERMAL							
		MINITRAN							
AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May	CAHN	
		POWDER; SUBLINGUAL							
		GONITRO							
	+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun	NEWA	
		TABLET; SUBLINGUAL							
		NITROGLYCERIN							
>A>	AB	DR REDDYS LABS INC	0.3MG	A208191	001	Aug 26, 2016	Aug	NEWA	
>A>	AB		0.4MG	A208191	002	Aug 26, 2016	Aug	NEWA	
>A>	AB		0.6MG	A208191	003	Aug 26, 2016	Aug	NEWA	
		NITROSTAT							
>D>		PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000	Aug	CFTG	
>A>	AB		0.3MG	N021134	001	May 01, 2000	Aug	CFTG	
>D>			0.4MG	N021134	002	May 01, 2000	Aug	CFTG	
>A>	AB		0.4MG	N021134	002	May 01, 2000	Aug	CFTG	
>D>	+		0.6MG	N021134	003	May 01, 2000	Aug	CFTG	
>A>	AB	+	0.6MG	N021134	003	May 01, 2000	Aug	CFTG	

NIZATIDINESOLUTION;ORAL
NIZATIDINE

+ AMNEAL PHARMS 15MG/ML

A090576 001 Nov 18, 2009 Feb CRLD

NOREPINEPHRINE BITARTRATEINJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATEAP CLARIS EQ 1MG BASE/ML
AP EUROHLTH INTL SARL EQ 1MG BASE/MLA040859 001 Mar 27, 2012 Jan CAHN
A040462 001 Oct 31, 2003 Apr CAHNNORETHINDRONETABLET;ORAL-28
CAMILA>D> AB1 BARR 0.35MG
>A> AB1 MAYNE PHARMA 0.35MGA076177 001 Oct 21, 2002 Aug CAHN
A076177 001 Oct 21, 2002 Aug CAHN

ERRIN

>D> AB2 BARR 0.35MG
>A> AB2 MAYNE PHARMA 0.35MGA076225 001 Oct 21, 2002 Aug CAHN
A076225 001 Oct 21, 2002 Aug CAHN

NOR-QD

AB1 + APIL 0.35MG

N017060 001 Jan CAHN

NORETHINDRONE

>A> AB1 AMNEAL PHARMS 0.35MG
>D> AB1 HAUPT PHARMA 0.35MGA202260 001 Aug 01, 2013 Aug CAHN
A202260 001 Aug 01, 2013 Aug CAHNNORTRIPTYLINE HYDROCHLORIDECAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC EQ 10MG BASE

A074835 001 Jun 30, 1997 Feb CAHN

@ EQ 25MG BASE

A074835 002 Jun 30, 1997 Feb CAHN

@ EQ 50MG BASE

A074835 003 Jun 30, 1997 Feb CAHN

@ EQ 75MG BASE

A074835 004 Jun 30, 1997 Feb CAHN

@ IDT AUSTRALIA LTD EQ 10MG BASE

A074054 001 Dec 31, 1992 May CAHN

@ EQ 25MG BASE

A074054 002 Dec 31, 1992 May CAHN

@ EQ 50MG BASE

A074054 003 Dec 31, 1992 May CAHN

@ EQ 75MG BASE

A074054 004 Dec 31, 1992 May CAHN

>A> AB MAYNE PHARMA EQ 10MG BASE

A073553 001 Mar 30, 1992 Aug CAHN

>A> AB EQ 25MG BASE

A073554 001 Mar 30, 1992 Aug CAHN

>A> AB EQ 50MG BASE

A073555 001 Mar 30, 1992 Aug CAHN

>A> AB EQ 75MG BASE

A073556 001 Mar 30, 1992 Aug CAHN

>D> AB WATSON LABS EQ 10MG BASE

A073553 001 Mar 30, 1992 Aug CAHN

>D> AB EQ 25MG BASE

A073554 001 Mar 30, 1992 Aug CAHN

>D> AB EQ 50MG BASE

A073555 001 Mar 30, 1992 Aug CAHN

>D> AB EQ 75MG BASE

A073556 001 Mar 30, 1992 Aug CAHN

NYSTATINPOWDER;TOPICAL
NYSTATIN>D> AT + COASTAL PHARMS 100,000 UNITS/GM
>A> AT + MAYNE PHARMA INC 100,000 UNITS/GMA065203 001 Jul 15, 2004 Aug CAHN
A065203 001 Jul 15, 2004 Aug CAHNTABLET;ORAL
NYSTATIN

AA SUN PHARM INDS 500,000 UNITS

A062838 001 Dec 22, 1988 Mar CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM;TOPICAL
NYSTATIN TRIAMCINOLONE ACETONIDE

@ PHARMADERM 100,000 UNITS/GM;0.1%

A062596 001 Oct 08, 1985 Mar CMS1

OINTMENT;TOPICAL
MYKACETAT G AND W LABS INC 100,000 UNITS/GM;0.1%
NYSTATIN AND TRIAMCINOLONE ACETONIDE

A062733 001 Mar 06, 1987 May CMS1

AT GLENMARK PHARMS LTD 100,000 UNITS/GM;0.1%

A208300 001 Jun 23, 2016 Jun NEWA

OBETICHOLIC ACIDTABLET;ORAL
OCALIVA+ INTERCEPT PHARMS INC 5MG
10MGN207999 001 May 27, 2016 May NEWA
N207999 002 May 27, 2016 May NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

@ WOCKHARDT USA EQ 0.2MG BASE/ML

A090986 001 May 11, 2011 Jan DISC

@ EQ 1MG BASE/ML

A090986 002 May 11, 2011 Jan DISC

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

@ WOCKHARDT USA EQ 0.05MG BASE/ML

A090985 001 May 11, 2011 Jan DISC

@ EQ 0.1MG BASE/ML

A090985 002 May 11, 2011 Jan DISC

@ EQ 0.5MG BASE/ML

A090985 003 May 11, 2011 Jan DISC

OCTREOTIDE ACETATE PRESERVATIVE FREE

@ WOCKHARDT USA EQ 0.05MG BASE/ML

A090985 001 May 11, 2011 Feb CMS1

@ EQ 0.1MG BASE/ML

A090985 002 May 11, 2011 Feb CMS1

@ EQ 0.5MG BASE/ML

A090985 003 May 11, 2011 Feb CMS1

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT ALVOGEN 0.3%

A076830 001 Aug 31, 2004 Mar CAHN

SOLUTION/DROPS; OTIC

OFLOXACIN

AT ALVOGEN 0.3%

A090395 001 Aug 11, 2009 Mar CAHN

AT + BAUSCH AND LOMB 0.3%

A076128 001 Mar 17, 2008 Feb CRLD

OLANZAPINE

TABLET; ORAL

OLANZAPINE

>A> AB AJANTA PHARMA LTD 2.5MG

A206711 001 Aug 30, 2016 Aug NEWA

>A> AB 5MG

A206711 002 Aug 30, 2016 Aug NEWA

>A> AB 7.5MG

A206711 003 Aug 30, 2016 Aug NEWA

>A> AB 10MG

A206711 004 Aug 30, 2016 Aug NEWA

>A> AB 15MG

A206711 005 Aug 30, 2016 Aug NEWA

>A> AB 20MG

A206711 006 Aug 30, 2016 Aug NEWA

AB INVAGEN PHARMS 2.5MG

A203333 001 Mar 15, 2016 Feb NEWA

AB 5MG

A203333 002 Mar 15, 2016 Feb NEWA

AB 7.5MG

A203333 003 Mar 15, 2016 Feb NEWA

AB 10MG

A203333 004 Mar 15, 2016 Feb NEWA

AB 15MG

A203333 005 Mar 15, 2016 Feb NEWA

AB 20MG

A203333 006 Mar 15, 2016 Feb NEWA

AB QILU PHARM CO LTD 2.5MG

A204319 001 Jan 27, 2016 Jan NEWA

AB 5MG

A204319 002 Jan 27, 2016 Jan NEWA

AB 7.5MG

A204319 003 Jan 27, 2016 Jan NEWA

AB 10MG

A204319 004 Jan 27, 2016 Jan NEWA

AB 15MG

A204319 005 Jan 27, 2016 Jan NEWA

AB 20MG

A204319 006 Jan 27, 2016 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB INVAGEN PHARMS 5MG

A203456 001 Mar 16, 2016 Feb NEWA

AB 10MG

A203456 002 Mar 16, 2016 Feb NEWA

AB 15MG

A203456 003 Mar 16, 2016 Feb NEWA

AB 20MG

A203456 004 Mar 16, 2016 Feb NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT SOMERSET THERAPS LLC EQ 0.1% BASE

A206306 001 Dec 07, 2015 Mar CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

AB AMNEAL PHARMS 1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY
ACIDS

A204940 001 Nov 27, 2015 Jan CMS1

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE; ORAL

OMTRYG

+ TRYGG 1.2GM CONTAINS AT LEAST 900MG OF
THE ETHYL ESTERS OF OMEGA-3 FATTY
ACIDS

N204977 001 Apr 23, 2014 Mar CAIN

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	20MG;1.1GM	A204228	001	Jul 15, 2016	Jul NEWA
AB			40MG;1.1GM	A204228	002	Jul 15, 2016	Jul NEWA
>A>	AB	AUROLIFE PHARMA LLC	20MG;1.1GM	A204922	001	Aug 19, 2016	Aug NEWA
>A>	AB		40MG;1.1GM	A204922	002	Aug 19, 2016	Aug NEWA
AB		DR REDDYS LABS LTD	20MG;1.1GM	A204068	001	Jul 15, 2016	Jul NEWA
AB			40MG;1.1GM	A204068	002	Jul 15, 2016	Jul NEWA

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AA		AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jul NEWA
AA			40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jul NEWA
		ZEGERID					
AA		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul CTEC
AA	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul CTEC

ONDANSETRON

FILM;ORAL

ZUPLENZ

		MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	Jun CAHN
	+		8MG	N022524	002	Jul 02, 2010	Jun CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

>D>	AP	CLARIS	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CRLD
>A>	AP	+	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CRLD
	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr CAHN
>D>	AP	LANNETT	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010	Aug DISC
>A>		@	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010	Aug DISC

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA	
>D>	AP	CLARIS	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CRLD	
>A>	AP	+	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CRLD	
	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr CAHN	
>D>		ZOFRAN						
>D>	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC
>D>	AP	+		EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC
>D>	AP	+		EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC
>D>	AP	+		EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC
>A>		@	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC	
>D>		ZOFRAN PRESERVATIVE FREE						
>D>	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Aug DISC
>A>		@	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Aug DISC	

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

	@	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
	@		EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
	@		EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		NATCO PHARMA LTD	EQ 30MG BASE	A202595	001	Aug 03, 2016	Jul NEWA
AB			EQ 45MG BASE	A202595	002	Aug 03, 2016	Jul NEWA
AB			EQ 75MG BASE	A202595	003	Aug 03, 2016	Jul NEWA

TAMIFLU

AB		ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul CFTG
AB			EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul CFTG
AB	+		EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul CFTG

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

		@ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun DISC
AP	+		200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May CFTG
			OXALIPLATIN				
>D>	AP	EBEWE PHARMA	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Aug DISC
>D>	AP		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Aug DISC
	AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May NEWA
	AP		50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
	AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May NEWA
	AP		100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
	+		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun CRLD
	AP		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May NEWA
>A>		@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Aug DISC
>A>		@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Aug DISC

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

@ SUN PHARM INDS

@

@

TABLET;ORAL

OXAZEPAM

@ FRONTIDA BIOPHARM

@ SUN PHARM INDS

10MG	A071026	002	Aug 10, 1987	Mar CAHN
15MG	A071026	003	Aug 10, 1987	Mar CAHN
30MG	A071026	001	Aug 10, 1987	Mar CAHN
15MG	A070683	001	Jan 16, 1987	Jul CAHN
15MG	A070683	001	Jan 16, 1987	Jun CAHN

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

AB		ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jun CMFD
AB			300MG	A078005	002	Dec 11, 2007	Jun CMFD
AB			600MG	A078005	003	Dec 11, 2007	Jun CMFD

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB		TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb NEWA
		OXISTAT					
AB	+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

AB	+	ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr CAHN
		GEL, METERED;TRANSDERMAL					
		GELNIQUE 3%					
	+	ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Apr CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

+ ALLERGAN SALES LLC 10%(100MG/PACKET)

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb NEWA
AB			10MG	A207138	002	Feb 29, 2016	Feb NEWA
AB			15MG	A207138	003	Feb 29, 2016	Feb NEWA
AB		OSMOTICA PHARM US	5MG	A078503	001	Feb 04, 2009	Jun CAHN
AB			10MG	A078503	002	Feb 04, 2009	Jun CAHN
AB			15MG	A078503	003	Feb 04, 2009	Jun CAHN
AB		UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	May NEWA
AB			10MG	A206121	002	May 27, 2016	May NEWA
AB			15MG	A206121	003	May 27, 2016	May NEWA

OXYCODONECAPSULE, EXTENDED RELEASE;ORAL
XTAMPZA ER

COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016	May CAIN
	13.5MG	N208090	002	Apr 26, 2016	May CAIN
	18MG	N208090	003	Apr 26, 2016	May CAIN
	27MG	N208090	004	Apr 26, 2016	May CAIN
+	36MG	N208090	005	Apr 26, 2016	May CAIN

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar NEWA	
>D>	AB	COASTAL PHARMS	5MG	A203107	001	Jul 26, 2012	Aug CAHN
>A>	AB	MAYNE PHARMA INC	5MG	A203107	001	Jul 26, 2012	Aug CAHN

CAPSULE, EXTENDED RELEASE;ORAL
XTAMPZA ER

COLLEGIUM PHARM INC	EQ 9MG BASE	N208090	001	Apr 26, 2016	Apr NEWA
	EQ 13.5MG BASE	N208090	002	Apr 26, 2016	Apr NEWA
	EQ 18MG BASE	N208090	003	Apr 26, 2016	Apr NEWA
	EQ 27MG BASE	N208090	004	Apr 26, 2016	Apr NEWA
+	EQ 36MG BASE	N208090	005	Apr 26, 2016	May CRLD
	EQ 36MG BASE	N208090	005	Apr 26, 2016	Apr NEWA

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

>D>	AA	COASTAL PHARMS	100MG/5ML	A204092	001	Jun 05, 2014	Aug CAHN
>A>	AA	MAYNE PHARMA INC	100MG/5ML	A204092	001	Jun 05, 2014	Aug CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan CAHN	
AB		15MG	A202116	002	Dec 30, 2011	Jan CAHN	
AB		30MG	A202116	003	Dec 30, 2011	Jan CAHN	
>D>	AB	COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Aug CAHN
>D>	AB		10MG	A091313	004	Apr 29, 2016	Aug CAHN
	AB		10MG	A091313	004	Apr 29, 2016	Apr NEWA
>D>	AB		15MG	A091313	002	Feb 18, 2011	Aug CAHN
>D>	AB		20MG	A091313	005	Apr 29, 2016	Aug CAHN
	AB		20MG	A091313	005	Apr 29, 2016	Apr NEWA
>D>	AB		30MG	A091313	003	Feb 18, 2011	Aug CAHN
	AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar NEWA
	AB		10MG	A207119	002	Apr 12, 2016	Mar NEWA
	AB		15MG	A207119	003	Apr 12, 2016	Mar NEWA
	AB		20MG	A207119	004	Apr 12, 2016	Mar NEWA
	AB		30MG	A207119	005	Apr 12, 2016	Mar NEWA
>A>	AB	MAYNE PHARMA INC	5MG	A091313	001	Feb 18, 2011	Aug CAHN
>A>	AB		10MG	A091313	004	Apr 29, 2016	Aug CAHN
>A>	AB		15MG	A091313	002	Feb 18, 2011	Aug CAHN
>A>	AB		20MG	A091313	005	Apr 29, 2016	Aug CAHN
>A>	AB		30MG	A091313	003	Feb 18, 2011	Aug CAHN

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

+	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016	Jun NEWA
---	------------	-----------------------	---------	-----	--------------	----------

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr NEWA
AB		10MG	A204459	002	Apr 26, 2016	Apr NEWA

PACLITAXEL

INJECTABLE;INJECTION

PACITAXEL

>A>	AP	GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Aug NEWA
	AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA

JANSSEN PHARMS 117MG/0.75ML (117MG/0.75ML)
+ 156MG/ML (156MG/ML)

N022264 003 Jul 31, 2009 Mar CRLD
N022264 004 Jul 31, 2009 Mar CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

AP DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG
BASE/ML)
AP EQ 0.25MG BASE/5ML (EQ 0.05MG
BASE/ML)

A201533 001 Apr 21, 2016 Apr NEWA
A201533 002 Apr 21, 2016 Apr NEWA

SOLUTION; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG
BASE/ML)
EQ 0.25MG BASE/5ML (EQ 0.05MG
BASE/ML)

N203050 001 Mar 01, 2016 Mar NEWA
N203050 002 Mar 01, 2016 Mar NEWA

>A> EXELA PHARMA SCIENCE EQ 0.25MG BASE/2ML (EQ 0.125MG
BASE/ML)

N207963 001 Aug 22, 2016 Aug NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP SAGENT PHARMS 30MG/10ML (3MG/ML)
AP 90MG/10ML (9MG/ML)

A078373 001 Dec 23, 2008 Jan CAHN
A078373 002 Dec 23, 2008 Jan CAHN

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

AP AUROBINDO PHARMA LTD EQ 40MG BASE/VIAL
TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

A205675 001 Mar 30, 2016 Mar NEWA

AB AMNEAL PHARMS EQ 20MG BASE
AB EQ 40MG BASE

A205119 001 Jan 26, 2016 Jan NEWA
A205119 002 Jan 26, 2016 Jan NEWA

PARICALCITOL

CAPSULE; ORAL
PARICALCITOL

AB BIONPHARMA INC 1MCG
AB 2MCG
AB 4MCG
AB LOTUS PHARM CO LTD 1MCG
AB 2MCG
AB 4MCG
>D> AB TEVA PHARMS USA 4MCG
>A> AB + 4MCG

A202539 001 Mar 27, 2014 Jan CAHN
A202539 002 Mar 27, 2014 Jan CAHN
A202539 003 Mar 27, 2014 Jan CAHN
A206710 001 Feb 24, 2016 Feb NEWA
A206710 002 Feb 24, 2016 Feb NEWA
A206710 003 Feb 24, 2016 Feb NEWA
A090829 003 Sep 27, 2013 Aug CRLD
A090829 003 Sep 27, 2013 Aug CRLD

ZEMPLAR

>D> AB + ABBVIE 4MCG
>A> @ 4MCG

N021606 003 May 26, 2005 Aug DISC
N021606 003 May 26, 2005 Aug DISC

SOLUTION; INTRAVENOUS
PARICALCITOL

AP ACCORD HLTHCARE 0.002MG/ML (0.002MG/ML)
AP 0.005MG/ML (0.005MG/ML)
AP 0.01MG/2ML (0.005MG/ML)
>A> AP DR REDDYS LABS LTD 0.002MG/ML (0.002MG/ML)
>A> AP 0.005MG/ML (0.005MG/ML)
>A> AP 0.01MG/2ML (0.005MG/ML)

N207174 001 Feb 04, 2016 Feb NEWA
N207174 002 Feb 04, 2016 Feb NEWA
N207174 003 Feb 04, 2016 Feb NEWA
A204910 001 Aug 17, 2016 Aug NEWA
A204910 002 Aug 17, 2016 Aug NEWA
A204910 003 Aug 17, 2016 Aug NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

AB KREMERS URBAN PHARMS EQ 12.5MG BASE
AB EQ 25MG BASE
AB EQ 37.5MG BASE

A204744 001 Jun 10, 2016 May NEWA
A204744 002 Jun 10, 2016 May NEWA
A204744 003 Jun 10, 2016 May NEWA

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

>D>	+	NOVEN THERAP	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Aug CAHN
>A>	+	SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Aug CAHN

TABLET;ORAL

PEXEVA

>D>		NOVEN THERAP	EQ 10MG BASE	N021299	001	Jul 03, 2003	Aug CAHN
>D>			EQ 20MG BASE	N021299	002	Jul 03, 2003	Aug CAHN
>D>			EQ 30MG BASE	N021299	003	Jul 03, 2003	Aug CAHN
>D>	+		EQ 40MG BASE	N021299	004	Jul 03, 2003	Aug CAHN
>A>		SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	Aug CAHN
>A>			EQ 20MG BASE	N021299	002	Jul 03, 2003	Aug CAHN
>A>			EQ 30MG BASE	N021299	003	Jul 03, 2003	Aug CAHN
>A>	+		EQ 40MG BASE	N021299	004	Jul 03, 2003	Aug CAHN

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

>D>	@	AUXILIUM PHARMS INC	10MG	N018976	001	Dec 30, 1987	Aug CAHN
			10MG	N018976	001	Dec 30, 1987	Mar CAHN
>D>	@		20MG	N018976	004	Jan 05, 1989	Aug CAHN
			20MG	N018976	004	Jan 05, 1989	Mar CAHN
>A>	@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Aug CAHN
>A>	@		20MG	N018976	004	Jan 05, 1989	Aug CAHN

PENCICLOVIR

CREAM;TOPICAL

DENA VIR

+	DENCO ASSET	1%	N020629	001	Sep 24, 1996	Apr CAIN
---	-------------	----	---------	-----	--------------	----------

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Apr CMFD
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb CAHN

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Apr CMFD
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb CAHN

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

NEMBUTAL SODIUM

AP	+	OAK PHARMS	50MG/ML	A083246	001		May CTEC
----	---	------------	---------	---------	-----	--	----------

PENTOBARBITAL SODIUM

AP		MYLAN INSTITUTIONAL	50MG/ML	A206404	001	May 23, 2016	May NEWA
----	--	---------------------	---------	---------	-----	--------------	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar CRLD
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar DISC
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar DISC
		TRENTAL					
	@	US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan CAHN

PERAMPANEL

SUSPENSION;ORAL

FYCOMPA

+	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016	Apr NEWA
---	-----------	----------	---------	-----	--------------	----------

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB		WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan CAHN
AB			4MG	A205973	002	Dec 17, 2015	Jan CAHN
AB			8MG	A205973	003	Dec 17, 2015	Jan CAHN
AB			16MG	A205973	004	Dec 17, 2015	Jan CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@ ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105	001	Jun 26, 2001	Jan CMS1
--------	-------------------------------	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar CAHN
	@	37.5MG	A040527	001	Oct 23, 2003	Mar CAHN

TABLET; ORAL

LOMAIRA

>A>						
>A>	+	AVANTHI INC	8MG	A203495	001	Sep 12, 2016 Aug NEWA

PHENTERMINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan CAHN
AA	SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

	@	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011 Jun DISC
	@		30MG	N202088	002	Jun 13, 2011 Jun DISC
	@		37.5MG	N202088	003	Mar 27, 2012 Jun DISC

PHENTERMINE RESIN COMPLEX

>D> CAPSULE, EXTENDED RELEASE; ORAL

>D> PHENTERMINE RESIN COMPLEX

>D>	+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011 Aug DISC
>A>		@	EQ 15MG BASE	A040872	001	Jul 28, 2011 Aug DISC
>D>	+		EQ 30MG BASE	A040872	002	Jul 28, 2011 Aug DISC
>A>		@	EQ 30MG BASE	A040872	002	Jul 28, 2011 Aug DISC

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

	@	SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985 Mar CAHN
--	---	----------------	-------	---------	-----	-----------------------

TABLET; ORAL

PHENYLBUTAZONE

	@	SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985 Mar CAHN
--	---	----------------	-------	---------	-----	-----------------------

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

	@	TELIGENT PHARMA INC	1MG/0.5ML	N012223	002	Jan CAHN
	@		10MG/ML	N012223	001	Jan CAHN
	@		10MG/ML	N012223	001	Jan CAHN

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016 Apr NEWA
---	-------------------	--------------	---------	-----	-----------------------

PINDOLOL

TABLET; ORAL

PINDOLOL

	@	IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993 May CAHN
	@		10MG	A073609	001	Mar 29, 1993 May CAHN
AB		SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994 Mar CAHN
AB			10MG	A074063	002	Jan 27, 1994 Mar CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

>A>	AB	FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016 Aug NEWA
>A>	AB		20MG	A207938	002	Sep 09, 2016 Aug NEWA
>A>	AB	MYLAN IRELAND LTD	10MG	A074116	001	Jun 15, 1993 Aug CAHN
>A>	AB		20MG	A074118	001	Jun 15, 1993 Aug CAHN
>D>	AB	MYLAN PHARMS INC	10MG	A074116	001	Jun 15, 1993 Aug CAHN
>D>	AB		20MG	A074118	001	Jun 15, 1993 Aug CAHN
	AB		20MG	A074118	001	Jun 15, 1993 Jan CAHN
		@	SUN PHARM INDS	20MG	A073536	001 Mar 12, 1993 Mar CAHN

PODOFILOXGEL; TOPICAL
CONDYLOX

	+	ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997	Mar CAHN
		SOLUTION; TOPICAL					
		CONDYLOX					
AT	+	ALLERGAN SALES LLC	0.5%	N019795	001	Dec 13, 1990	Mar CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSFOR SOLUTION; ORAL
COLYTE

	@	MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	May DISC
		COLYTE WITH FLAVOR PACKS					
AA		MEDA PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC

POLYMYXIN B SULFATEINJECTABLE; INJECTION
POLYMYXIN B SULFATE

AP		AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar NEWA
AP		GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr NEWA

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB		GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan NEWA
AB		KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar NEWA
AB			10MEQ	A204210	002	Mar 28, 2016	Mar NEWA
>A>	AB	NOVEL LABS INC	8MEQ	A204828	001	Aug 16, 2016	Aug NEWA
>A>	AB		10MEQ	A204828	002	Aug 16, 2016	Aug NEWA
AB		TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb NEWA
AB			10MEQ	A201944	002	Mar 04, 2016	Feb NEWA

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

+ PHARMA RES SOFTWARE 20MEQ

N208019 001 Aug 19, 2015 Jul CRLD

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1		GLENMARK PHARMS LTD	10MEQ	A203562	001	Jul 26, 2016	Jul NEWA
AB1			20MEQ	A203562	002	Jul 26, 2016	Jul NEWA
AB2		NOVEL LABS INC	8MEQ	A206759	001	Aug 09, 2016	Jul NEWA
AB1			10MEQ	A206347	001	Jan 21, 2016	Jan NEWA
AB2			10MEQ	A206759	002	Aug 09, 2016	Jul NEWA
AB1			20MEQ	A206347	002	Jan 21, 2016	Jan NEWA
>A>	AB2	SIGMAPHARM LABS LLC	8MEQ	A207528	001	Aug 19, 2016	Aug NEWA
>A>	AB2		10MEQ	A207528	002	Aug 19, 2016	Aug NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr NEWA
AB			0.75MG	A201963	002	Apr 21, 2016	Apr NEWA
AB			1.5MG	A201963	003	Apr 21, 2016	Apr NEWA
AB			3MG	A201963	004	Apr 21, 2016	Apr NEWA
AB			4.5MG	A201963	005	Apr 21, 2016	Apr NEWA
AB		MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun NEWA
AB			0.75MG	A206156	002	Jun 24, 2016	Jun NEWA
AB			1.5MG	A206156	003	Jun 24, 2016	Jun NEWA
AB			2.25MG	A206156	004	Jun 24, 2016	Jun NEWA
AB			3MG	A206156	005	Jun 24, 2016	Jun NEWA
AB			4.5MG	A206156	007	Jun 24, 2016	Jun NEWA
AB		SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul CDFR
AB			0.75MG	A202353	002	Dec 04, 2014	Jul CDFR
AB			1.5MG	A202353	003	Dec 04, 2014	Jul CDFR
AB			3MG	A202353	004	Dec 04, 2014	Jul CDFR
AB			4.5MG	A202353	005	Dec 04, 2014	Jul CDFR

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
	@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
	@	20MG	A077013	002	Oct 23, 2006	Mar DISC
	@	40MG	A077013	003	Oct 23, 2006	Mar DISC
	@	80MG	A077013	004	Dec 28, 2007	Mar DISC

PRazosin Hydrochloride

CAPSULE; ORAL

PRazosin Hydrochloride

@	IDT AUSTRALIA LTD	EQ 1MG BASE
@		EQ 2MG BASE
@		EQ 5MG BASE

A072576	001	May 16, 1989	May CAHN
A072577	001	May 16, 1989	May CAHN
A072578	001	May 16, 1989	May CAHN

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

@ AUROLIFE PHARMA LLC 5MG

A084773 001 Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA + WOCKHARDT EQ 15MG BASE/5ML

A076895 001 Oct 04, 2004 Mar CRLD

PREDNISON

TABLET; ORAL

PREDNISON

@	AUROLIFE PHARMA LLC	5MG
@		10MG
@		20MG
@		50MG

A084774	001		Mar CAHN
A089983	001	Jan 12, 1989	Mar CAHN
A085813	001		Mar CAHN
A089984	001	Jan 12, 1989	Mar CAHN

AB DELCOR ASSET CORP 5MG

A080292 001 Mar CAHN

AB 10MG

A088832 001 Dec 04, 1985 Mar CAHN

AB 20MG

A083677 001 Mar CAHN

AB SUN PHARM INDS 20MG

A089247 001 Dec 04, 1985 Mar CAHN

@ 50MG

A086596 001 Jun CAHN

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE PHOSPHATE

AB INGENUS PHARMS NJ EQ 15MG BASE

A206043 001 Jun 23, 2016 Jun NEWA

PRIMIDONE

TABLET; ORAL

PRIMIDONE

AB FRONTIDA BIOPHARM 50MG

A040626 001 Sep 29, 2005 Jul CAHN

AB 250MG

A040626 002 Sep 29, 2005 Jul CAHN

@ HIKMA INTL PHARMS 50MG

A040667 001 Jul 27, 2006 Jul CAHN

AB 250MG

A040667 002 Jul 27, 2006 Jul CAHN

@ IMPAX LABS 50MG

A040717 001 Feb 12, 2008 Mar DISC

@ 250MG

A040717 002 Feb 12, 2008 Mar DISC

AB SUN PHARM INDS 50MG

A040626 001 Sep 29, 2005 Mar CAHN

AB 250MG

A040626 002 Sep 29, 2005 Mar CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@ IDT AUSTRALIA LTD 375MG

A089220 001 Jul 01, 1986 May CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

>D> AP AMPHASTAR PHARMS INC EQ 5MG BASE/ML

A040540 001 May 28, 2004 Aug DISC

>A> @ EQ 5MG BASE/ML

A040540 001 May 28, 2004 Aug DISC

AP EQ 5MG BASE/ML

A040540 001 May 28, 2004 Jun CAHN

>D> AP EMCURE PHARMS LTD EQ 5MG BASE/ML

A204147 001 Oct 15, 2013 Aug CRLD

>A> AP + EQ 5MG BASE/ML

A204147 001 Oct 15, 2013 Aug CRLD

AP EUROHLTH INTL SARL EQ 5MG BASE/ML

A040540 001 May 28, 2004 Apr CAHN

>D> AP + EQ 5MG BASE/ML

A089903 001 Aug 29, 1989 Aug DISC

		INJECTABLE; INJECTION							
		PROCHLORPERAZINE EDISYLATE							
>A>	@	EQ 5MG BASE/ML		A089903	001	Aug 29, 1989		Aug	DISC
<u>PROGESTERONE</u>									
		CAPSULE; ORAL							
		PROGESTERONE							
AB	BIONPHARMA INC	100MG		A200900	001	Aug 16, 2013		Jan	CAHN
AB		200MG		A200900	002	Aug 16, 2013		Jan	CAHN
		PROMETRIUM							
AB	VIRTUS PHARMS	100MG		N019781	001	May 14, 1998		Jun	CAHN
AB	+	200MG		N019781	002	Oct 15, 1999		Jun	CAHN
	@	300MG		N019781	003	Oct 15, 1999		Jun	CAHN
		GEL; VAGINAL							
		CRINONE							
+	ALLERGAN SALES LLC	4%		N020701	001	Jul 31, 1997		Apr	CAHN
+		8%		N020701	002	Jul 31, 1997		Apr	CAHN
		INJECTABLE; INJECTION							
		PROGESTERONE							
AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002			Apr	CAHN
<u>PROMETHAZINE HYDROCHLORIDE</u>									
		SYRUP; ORAL							
		PROMETHAZINE HYDROCHLORIDE							
AA	NOSTRUM LABS INC	6.25MG/5ML		A040891	001	Mar 13, 2009		Feb	CAHN
		TABLET; ORAL							
		PROMETHAZINE HYDROCHLORIDE							
	@ IMPAX LABS	12.5MG		A040724	001	Feb 12, 2008		Mar	DISC
	@	25MG		A040724	002	Feb 12, 2008		Mar	DISC
	@	50MG		A040791	001	May 20, 2008		Mar	DISC
	@ SUN PHARM INDS	12.5MG		A084555	001			Mar	CAHN
	@	25MG		A084554	001			Mar	CAHN
	@	50MG		A084557	001			Jan	CAHN
<u>PROPAFENONE HYDROCHLORIDE</u>									
		CAPSULE, EXTENDED RELEASE; ORAL							
		PROPAFENONE HYDROCHLORIDE							
AB	MYLAN PHARMS INC	225MG		A203803	001	Apr 29, 2016		Apr	NEWA
AB		325MG		A203803	002	Apr 29, 2016		Apr	NEWA
AB		425MG		A203803	003	Apr 29, 2016		Apr	NEWA
		TABLET; ORAL							
		PROPAFENONE HYDROCHLORIDE							
AB	ORION CORP ORION	150MG		A202445	001	May 11, 2016		Apr	NEWA
AB		225MG		A202445	002	May 11, 2016		Apr	NEWA
AB		300MG		A202445	003	May 11, 2016		Apr	NEWA
AB	SUN PHARM INDS	150MG		A075998	001	Nov 29, 2001		Mar	CAHN
AB		225MG		A075998	002	Nov 29, 2001		Mar	CAHN
AB		300MG		A075998	003	Nov 29, 2001		Mar	CAHN
<u>PROPOFOL</u>									
		INJECTABLE; INJECTION							
		PROPOFOL							
>A>	AB	SAGENT PHARMS	10MG/ML	A075102	001	Jan 04, 1999		Aug	CAHN
>D>	AB	TEVA PHARMS USA	10MG/ML	A075102	001	Jan 04, 1999		Aug	CAHN
<u>PROPRANOLOL HYDROCHLORIDE</u>									
		CAPSULE, EXTENDED RELEASE; ORAL							
		INDERAL LA							
AB	ANI PHARMS INC	60MG		N018553	004	Mar 18, 1987		Apr	CAHN
AB		80MG		N018553	002	Apr 19, 1983		Apr	CAHN
AB		120MG		N018553	003	Apr 19, 1983		Apr	CAHN
AB	+	160MG		N018553	001	Apr 19, 1983		Apr	CAHN
		PROPRANOLOL HYDROCHLORIDE							
BX	UPSHER SMITH	60MG		A078311	001	Mar 06, 2009		Jun	CMFD
	@	60MG		A078311	001	Mar 06, 2009		May	DISC
BX		60MG		A078311	001	Mar 06, 2009		Mar	CTEC
BX		80MG		A078311	002	Mar 06, 2009		Jun	CMFD
	@	80MG		A078311	002	Mar 06, 2009		May	DISC
BX		80MG		A078311	002	Mar 06, 2009		Mar	CTEC
BX		120MG		A078311	003	Mar 06, 2009		Jun	CMFD
	@	120MG		A078311	003	Mar 06, 2009		May	DISC
BX		120MG		A078311	003	Mar 06, 2009		Mar	CTEC

CAPSULE, EXTENDED RELEASE;ORAL
PROPRANOLOL HYDROCHLORIDE

BX		160MG	A078311	004	Mar 06, 2009	Jun CMFD
	@	160MG	A078311	004	Mar 06, 2009	May DISC
BX		160MG	A078311	004	Mar 06, 2009	Mar CTEC

INJECTABLE;INJECTION
PROPRANOLOL HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000	Jun CAHN
AP	EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Apr CAHN
	@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar DISC

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	@ FRONTIDA BIOPHARM	10MG	A070319	001	Oct 22, 1985	Jul CAHN
	@	20MG	A070320	001	Oct 22, 1985	Jul CAHN
	@	40MG	A070103	001	Oct 22, 1985	Jul CAHN
	@	60MG	A070321	001	Sep 24, 1986	Jul CAHN
	@	80MG	A070322	001	Aug 04, 1986	Jul CAHN
>A> AB	IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988	Aug CAHN
>A> AB		20MG	A071973	001	Apr 06, 1988	Aug CAHN
>A> AB		40MG	A071974	001	Apr 06, 1988	Aug CAHN
>A> AB		60MG	A071975	001	Apr 06, 1988	Aug CAHN
>A> AB	+	80MG	A071976	001	Apr 06, 1988	Aug CAHN
>D> AB	PLIVA	10MG	A071972	001	Apr 06, 1988	Aug CAHN
>D> AB		20MG	A071973	001	Apr 06, 1988	Aug CAHN
>D> AB		40MG	A071974	001	Apr 06, 1988	Aug CAHN
>D> AB		60MG	A071975	001	Apr 06, 1988	Aug CAHN
>D> AB	+	80MG	A071976	001	Apr 06, 1988	Aug CAHN
	@ SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar CAHN
	@	20MG	A070320	001	Oct 22, 1985	Mar CAHN
	@	40MG	A070103	001	Oct 22, 1985	Mar CAHN
	@	60MG	A070321	001	Sep 24, 1986	Jun CAHN
	@	80MG	A070322	001	Aug 04, 1986	Mar CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

	@ HIKMA INTL PHARMS	50MG	A080154	001		Jul CAHN
	@ SUN PHARM INDS	50MG	A083982	001		Mar CAHN

PYRIDOSTIGMINE BROMIDETABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan CAHN
----	---------------	-------	---------	-----	--------------	----------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

AP	+ FRESENIUS KABI USA	100MG/ML	A080618	001		Jul CTEC
AP	MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016	Jul NEWA

QUAZEPAM

TABLET;ORAL

DORAL

	@ CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar CAHN
+		15MG	N018708	001	Dec 27, 1985	Apr CMFD
	@	15MG	N018708	001	Dec 27, 1985	Mar CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

	@ ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr DISC
	@	EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr DISC
	@	EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr DISC
	@	EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr DISC
	@	EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr DISC
	@	EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr DISC
	@	EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr DISC
AB	MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May NEWA
AB		EQ 50MG BASE	A203359	002	May 17, 2016	May NEWA
AB		EQ 100MG BASE	A203359	003	May 17, 2016	May NEWA
AB		EQ 200MG BASE	A203359	004	May 17, 2016	May NEWA
AB		EQ 300MG BASE	A203359	005	May 17, 2016	May NEWA

TABLET;ORAL

QUETIAPINE FUMARATE

AB		EQ 400MG BASE	A203359	006	May 17, 2016	May NEWA
AB	UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb NEWA
AB		EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb NEWA
AB		EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb NEWA
AB		EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb NEWA
AB		EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb NEWA
AB		EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan DISC
@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan DISC
@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan DISC
@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@	AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar CAHN
BX +	SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar CAHN

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

@	SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun CAHN
AB		200MG	A081030	001	Apr 14, 1989	Mar CAHN
AB		300MG	A081031	001	Apr 14, 1989	Mar CAHN

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

AB +	SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun CAHN
------	----------------	-------	---------	-----	--------------	----------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun CAHN
+	10MG	N204736	002	Mar 26, 2013	Jun CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB	AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar NEWA
AB	GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

>A> AB	DR REDDYS LABS INTL	8MG	A091693	001	Jul 26, 2013	Aug CAHN
>D> AB	TEVA PHARMS USA	8MG	A091693	001	Jul 26, 2013	Aug CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

>D> AB	SANDOZ	1.25MG	A077514	001	Jun 18, 2008	Aug DISC
>A>	@	1.25MG	A077514	001	Jun 18, 2008	Aug DISC
>D> AB		2.5MG	A077514	002	Jun 18, 2008	Aug DISC
>A>	@	2.5MG	A077514	002	Jun 18, 2008	Aug DISC
>D> AB		5MG	A077514	003	Jun 18, 2008	Aug DISC
>A>	@	5MG	A077514	003	Jun 18, 2008	Aug DISC
>D> AB		10MG	A077514	004	Jun 18, 2008	Aug DISC
>A>	@	10MG	A077514	004	Jun 18, 2008	Aug DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP	MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May NEWA
AP	ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May CPOT

INJECTABLE; INJECTION

ZANTAC

AP	+	IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
		ZANTAC IN PLASTIC CONTAINER					
		@ IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan CAHN
		@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar CAHN
		@ WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr DISC
		@	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr DISC

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>A>	AB	STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Aug NEWA
>A>	AB		EQ 300MG BASE	A205512	002	Aug 22, 2016	Aug NEWA

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

AB		ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb NEWA
AB			EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb NEWA

RESERPINE

TABLET; ORAL

RESERPINE

	@	HIKMA INTL PHARMS	0.1MG	A080975	001		Feb CAHN
	@		0.25MG	A080975	002		Feb CAHN
	@		1MG	A080975	003		Feb CAHN

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan CAHN
---	-----------------	----	---------	-----	--------------	----------

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

+	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr NEWA
	PHOTREXA VISCOUS IN DEXTRAN 20%					
+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun CMS1
	PHOTREXA VISCOUS IN DEXTROSE 20%					
+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Apr NEWA

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP		EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Apr CAHN
AP		HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb NEWA
AP		WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan NEWA

RILUZOLE

TABLET; ORAL

RILUZOLE

AB		ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar NEWA
----	--	----------------	------	---------	-----	--------------	----------

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

@	ALCON	1%	N020474	001	Dec 30, 1994	Jun DISC
---	-------	----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB		APIL	5MG	N020835	002	Apr 14, 2000	Jan CAHN
AB			30MG	N020835	001	Mar 27, 1998	Jan CAHN
AB	+		35MG	N020835	003	May 25, 2002	Jan CAHN
	@		75MG	N020835	004	Apr 16, 2007	Jan CAHN
AB	+		150MG	N020835	005	Apr 22, 2008	Jan CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+	APIL	35MG	N022560	001	Oct 08, 2010	Jan CAHN
----	---	------	------	---------	-----	--------------	----------

RISPERIDONESOLUTION;ORAL
RISPERIDONE

>D> AA	SILARX PHARMS INC	1MG/ML	A202386	001	Jan 12, 2015	Aug DISC
>A>	@	1MG/ML	A202386	001	Jan 12, 2015	Aug DISC
	@ WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009	Apr DISC

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN

RIVASTIGMINE TARTRATECAPSULE;ORAL
EXELON

AB	+ NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
	RIVASTIGMINE TARTRATE					
AB	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB		EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB		EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB		EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA

RIZATRIPTAN BENZOATETABLET;ORAL
RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

ROPIVACAINE HYDROCHLORIDEINJECTABLE;INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar NEWA
----	-----------	--------	---------	-----	--------------	----------

SOLUTION;INJECTION
NAROPIN

	@ FRESenius KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May DISC
		50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May NEWA
AP		20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May CMS1
AP		20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar CDFR
AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar NEWA
	@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr DISC
		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr NEWA
AP		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun CFTG
		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May CMS1
		100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar CDFR
AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar NEWA
AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar CDFR
AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar NEWA
AP		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun CFTG
		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar NEWA
AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar NEWA
		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar NEWA
		500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr CMS1
		500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar NEWA
		1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr CMS1
		1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar NEWA

ROPIVACAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun NEWA
AP		100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun NEWA
AP		100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun NEWA
AP		150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun NEWA
AP		150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun NEWA
AP		200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun NEWA
AP		200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun NEWA
AP	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar CDFR
AP		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar NEWA
AP		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar CDFR
AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar CDFR

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar	NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar	CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar	CDFR

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr	CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr	CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr	CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr	CFTG

ROSUVASTATIN CALCIUM

AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079145	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079145	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079145	004	Jul 19, 2016	Jul	NEWA
AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079170	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079170	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079170	004	Jul 19, 2016	Jul	NEWA
AB	GLENMARK PHARMS LTD	5MG	A079172	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079172	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079172	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079172	004	Jul 19, 2016	Jul	NEWA
AB	MYLAN PHARMS INC	5MG	A079161	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079161	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079161	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079161	004	Jul 19, 2016	Jul	NEWA
AB	PAR PHARM INC	5MG	A079168	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079168	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079168	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079168	004	Jul 19, 2016	Jul	NEWA
AB	SANDOZ INC	5MG	A079171	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079171	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079171	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079171	004	Jul 19, 2016	Jul	NEWA
AB	SUN PHARMA GLOBAL	5MG	A079169	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079169	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079169	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079169	004	Jul 19, 2016	Jul	NEWA
AB	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079166	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079166	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079166	004	Jul 19, 2016	Jul	NEWA
AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	NEWA
AB		10MG	A079167	002	Apr 29, 2016	Apr	NEWA
AB		20MG	A079167	003	Apr 29, 2016	Apr	NEWA
AB		40MG	A079167	004	Apr 29, 2016	Apr	NEWA

RUFINAMIDE

TABLET; ORAL

BANZEL

AB	EISAI INC	200MG	N021911	002	Nov 14, 2008	May	CFTG
AB	+	400MG	N021911	003	Nov 14, 2008	May	CFTG

RUFINAMIDE

AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May	NEWA
AB		400MG	A205075	002	May 16, 2016	May	NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May	NEWA
AB		400MG	A205095	002	May 16, 2016	May	NEWA
AB	ROXANE	200MG	A204988	001	May 16, 2016	May	NEWA
AB		400MG	A204988	002	May 16, 2016	May	NEWA

SCOPOLAMINEFILM, EXTENDED RELEASE;TRANSDERMAL
TRANSDERM SCOP

AB + GLAXOSMITHKLINE CON 1MG/72HR

N017874 001

May CAHN

SECOBARBITAL SODIUMCAPSULE;ORAL
SECONAL SODIUM

>D> + MARATHON PHARMS 50MG
 >D> + 100MG
 >A> + VALEANT PHARMS NORTH 50MG
 >A> + 100MG

A086101 001 Oct 03, 1983 Aug CAHN
 A086101 002 Oct 03, 1983 Aug CAHN
 A086101 001 Oct 03, 1983 Aug CAHN
 A086101 002 Oct 03, 1983 Aug CAHN

SERTRALINE HYDROCHLORIDETABLET;ORAL
SERTRALINE HYDROCHLORIDE

@ FRONTIDA BIOPHARM EQ 25MG BASE
 @ EQ 50MG BASE
 @ EQ 100MG BASE
 @ SUN PHARM INDS EQ 25MG BASE
 @ EQ 50MG BASE
 @ EQ 100MG BASE

A077818 001 Feb 06, 2007 Jul CAHN
 A077818 002 Feb 06, 2007 Jul CAHN
 A077818 003 Feb 06, 2007 Jul CAHN
 A077818 001 Feb 06, 2007 Mar CAHN
 A077818 002 Feb 06, 2007 Mar CAHN
 A077818 003 Feb 06, 2007 Mar CAHN

SILDENAFIL CITRATETABLET;ORAL
SILDENAFIL CITRATE

AB @ ACTAVIS GRP PTC EQ 20MG BASE
 RUBICON RES PVT LTD EQ 20MG BASE
 @ TEVA EQ 25MG BASE
 EQ 25MG BASE
 @ EQ 50MG BASE
 EQ 50MG BASE
 @ EQ 100MG BASE
 EQ 100MG BASE

A200149 001 Feb 25, 2013 Apr DISC
 A204883 001 Jun 20, 2016 Jun NEWA
 A077342 001 Mar 09, 2016 Feb DISC
 A077342 001 Mar 09, 2016 Feb NEWA
 A077342 002 Mar 09, 2016 Feb DISC
 A077342 002 Mar 09, 2016 Feb NEWA
 A077342 003 Mar 09, 2016 Feb DISC
 A077342 003 Mar 09, 2016 Feb NEWA

SILODOSINCAPSULE;ORAL
RAPAFLO+ ALLERGAN SALES LLC 4MG
8MG

N022206 001 Oct 08, 2008 Apr CAHN
 N022206 002 Oct 08, 2008 Apr CAHN

SIMVASTATINSUSPENSION;ORAL
SIMVASTATIN

ROSEMONT PHARMS LTD 20MG/5ML
 + 40MG/5ML

N206679 001 Apr 21, 2016 Apr NEWA
 N206679 002 Apr 21, 2016 Apr NEWA

TABLET;ORAL

SIMVASTATIN
 @ SUN PHARM INDS LTD 5MG
 @ 10MG
 @ 20MG
 @ 40MG
 @ 80MG

A076285 001 Dec 20, 2006 Feb DISC
 A076285 002 Dec 20, 2006 Feb DISC
 A076285 003 Dec 20, 2006 Feb DISC
 A076285 004 Dec 20, 2006 Feb DISC
 A076285 005 Jun 23, 2006 Feb DISC

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION;IV (INFUSION)
AMMONUL

AP + MEDICIS 10%;10% (5GM/50ML;5GM/50ML)
 SODIUM PHENYLACETATE AND SODIUM BENZOATE

N020645 001 Feb 17, 2005 Feb CFTG

AP AILEX PHARMS PVT LTD 10%;10% (5GM/50ML;5GM/50ML)
 AP NAVINTA LLC 10%;10% (5GM/50ML; 5GM/50ML)

A207096 001 Feb 24, 2016 Feb NEWA
 A205880 001 Aug 04, 2016 Jul NEWA

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

HOSPIRA INC 0.5MEQ/ML

A202981 001 Mar 04, 2016 Feb NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	450MG/100ML	N018090	001		Aug	CRLD
>A>	AP	+	450MG/100ML	N018090	001		Aug	CRLD
		SODIUM CHLORIDE 0.9%						
>A>		B BRAUN	900MG/10ML	N019635	005	Aug 11, 2016	Aug	NEWA
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	AP	JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May	NEWA
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER						
>D>		BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Aug	CRLD
>A>		+	3GM/100ML	N019022	001	Nov 01, 1983	Aug	CRLD

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May	NEWA
AP		ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

JUBILANT DRAXIMAGE 0.009-0.1mCi
@ 2-200mCi

N021305	006	May 19, 2005	Mar	CMS1
N021305	004	Nov 18, 2004	Mar	CMS1

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB	+	HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar	CAHN
		SODIUM PHENYLBUTYRATE						
AB		PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun	NEWA
		TABLET;ORAL						
		BUPHENYL						
AB	+	HORIZON PHARMA INC	500MG	N020572	001	May 13, 1996	Mar	CAHN
		SODIUM PHENYLBUTYRATE						
AB		PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr	NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb	NEWA
AA		INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb	NEWA

SOFOBUVIR; VELPATASVIR

TABLET;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016	Jun	NEWA
---	---------------------	-------------	---------	-----	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

@	IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar	DISC
@		120MG	A075663	002	Nov 07, 2000	Mar	DISC
@		160MG	A075663	003	Nov 07, 2000	Mar	DISC
@		240MG	A075663	004	Nov 07, 2000	Mar	DISC
@	SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar	CAHN
@		80MG	A076576	001	Apr 08, 2004	Mar	CAHN
@		120MG	A075515	004	Oct 15, 2001	Mar	CAHN
@		120MG	A076576	002	Apr 08, 2004	Mar	CAHN
@		160MG	A075515	002	Oct 15, 2001	Mar	CAHN
@		160MG	A076576	003	Apr 08, 2004	Mar	CAHN
@		240MG	A075515	003	Oct 15, 2001	Mar	CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB		SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar	CAHN
AB			50MG	A089424	002	Aug 11, 1999	Mar	CAHN
AB			100MG	A089424	003	Aug 11, 1999	Mar	CAHN

SUCRALFATE

TABLET; ORAL							
SUCRALFATE							
AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan	CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS
BRIDION

	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan	CPOT
+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan	CPOT

SULFAMETHOXAZOLE

TABLET; ORAL
SULFAMETHOXAZOLE

@ AUROLIFE PHARMA LLC	500MG	A085844	001			Feb	CAHN
-----------------------	-------	---------	-----	--	--	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
BACTRIM

@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	001			Jun	CAHN
------------------	---------------------	---------	-----	--	--	-----	------

BACTRIM PEDIATRIC							
-------------------	--	--	--	--	--	--	--

@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	002			Jun	CAHN
------------------	---------------------	---------	-----	--	--	-----	------

TABLET; ORAL
BACTRIM

AB	SUN PHARM INDS	400MG; 80MG	N017377	001		Mar	CAHN
----	----------------	-------------	---------	-----	--	-----	------

AB	+ SUN PHARM INDS	800MG; 160MG	N017377	002		Mar	CAHN
----	------------------	--------------	---------	-----	--	-----	------

	SULFAMETHOXAZOLE AND TRIMETHOPRIM						
--	-----------------------------------	--	--	--	--	--	--

AB	SUN PHARM INDS	800MG; 160MG	A071017	001	Aug 25, 1986	Mar	CAHN
----	----------------	--------------	---------	-----	--------------	-----	------

SULFASALAZINE

TABLET; ORAL
SULFASALAZINE

@ SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987	Mar	CAHN
------------------	-------	---------	-----	--------------	-----	------

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE

@ AUROLIFE PHARMA LLC	500MG	A085628	001			Feb	CAHN
-----------------------	-------	---------	-----	--	--	-----	------

SULINDAC

TABLET; ORAL
SULINDAC

AB	SUN PHARM INDS	150MG	A072050	001	Apr 17, 1991	Mar	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

AB		200MG	A072051	001	Apr 17, 1991	Mar	CAHN
----	--	-------	---------	-----	--------------	-----	------

SUMATRIPTAN

SPRAY; NASAL
IMITREX

AB	+ GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997	Feb	CFTG
----	-------------------	-----------	---------	-----	--------------	-----	------

AB	+	20MG/SPRAY	N020626	003	Aug 26, 1997	Feb	CFTG
----	---	------------	---------	-----	--------------	-----	------

SUMATRIPTAN

AB	LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016	Feb	NEWA
----	---------	-----------	---------	-----	--------------	-----	------

AB		20MG/SPRAY	A204841	002	Feb 19, 2016	Feb	NEWA
----	--	------------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AP	EUROHLTH INTL SARL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jun	CAHN
----	--------------------	--	---------	-----	--------------	-----	------

POWDER; INHALATION
ONZETRA XSAIL

+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan	NEWA
---	---------------	--------------	---------	-----	--------------	-----	------

SOLUTION; SUBCUTANEOUS
ZEMBRACE SYMTOUCH

	DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan	NEWA
--	--------------------	--	---------	-----	--------------	-----	------

TACROLIMUSOINTMENT; TOPICAL
PROTOPIC

AB	+	LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun CAHN
AB	+		0.1%	N050777	002	Dec 08, 2000	Jun CAHN

TAMOXIFEN CITRATESOLUTION; ORAL
SOLTAMOX

MIDATECH PHARMA US EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005 Jan CAHN

TABLET; ORAL

TAMOXIFEN CITRATE

@ ACTAVIS LABS FL INC EQ 10MG BASE

A076179 001 Feb 20, 2003 Jan DISC

@ EQ 20MG BASE

A076179 002 Feb 20, 2003 Jan DISC

>A> AB MAYNE PHARMA EQ 10MG BASE

A075797 001 Feb 20, 2003 Aug CAHN

>A> AB + EQ 20MG BASE

A074858 001 Feb 20, 2003 Aug CAHN

>D> AB TEVA EQ 10MG BASE

A075797 001 Feb 20, 2003 Aug CAHN

>D> AB + TEVA PHARMS EQ 20MG BASE

A074858 001 Feb 20, 2003 Aug CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

ULTRA-TECHNEKOW FM

+ MALLINKRODT NUCLEAR 1-19 CI/GENERATOR
@ 0.25-3 CI/GENERATORN017243 003 Feb 18, 2014 Jan CAHN
N017243 002 Jan CAHN>D> TECHNETIUM TC-99M SUCCIMER KIT

>D> INJECTABLE; INJECTION

>D> MPI DMSA KIDNEY REAGENT

>D> GE HEALTHCARE N/A

N017944 001 May 18, 1982 Aug DISC

>A> @ N/A

N017944 001 May 18, 1982 Aug DISC

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

@ US WORLDMEDS LLC EQ 2MG BASE

N021200 001 Jul 24, 2002 Jan CAHN

@ EQ 6MG BASE

N021200 002 Jul 24, 2002 Jan CAHN

TELITHROMYCIN

TABLET; ORAL

KETEK

@ SANOFI AVENTIS US 300MG

N021144 002 Feb 09, 2005 Mar DISC

@ 400MG

N021144 001 Apr 01, 2004 Mar DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB HETERO LABS LTD V 20MG

A205901 001 Apr 22, 2016 Apr NEWA

AB 40MG

A205901 002 Apr 22, 2016 Apr NEWA

AB 80MG

A205901 003 Apr 22, 2016 Apr NEWA

>A> AB JUBILANT GENERICS 20MG

A204164 001 Aug 22, 2016 Aug NEWA

>A> AB 40MG

A204164 002 Aug 22, 2016 Aug NEWA

>A> AB 80MG

A204164 003 Aug 22, 2016 Aug NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB AMNEAL PHARMS 7.5MG

A203482 001 May 23, 2016 May NEWA

AB 15MG

A203482 002 May 23, 2016 May NEWA

AB 22.5MG

A203482 003 May 23, 2016 May NEWA

AB 30MG

A203482 004 May 23, 2016 May NEWA

AB SUN PHARM INDS 7.5MG

A078581 001 Sep 08, 2009 Mar CAHN

@ 15MG

A071174 001 Jul 10, 1986 Mar CAHN

AB 22.5MG

A071175 002 Sep 14, 2009 Mar CAHN

@ 30MG

A071175 001 Jul 10, 1986 Mar CAHN

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB AMERIGEN PHARMS LTD 5MG

A203490 001 Jul 13, 2016 Jul NEWA

AB 20MG

A203490 002 Jul 13, 2016 Jul NEWA

AB 100MG

A203490 003 Jul 13, 2016 Jul NEWA

CAPSULE;ORAL							
TEMOZOLOMIDE							
AB		140MG	A203490	004	Jul 13, 2016	Jul	NEWA
AB		180MG	A203490	005	Jul 13, 2016	Jul	NEWA
AB		250MG	A203490	006	Jul 13, 2016	Jul	NEWA
AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA
AB		20MG	A206413	002	Apr 12, 2016	Mar	NEWA
AB		100MG	A206413	003	Apr 12, 2016	Mar	NEWA
AB		140MG	A206413	004	Apr 12, 2016	Mar	NEWA
AB		180MG	A206413	005	Apr 12, 2016	Mar	NEWA
AB		250MG	A206413	006	Apr 12, 2016	Mar	NEWA
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA
AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA
AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA
AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA
AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA
AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA
AB	LOTUS PHARM CO LTD	5MG	A206309	001	Apr 27, 2016	Apr	NEWA
AB		20MG	A206309	002	Apr 27, 2016	Apr	NEWA
AB		100MG	A206309	003	Apr 27, 2016	Apr	NEWA
AB		140MG	A206309	004	Apr 27, 2016	Apr	NEWA
AB		180MG	A206309	005	Apr 27, 2016	Apr	NEWA
AB		250MG	A206309	006	Apr 27, 2016	Apr	NEWA
AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Jun	NEWA
AB		20MG	A205227	002	Jun 29, 2016	Jun	NEWA
AB		100MG	A205227	003	Jun 29, 2016	Jun	NEWA
AB		140MG	A205227	004	Jun 29, 2016	Jun	NEWA
AB		180MG	A205227	005	Jun 29, 2016	Jun	NEWA
AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA
<u>TERBUTALINE SULFATE</u>							
INJECTABLE;INJECTION							
TERBUTALINE SULFATE							
AP	+ AMPHASTAR PHARMS INC	1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
AP	+ EUROHLTH INTL SARL	1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN
TABLET;ORAL							
TERBUTALINE SULFATE							
	@ IMPAX LABS	2.5MG	A075877	001	Jun 26, 2001	Mar	DISC
	@	5MG	A075877	002	Jun 26, 2001	Mar	DISC
	LANNETT	2.5MG	A077152	001	Mar 25, 2005	Mar	CTEC
		5MG	A077152	002	Mar 25, 2005	Mar	CTEC
<u>TESTOSTERONE</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
ANDRODERM							
+	ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011	Mar	CAHN
@		2.5MG/24HR	N020489	001	Sep 29, 1995	Mar	CAHN
+		4MG/24HR	N020489	004	Oct 20, 2011	Mar	CAHN
@		5MG/24HR	N020489	002	May 02, 1997	Mar	CAHN
GEL, METERED;NASAL							
NATESTO							
	AYTU BIOSCIENCE INC	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	CAHN
PELLET;IMPLANTATION							
TESTOPEL							
+	AUXILIUM PHARMS INC	75MG	A080911	001		Mar	CAHN
TABLET, EXTENDED RELEASE;BUCCAL							
STRIANT							
+	AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	Mar	CAHN
<u>TESTOSTERONE CYPIONATE</u>							
INJECTABLE;INJECTION							
TESTOSTERONE CYPIONATE							
AO	EUROHLTH INTL SARL	100MG/ML	A090387	001	Jul 15, 2010	Jun	CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jun	CAHN
<u>TETRABENAZINE</u>							
TABLET;ORAL							
TETRABENAZINE							
AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan	NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan	NEWA

TETRACAINE HYDROCHLORIDESOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

+ ALCON RES LTD 0.5%

N208135 001 Feb 29, 2016 Feb NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

TETRACYCLINE HYDROCHLORIDE

AB CHARTWELL CIENCA 250MG
 AB 500MG
 >A> @ IDT AUSTRALIA LTD 250MG
 >D> @ SANDOZ 250MG
 @ SUN PHARM INDS 250MG
 @ 500MG

A062752 001 Aug 12, 1988 Apr CMFD
 A062752 002 Aug 12, 1988 Apr CMFD
 A061471 001 Aug CAHN
 A061471 001 Aug CAHN
 A060736 001 Mar CAHN
 A060736 002 Mar CAHN

THEOPHYLLINECAPSULE, EXTENDED RELEASE;ORAL
THEO-24

AUXILIUM PHARMS INC 200MG
 300MG
 + 400MG
 AUXILIUM PHARMS LLC 200MG
 300MG

A087943 001 Aug 22, 1983 Mar CAHN
 A087944 001 Aug 22, 1983 Mar CAHN
 A081034 001 Feb 28, 1992 Mar CAHN
 A087943 001 Aug 22, 1983 Jul CAHN
 A087944 001 Aug 22, 1983 Jul CAHN

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

+ NOSTRUM LABS INC 80MG/15ML

A085186 001 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

AB NOSTRUM LABS INC 100MG
 AB 200MG
 @ 300MG
 THEOPHYLLINE
 AB MYLAN IRELAND LTD 400MG
 AB + 600MG
 >A> AB RHODES PHARMS 400MG
 >D> UNIPHYL
 >D> AB RHODES PHARMS 400MG

A088320 001 Feb 21, 1985 Jan CAHN
 A088321 001 Feb 21, 1985 Jan CAHN
 A087400 002 Jan 11, 1983 Jan CAHN
 A040560 003 Apr 21, 2006 Jan CAHN
 A040560 002 Apr 21, 2006 Jan CAHN
 A087571 001 Sep 01, 1982 Aug CTNA
 A087571 001 Sep 01, 1982 Aug CTNA

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

AB SUN PHARM INDS 10MG
 @ 15MG
 AB 25MG
 AB 50MG
 AB 100MG
 @ 150MG
 @ 200MG

A089953 004 Aug 01, 1986 Mar CAHN
 A088461 001 Nov 18, 1983 Mar CAHN
 A089953 003 Aug 01, 1986 Mar CAHN
 A089953 002 Aug 01, 1986 Mar CAHN
 A089953 001 Oct 07, 1988 Mar CAHN
 A088737 001 Sep 26, 1984 Mar CAHN
 A088738 001 Oct 16, 1984 Mar CAHN

THIOTHIXENE

CAPSULE;ORAL

>D> NAVANE
 >D> AB PFIZER 1MG
 >A> @ 1MG
 >D> AB 2MG
 >A> @ 2MG
 >D> AB + 5MG
 >A> @ 5MG
 >D> AB 10MG
 >A> @ 10MG

N016584 001 Aug DISC
 N016584 001 Aug DISC
 N016584 002 Aug DISC
 N016584 002 Aug DISC
 N016584 003 Aug DISC
 N016584 003 Aug DISC
 N016584 004 Aug DISC
 N016584 004 Aug DISC

THIOTHIXENE

>D> AB MYLAN 1MG
 >A> 1MG
 >D> AB 2MG
 >A> 2MG
 >D> AB 5MG
 >A> + 5MG
 >D> AB 10MG
 >A> 10MG
 @ SANDOZ 1MG
 @ 2MG

A071093 002 Jun 23, 1987 Aug CTEC
 A071093 002 Jun 23, 1987 Aug CTEC
 A071093 003 Jun 23, 1987 Aug CTEC
 A071093 003 Jun 23, 1987 Aug CTEC
 A071093 004 Jun 23, 1987 Aug CRLD
 A071093 004 Jun 23, 1987 Aug CRLD
 A071093 001 Jun 23, 1987 Aug CTEC
 A071093 001 Jun 23, 1987 Aug CTEC
 A071610 001 Jun 24, 1987 Mar DISC
 A071570 001 Jun 24, 1987 Mar DISC

CAPSULE;ORAL
THIOTHIXENE

@	5MG	A071529	001	Jun 24, 1987	Mar DISC
@	10MG	A071530	001	Jun 24, 1987	Mar DISC

TINIDAZOLETABLET;ORAL
TINIDAZOLE

BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr CTEC
BX		500MG	A202489	002	Oct 09, 2013	Apr CTEC

TIROFIBAN HYDROCHLORIDESOLUTION;INJECTION
AGGRASTAT

>A>	+ MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016	Aug NEWA
-----	------------	---	---------	-----	--------------	----------

TOBRAMYCIN SULFATEINJECTABLE;INJECTION
TOBRAMYCIN SULFATE

AP	CLARIS	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Jun NEWA
----	--------	-----------------	---------	-----	--------------	----------

TOFACITINIB CITRATETABLET, EXTENDED RELEASE;ORAL
XELJANZ XR

+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb NEWA
---	------------	--------------	---------	-----	--------------	----------

TOLAZAMIDETABLET;ORAL
TOLAZAMIDE

@	SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar CAHN
@		250MG	A071358	001	Jul 16, 1987	Mar CAHN
@		500MG	A071359	001	Jul 16, 1987	Mar CAHN

TOLMETIN SODIUMCAPSULE;ORAL
TOLMETIN SODIUM

@	SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar CAHN
---	----------------	---------------	---------	-----	--------------	----------

TABLET;ORAL

TOLMETIN SODIUM

AB	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar CAHN
----	----------------	---------------	---------	-----	--------------	----------

TOPIRAMATETABLET;ORAL
TOPIRAMATE

@	ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Apr DISC
AB		25MG	A078637	001	Feb 27, 2013	Jan CAHN
@		50MG	A078637	002	Feb 27, 2013	Apr DISC
AB		50MG	A078637	002	Feb 27, 2013	Jan CAHN
@		100MG	A078637	003	Feb 27, 2013	Apr DISC
AB		100MG	A078637	003	Feb 27, 2013	Jan CAHN
@		200MG	A078637	004	Feb 27, 2013	Apr DISC
AB		200MG	A078637	004	Feb 27, 2013	Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar CAHN
AB	SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
ULTRAM ER

AB1	+ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar CAHN
AB1		200MG	N021692	002	Sep 08, 2005	Mar CAHN
AB1		300MG	N021692	003	Sep 08, 2005	Mar CAHN

TRANEXAMIC ACIDINJECTABLE;INJECTION
TRANEXAMIC ACID

AP	AKORN	100MG/ML	A206634	001	Jun 09, 2016	May NEWA
AP	AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan NEWA
AP	NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb NEWA

TABLET;ORAL

TRANEXAMIC ACID

	@ AMERIGEN PHARMS LTD	650MG	A203256	001	Jul 25, 2016	Jul DISC
AB		650MG	A203256	001	Jul 25, 2016	Jul NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb CAHN
AB	SUN PHARM INDS	50MG	A073137	002	Mar 24, 1993	Mar CAHN
AB		100MG	A073137	001	Mar 24, 1993	Mar CAHN
AB		150MG	A073137	003	Dec 22, 1995	Mar CAHN

TRETINOIN

CREAM;TOPICAL

TRETINOIN

	+ ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Jul CAHN
		0.075%	A202209	001	Oct 11, 2012	Jul CAHN
AB	ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Feb CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Feb CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Feb CAHN
AB	PERRIGO PHARMA INTL	0.025%	A075264	001	Dec 24, 1998	Jul CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Jul CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Jul CAHN

GEL;TOPICAL

TRETINOIN

AB	ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Feb CAHN
AB	PERRIGO PHARMA INTL	0.01%	A075589	001	Jun 11, 2002	Jul CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Jul CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul NEWA
----	---------------------	------	---------	-----	--------------	----------

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	TELIGENT PHARMA INC	0.025%	A204608	001	Jul 07, 2016	Jun NEWA
AT		0.1%	A204606	001	Jul 07, 2016	Jun NEWA

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul NEWA
AT	TELIGENT PHARMA INC	0.1%	A205373	001	May 13, 2016	May NEWA

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

AT	VERSAPHARM INC	0.1%	A206312	001	Aug 11, 2016	Jul NEWA
----	----------------	------	---------	-----	--------------	----------

SPRAY;TOPICAL

KENALOG

AT	+ RANBAXY LABS LTD	0.147MG/GM	N012104	001		Jul CAHN
----	--------------------	------------	---------	-----	--	----------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar CAHN
----	----------------	-------	---------	-----	--------------	----------

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

>A>	AB	+ MAYNE PHARMA	100MG	N018679	001	Jul 30, 1982	Aug CAHN
		@ SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun CAHN
		@	200MG	A070495	001	Sep 24, 1986	Mar CAHN
>D>	AB	+ TEVA	100MG	N018679	001	Jul 30, 1982	Aug CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

	+ AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun CAHN
	@ AYTU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun CMS2
	@	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jan CAHN
	+	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr NEWA
AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr NEWA
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr NEWA

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

TRELSTAR

+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr CAHN

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIMUM CHLORIDE

>D> AB	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Aug CRLD
>A> AB	+	60MG	A091289	001	Oct 12, 2012	Aug CRLD
	@ SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr DISC

TABLET;ORAL

TROSPIMUM CHLORIDE

>D> AB	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Aug CRLD
>A> AB	+	20MG	A091575	001	Aug 13, 2010	Aug CRLD
>A> AB	HERITAGE PHARMS INC	20MG	A204945	001	Aug 30, 2016	Aug NEWA
>A> AB	INVAGEN PHARMS	20MG	A091688	001	Aug 23, 2016	Aug NEWA

URSODIOL

CAPSULE;ORAL

ACTIGALL

	@ ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
AB	+	300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	Jul CFTG
		VALGANCICLOVIR HYDROCHLORIDE					
AB		ACTAVIS LABS FL INC	50MG/ML	A205220	001	Jul 18, 2016	Jul NEWA

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar NEWA
AB	HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar NEWA

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

AP	AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun CAHN
AP	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

SYRUP;ORAL

VALPROIC ACID

AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
----	------------------	-----------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar NEWA
AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar NEWA
AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar NEWA
AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar NEWA
AP	CFT PHARMS LLC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015	Jul CAHN
AP		EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015	Jul CAHN
AP		EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Jul CAHN
AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Jul CAHN

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

>A>	AP	FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A062663	005	Aug 17, 2016	Aug NEWA
	AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan NEWA
	AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan NEWA

VANDETANIB

TABLET; ORAL
CAPRELSA

		GENZYME CORP	100MG	N022405	001	Apr 06, 2011	Jun CAHN
	+		300MG	N022405	002	Apr 06, 2011	Jun CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP		EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Apr CAHN
AP			20MG/VIAL	A075549	002	Jun 13, 2000	Apr CAHN
AP		GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May NEWA
AP			20MG/VIAL	A205390	002	May 26, 2016	May NEWA
AP		SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan CAHN
AP			20MG/VIAL	A078274	002	Dec 29, 2008	Jan CAHN

VENETOCLAX

TABLET; ORAL
VENCLEXTA

		ABBVIE INC	10MG	N208573	001	Apr 11, 2016	Apr NEWA
			50MG	N208573	002	Apr 11, 2016	Apr NEWA
	+		100MG	N208573	003	Apr 11, 2016	Apr NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

AP		EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr CMFD
----	--	----------------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE
@ SUN PHARM INDS 80MG
@ 120MG

A071489	002	Jan 13, 1988	Jun CAHN
A071489	001	Jan 13, 1988	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

@ PFIZER

VERAPAMIL HYDROCHLORIDE

>D>	AB	GLENMARK GENERICS	180MG	A090700	002	Aug 03, 2011	Aug CRLD
>A>	AB	+	180MG	A090700	002	Aug 03, 2011	Aug CRLD

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

AP		EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr CAHN
----	--	--------------------	-----------------	---------	-----	--------------	----------

VORICONAZOLE

FOR SUSPENSION; ORAL
VORICONAZOLE

AB		AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar NEWA
AB		NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May NEWA

INJECTABLE; IV (INFUSION)
VORICONAZOLE

AP		ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar NEWA
----	--	-------------	------------	---------	-----	--------------	----------

TABLET; ORAL

VORICONAZOLE

AB		AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May NEWA
AB			200MG	A206181	002	May 24, 2016	May NEWA
AB		APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May NEWA
AB			200MG	A206762	002	May 24, 2016	May NEWA
AB		AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan NEWA
AB			200MG	A206837	002	Jan 22, 2016	Jan NEWA
AB		NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May NEWA
AB			200MG	A207371	002	May 24, 2016	May NEWA
AB		PRINSTON INC	50MG	A206654	001	Aug 08, 2016	Jul NEWA
AB			200MG	A206654	002	Aug 08, 2016	Jul NEWA
>A>	AB	VERSAPHARM INC	50MG	A207049	001	Sep 07, 2016	Aug NEWA
>A>	AB		200MG	A207049	002	Sep 07, 2016	Aug NEWA
AB		ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May NEWA

TABLET;ORAL							
VORICONAZOLE							
AB		200MG	A206747	002	May 24, 2016	May	NEWA
<u>VORTIOXETINE HYDROBROMIDE</u>							
TABLET;ORAL							
TRINTELLIX							
	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun	CTNA
		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun	CTNA
		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun	CTNA
+		EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun	CTNA
<u>XENON XE-133</u>							
GAS;INHALATION							
XENON XE 133							
	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb	CTEC
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD
		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD
<u>ZIDOVUDINE</u>							
TABLET;ORAL							
ZIDOVUDINE							
>D> AB	SUNSHINE LAKE	300MG	A202058	001	Oct 07, 2011	Aug	DISC
>A>	@	300MG	A202058	001	Oct 07, 2011	Aug	DISC
<u>ZOLEDRONIC ACID</u>							
INJECTABLE;IV (INFUSION)							
ZOLEDRONIC ACID							
>A> AP	GLAND PHARMA LTD	EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Aug	NEWA
<u>ZOLMITRIPTAN</u>							
TABLET;ORAL							
ZOLMITRIPTAN							
AB	AJANTA PHARMA LTD	2.5MG	A204041	001	May 20, 2016	May	NEWA
AB		5MG	A204041	002	May 20, 2016	May	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr	NEWA
AB		5MG	A207021	002	May 11, 2016	Apr	NEWA
<u>ZOLPIDEM TARTRATE</u>							
TABLET;ORAL							
ZOLPIDEM TARTRATE							
>D> AB	LEK PHARMS DD	5MG	A077322	001	Apr 23, 2007	Aug	CAHN
>D> AB		10MG	A077322	002	Apr 23, 2007	Aug	CAHN
>A> AB	SANDOZ INC	5MG	A077322	001	Apr 23, 2007	Aug	CAHN
>A> AB		10MG	A077322	002	Apr 23, 2007	Aug	CAHN
	@ SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007	Mar	CAHN
	@	10MG	A077288	002	Apr 23, 2007	Mar	CAHN
TABLET;SUBLINGUAL							
EDLUAR							
AB	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009	Jul	CFTG
AB	+	10MG	N021997	002	Mar 13, 2009	Jul	CFTG
ZOLPIDEM TARTRATE							
AB	MYLAN PHARMS INC	5MG	A202657	001	Aug 08, 2016	Jul	NEWA
AB		10MG	A202657	002	Aug 08, 2016	Jul	NEWA
AB	PAR FORM	5MG	A201509	001	Aug 01, 2016	Jul	NEWA
AB		10MG	A201509	002	Aug 01, 2016	Jul	NEWA
<u>ZONISAMIDE</u>							
CAPSULE;ORAL							
ZONEGRAN							
AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb	CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb	CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb	CAHN
ZONISAMIDE							
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan	CAHN
	@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar	CAHN
	@	50MG	A077635	002	Dec 22, 2005	Mar	CAHN
	@	100MG	A077635	003	Dec 22, 2005	Mar	CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG; 250MG; 65MG N020802 001 Jan 14, 1998 Feb CAHN

ADAPALENE

GEL; TOPICAL

DIFFERIN

>A> + GALDERMA LABS LP 0.1% N020380 002 Jul 08, 2016 Aug NEWA

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

APOTEX INC 0.032MG/SPRAY A078949 002 Nov 20, 2015 Apr NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

>D> CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE A077355 001 Feb 06, 2008 Aug CTNA

>D> PERRIGO R AND D 800MG; 10MG; 165MG A077355 001 Feb 06, 2008 Aug CTNA

>A> FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE A077355 001 Feb 06, 2008 Aug CTNA

>A> PERRIGO R AND D 800MG; 10MG; 165MG A204782 001 Aug 29, 2016 Aug NEWA

>A> 800MG; 10MG; 165MG A204782 001 Aug 29, 2016 Aug NEWA

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A> APOTEX INC 10MG A207235 001 Aug 12, 2016 Aug NEWA

BIONPHARMA INC 5MG N022429 001 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG N022429 002 Jul 23, 2009 Jan CAHN

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ CYPRESS PHARM 5MG/5ML A090300 001 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML A091327 001 Oct 17, 2011 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CYPRESS PHARM 5MG/5ML A090300 002 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML A091327 002 Oct 17, 2011 Mar CAHN

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG A206793 001 Mar 08, 2016 Feb NEWA

10MG A206793 002 Mar 08, 2016 Feb NEWA

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

+ BECTON DICKINSON 4% A072525 001 Oct 24, 1989 Jun CRLD

PHARMASEAL SCRUB CARE

@ CAREFUSION 4% N019793 001 Dec 02, 1988 Jun DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+ BECTON DICKINSON CO 2%; 70% (3ML) N020832 001 Jul 14, 2000 May CAHN

+ 2%; 70% (10.5ML) N020832 004 Aug 20, 2003 May CAHN

+ 2%; 70% (26ML) N020832 006 Nov 21, 2006 May CAHN

CHLORAPREP ONE-STEP FREPP

+ BECTON DICKINSON CO 2%; 70% (1.5ML) N020832 003 Apr 26, 2002 May CAHN

CHLORAPREP WITH TINT

+ BECTON DICKINSON CO 2%; 70% (26ML) N020832 002 May 03, 2005 May CAHN

+ 2%; 70% (10.5ML) N020832 005 Apr 03, 2006 May CAHN

+ 2%; 70% (3ML) N020832 007 Oct 10, 2006 May CAHN

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ BECTON DICKINSON CO 2%; 70% (0.67ML) N021555 001 Oct 07, 2002 May CAHN

CHLORAPREP SINGLE SWABSTICK

+ BECTON DICKINSON CO 2%; 70% (1.75ML) N021555 002 May 10, 2005 May CAHN

CHLORAPREP TRIPLE SWABSTICK

+ BECTON DICKINSON CO 2%; 70% (5.25ML) N021555 003 Jun 10, 2009 May CAHN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL
 CHLORPHENIRAMINE MALEATE
 @ AUROLIFE PHARMA LLC 12MG

A070797 001 Aug 12, 1988 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE
 BIONPHARMA INC 25MG;EQ 200MG FREE ACID AND
 POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL
 FAMOTIDINE
 AUROBINDO PHARMA LTD 10MG
 20MG

A206531 001 Apr 26, 2016 Apr NEWA
 A206531 002 Apr 26, 2016 Apr NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
 HETERO LABS LTD V 30MG
 FEXOFENADINE HYDROCHLORIDE ALLERGY

>A> A204097 001 Aug 19, 2016 Aug NEWA

>A> A204097 002 Aug 19, 2016 Aug NEWA

>A> A204097 003 Aug 19, 2016 Aug NEWA

FLUTICASONE FUROATE

SPRAY, METERED;NASAL
 FLONASE SENSIMIST ALLERGY RELIEF
 + GLAXOSMITHKLINE 0.0275MG/SPRAY

>A> N022051 002 Aug 02, 2016 Aug NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
 FLUTICASONE PROPIONATE
 APOTEX INC 0.05MG/SPRAY
 APOTEX TECHNOLOGIES 0.05MG/SPRAY
 ROXANE 0.05MG/SPRAY

A208150 001 Feb 29, 2016 Jul CAHN
 A208150 001 Feb 29, 2016 Feb NEWA
 A207957 001 May 26, 2016 May NEWA

IBUPROFEN

CAPSULE;ORAL
 IBUPROFEN
 BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM
 SALT
 PURACAP PHARM LLC EQ 200MG FREE ACID AND POTASSIUM
 SALT
 SOFGEN PHARMS EQ 200MG FREE ACID AND POTASSIUM
 SALT
 MIDOL LIQUID GELS
 + BIONPHARMA INC 200MG
 TABLET;ORAL
 IBUPROFEN
 STRIDES PHARMA 200MG
 200MG
 @ SUN PHARM INDS 200MG
 @ 200MG
 @ 200MG

A078682 001 Mar 24, 2009 Jan CAHN
 A206568 001 Jun 21, 2016 Jun NEWA
 A203599 001 Sep 07, 2016 Aug NEWA
 N021472 001 Oct 18, 2002 Jan CAHN
 A079129 001 Mar 28, 2011 May CAHN
 A091355 001 Apr 04, 2011 May CAHN
 A070493 001 Dec 24, 1985 Mar CAHN
 A070908 001 Sep 26, 1986 Mar CAHN
 A071462 001 Oct 02, 1986 Mar CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
 KETOTIFEN FUMARATE
 ALCON PHARMS LTD EQ 0.025% BASE
 + EQ 0.025% BASE
 ZADITOR
 + ALCON PHARMA EQ 0.025% BASE
 @ EQ 0.025% BASE

>D> A077200 001 Sep 02, 2008 Aug CRLD
 >A> A077200 001 Sep 02, 2008 Aug CRLD
 >D>
 >D> N021066 002 Oct 19, 2006 Aug DISC
 >A> N021066 002 Oct 19, 2006 Aug DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
 LANSOPRAZOLE
 MYLAN PHARMS INC 15MG
 PREVACID 24 HR
 + GLAXOSMITHKLINE CONS 15MG

A203187 001 Jun 01, 2016 May NEWA
 N022327 001 May 18, 2009 Aug CAHN

	CAPSULE, DELAYED REL PELLETS;ORAL						
	PREVACID 24 HR						
>D>	+	NOVARTIS 15MG	N022327	001	May 18, 2009	Aug	CAHN
	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL						
	LANSOPRAZOLE						
		DEXCEL PHARMA 15MG	N208025	001	Jun 07, 2016	Jun	NEWA
	<u>LEVONORGESTREL</u>						
	TABLET;ORAL						
	HER STYLE						
		NOVAST LABS LTD 1.5MG	A207976	001	Mar 11, 2016	Feb	NEWA
	LEVONORGESTREL						
		GLENMARK PHARMS LTD 1.5MG	A207044	001	Mar 25, 2016	Mar	NEWA
>A>		JAI PHARMA LTD 0.75MG	A202740	001	Sep 02, 2016	Aug	NEWA
>A>		LOTUS PHARM CO LTD 0.75MG	A202684	001	Sep 02, 2016	Aug	NEWA
	<u>LOPERAMIDE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	LOPERAMIDE HYDROCHLORIDE						
		BIONPHARMA INC 1MG	N021855	001	Aug 04, 2005	Jan	CAHN
	+	2MG	N021855	002	Aug 04, 2005	Jan	CAHN
	<u>MICONAZOLE NITRATE</u>						
	CREAM, SUPPOSITORY;TOPICAL, VAGINAL						
	MONISTAT 3 COMBINATION PACK						
	+	MEDTECH PRODUCTS 2%,200MG	N020670	002	Apr 16, 1996	Mar	CMS1
	<u>NAPROXEN SODIUM</u>						
	CAPSULE;ORAL						
	NAPROXEN SODIUM						
	+	BIONPHARMA INC EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar	CAHN
	TABLET;ORAL						
	NAPROXEN SODIUM						
		AUROBINDO PHARMA LTD EQ 200MG BASE	A205497	001	Mar 18, 2016	Mar	NEWA
	<u>NICOTINE</u>						
	FILM, EXTENDED RELEASE;TRANSDERMAL						
	HABITROL						
>D>	+	DR REDDYS LABS INC 7MG/24HR	N020076	004	Nov 12, 1999	Aug	CRLD
>A>		7MG/24HR	N020076	004	Nov 12, 1999	Aug	CRLD
>D>	+	14MG/24HR	N020076	005	Nov 12, 1999	Aug	CRLD
>A>		14MG/24HR	N020076	005	Nov 12, 1999	Aug	CRLD
	NICODERM CQ						
>D>	+	SANOFI AVENTIS US 7MG/24HR	N020165	006	Aug 02, 1996	Aug	CRLD
>A>		7MG/24HR	N020165	006	Aug 02, 1996	Aug	CRLD
>D>	+	14MG/24HR	N020165	005	Aug 02, 1996	Aug	CRLD
>A>		14MG/24HR	N020165	005	Aug 02, 1996	Aug	CRLD
	<u>NICOTINE POLACRILEX</u>						
	GUM, CHEWING;BUCCAL						
	NICOTINE POLACRILEX						
		ACTAVIS LABS NY INC EQ 2MG BASE	A204794	001	May 10, 2016	Apr	NEWA
		EQ 4MG BASE	A204833	001	Feb 26, 2016	Feb	NEWA
	<u>OMEPRAZOLE; SODIUM BICARBONATE</u>						
	CAPSULE;ORAL						
	OMEPRAZOLE AND SODIUM BICARBONATE						
		ACTAVIS ELIZABETH 20MG;1.1GM	A204137	001	Jul 15, 2016	Jul	NEWA
		PAR PHARM 20MG;1.1GM	A201946	001	Jul 15, 2016	Jul	NEWA
		PERRIGO R AND D 20MG;1.1GM	A201361	001	Jul 15, 2016	Jul	NEWA
	<u>OXYBUTYNIN</u>						
	FILM, EXTENDED RELEASE;TRANSDERMAL						
	OXYTROL FOR WOMEN						
	+	ALLERGAN SALES LLC 3.9MG/24HR	N202211	001	Jan 25, 2013	Jan	CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

>A>	STRIDES PHARMA	17GM/SCOOPFUL	A203928	001	Aug 24, 2016	Aug NEWA
>A>		17GM/PACKET	A203928	002	Aug 24, 2016	Aug NEWA

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA EQ 75MG BASE

A201745 001 Feb 29, 2012 May CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2016

NO AUGUST 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP		PED	Jan 11, 2017
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	>A> 9399012	Sep 11, 2031	U-1882			
	>A> 9399012*PED	Mar 11, 2032				
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 001					RTO	Jul 08, 2019
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	001				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	002				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	001				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	002				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	003				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	004				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	005				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	006				M-177	Apr 05, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081	001				NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	001	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	002	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	003	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	004	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	005	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	006	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001						

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156 004					PC	Nov 28, 2016
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	>A> 5763476	Jun 09, 2020	DP U-1893			
	>A> 5763476*PED	Dec 09, 2020				
	>A> 7741358	Apr 06, 2026	DS DP U-1893			
	>A> 7741358*PED	Oct 06, 2026				
	>A> 8022228	Apr 06, 2026	DS DP			
	>A> 8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
	9351984	Dec 19, 2021	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023	U-644			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
	>A> 9433630	Aug 31, 2030	DP U-1858			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	8906410	Feb 02, 2027	DP			
>A>	9408858	Apr 25, 2028	U-1888			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					I-735	May 20, 2019
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	8129346	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	>A> 7232818	Apr 14, 2025	DS DP			
	>A> 7417042	Jul 20, 2026	DS DP			
	>A> 7491704	Apr 14, 2025		U-1260		
	>A> 7737112	Dec 07, 2027	DP			
	>A> 8129346	Apr 14, 2025		U-1260		
	>A> 8207125	Apr 14, 2025	DS DP			
	>A> 8207126	Apr 14, 2025	DP			
	>A> 8207127	Apr 14, 2025		U-1260		
	>A> 8207297	Apr 14, 2025	DS DP			
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP	U-1676		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	>A> 9402805	Sep 13, 2022	DP U-1578			
	>A> 9402805	Sep 13, 2022	DP U-1679			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	>A> 9399036	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DAKLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DAKLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	>A> 7148359	Jul 19, 2019	DP		NCE	Dec 19, 2019
	>A> 7364752	Nov 10, 2020	DP			
	>A> 8188104	May 17, 2029	DS DP	U-1636		
	>A> 8268349	Aug 25, 2024	DP			
	>A> 8399015	Aug 25, 2024	DP			
	>A> 8420596	Apr 10, 2031	DS DP			
	>A> 8466159	Sep 04, 2032		U-1637		
	>A> 8492386	Sep 04, 2032		U-1840		
	>A> 8501238	Sep 17, 2028	DS DP	U-1636		
	>A> 8642538	Sep 10, 2029	DS DP	U-1638		
	>A> 8680106	Sep 04, 2032		U-1637		
	>A> 8685984	Sep 04, 2032		U-1840		
	>A> 8686026	Jun 09, 2031	DP			
	>A> 8691938	Apr 13, 2032	DS DP			
	>A> 9006387	Jun 10, 2030		U-1687		
	>A> 9044480	Apr 10, 2031		U-1638		
	>A> 9139536	Nov 09, 2028		U-1753		
	>A> 9333204	Jan 02, 2035	DP	U-1889		
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103 9238029	Mar 05, 2032 Jan 17, 2026	U-1805 DP		NPP NPP NPP	Jul 08, 2019 Jul 08, 2019 Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103 9238029	Mar 05, 2032 Jan 17, 2026	U-1805 DP		NPP NPP NPP	Jul 08, 2019 Jul 08, 2019 Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6328994 6328994*PED 6462058 6462058 6462058*PED 6664276 6664276 6664276*PED 6939971 6939971 6939971*PED 7285668 7285668*PED 7399485 7399485*PED 7431942 7431942*PED 7875292 7875292*PED 8461187 8461187*PED 8784885 8784885*PED 8871273 8871273*PED 9011926 9145389 9238029 9241910	May 17, 2019 Nov 17, 2019 Jun 15, 2020 Jun 15, 2020 Dec 15, 2020 Jan 30, 2023 Jan 30, 2023 Jul 30, 2023 Jun 15, 2020 Jun 15, 2020 Dec 15, 2020 Jun 15, 2020 Dec 15, 2020 May 26, 2018 Nov 26, 2018 May 17, 2019 Nov 17, 2019 May 17, 2019 Nov 17, 2019 Jan 17, 2026 Jul 17, 2026 Oct 15, 2023 Apr 15, 2024 Jan 11, 2028 Jul 11, 2028 Feb 24, 2026 Jun 15, 2020 Jan 17, 2026 Mar 10, 2029	DP DS DP U-950 DS DP U-951 DS DP U-950 DS DP U-951 U-950 U-951 DS DP DP DP DP DS DP DP DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784 9339551 9339552 >A> 9370501 >A> 9375412 >A> 9415029	Oct 17, 2027 Oct 17, 2027 Oct 17, 2027 Jul 10, 2029 Jul 10, 2029 Jul 10, 2029	U-1488 U-1488 DP U-1488 U-1614 U-1614 U-1614			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003					PC	Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	>A> 8039009	Mar 24, 2029	U-1641			
	>A> 8039009*PED	Sep 24, 2029				
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8329752*PED	May 22, 2026				
	>A> 8338485	Nov 22, 2025	DP			
	>A> 8338486	Nov 22, 2025	U-1641			
	>A> 8362085	Nov 22, 2025	U-1641			
	>A> 8362085*PED	May 22, 2026				
	>A> 8580858	Nov 22, 2025	U-1641			
	>A> 8598233	Nov 22, 2025	DP			
	>A> 8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 003	>A> 8039009	Mar 24, 2029	U-1641			
	>A> 8039009*PED	Sep 24, 2029				
	>A> 8058291	Dec 05, 2029	U-1641			
	>A> 8168209	Nov 22, 2025	DP			
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-1641			
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-1641			
	>A> 8283379*PED	May 22, 2026				
	>A> 8293794	Nov 22, 2025	DP			
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8329752*PED	May 22, 2026				
	>A> 8338485	Nov 22, 2025	DP			
	>A> 8338486	Nov 22, 2025	U-1641			
	>A> 8362085	Nov 22, 2025	U-1641			
	>A> 8362085*PED	May 22, 2026				
	>A> 8580858	Nov 22, 2025	U-1641			
	>A> 8598233	Nov 22, 2025	DP			
	>A> 8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	>A> 8039009	Mar 24, 2029	U-1641			
	>A> 8039009*PED	Sep 24, 2029				
	>A> 8058291	Dec 05, 2029	U-1641			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	>A> 8168209	Nov 22, 2025	DP			
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-1641			
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-1641			
	>A> 8283379*PED	May 22, 2026				
	>A> 8293794	Nov 22, 2025	DP			
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8329752*PED	May 22, 2026				
	>A> 8338485	Nov 22, 2025	DP			
	>A> 8338486	Nov 22, 2025	U-1641			
	>A> 8362085	Nov 22, 2025	U-1641			
	>A> 8362085*PED	May 22, 2026				
	>A> 8580858	Nov 22, 2025	U-1641			
	>A> 8598233	Nov 22, 2025	DP			
	>A> 8598233*PED	May 22, 2026				
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 005					PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9302009	Oct 24, 2030	DP			
<u>ELBASVIR; GRAZOPREVIR - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	9364489	Jul 07, 2028	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	9364489	Jul 07, 2028	U-1709			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 14, 2029	DP U-1651		M-174	Mar 18, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 14, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
	8551957	Oct 14, 2029	DP U-1651			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004					M-174	Mar 18, 2019
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-257		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
>A>	7125879	Apr 21, 2025	DS DP	U-257		
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022		U-257		
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP	U-257		
	9296769	Aug 15, 2032	DS DP	U-257		
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	>A> 7125879	Apr 21, 2025	DS DP	U-257		
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-257		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022		U-257		
	8754065	Aug 15, 2032	DS DP	U-257		
	9296769	Aug 15, 2032	DS DP	U-257		
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017		U-248		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-541		
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-1259		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-541		
	5935946	Jul 25, 2017	DS DP	U-1170		
	5935946	Jul 25, 2017	DS DP	U-1259		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-541		
	5977089	Jul 25, 2017	DS DP	U-1170		
	5977089	Jul 25, 2017	DS DP	U-1259		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-541		
	6043230	Jul 25, 2017		U-1170		
	6043230	Jul 25, 2017		U-1259		
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245	Nov 04, 2020		U-1259		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-541		
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-1259		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-541		
	5935946	Jul 25, 2017	DS DP	U-1170		
	5935946	Jul 25, 2017	DS DP	U-1259		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-541		
	5977089	Jul 25, 2017	DS DP	U-1170		
	5977089	Jul 25, 2017	DS DP	U-1259		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-541		
	6043230	Jul 25, 2017		U-1170		
	6043230	Jul 25, 2017		U-1259		
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245	Nov 04, 2020		U-1259		
	6642245*PED	May 04, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-541		
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-1259		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-541		
	5935946	Jul 25, 2017	DS DP	U-1170		
	5935946	Jul 25, 2017	DS DP	U-1259		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-541		
	5977089	Jul 25, 2017	DS DP	U-1170		
	5977089	Jul 25, 2017	DS DP	U-1259		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-541		
	6043230	Jul 25, 2017		U-1170		
	6043230	Jul 25, 2017		U-1259		
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245	Nov 04, 2020		U-1259		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	>A> 8778366	Nov 06, 2032		U-3		
	>A> 8778366	Nov 06, 2032		U-71		
	>A> 8778366	Nov 06, 2032		U-185		
	>A> 8778366	Nov 06, 2032		U-1723		
	>A> 8778366	Nov 06, 2032		U-1892		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035		U-1829		
	9295657	Mar 13, 2035		U-1830		
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035		U-1829		
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP	U-1828		
	9283197	Aug 15, 2034	DP	U-1829		
	9283197	Aug 15, 2034	DP	U-1830		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
					M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
					M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
					M-181	Jun 01, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021	DP			
	6528540*PED	Jul 12, 2021				
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021	DP			
	6528540*PED	Jul 12, 2021				
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	6369085	May 25, 2018	DS DP U-1509			
	6369085	May 25, 2018	DS DP U-1875			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810	Nov 03, 2019	DP U-1874			
	6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031	U-1781			
	9345695	May 31, 2022	DP			
>A>	9393208	Sep 03, 2029	U-1781			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9345695	May 31, 2022	DP			
>A>	9393208	Sep 03, 2029	U-1781			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
>A>	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
>A>	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9387191	Jul 21, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2016	DS		NCE	May 27, 2021
	9387266	Nov 28, 2026	U-1879			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	>A> 6858596	Aug 03, 2021	DP U-1890			
	>A> 7101866	Aug 03, 2021	DS DP U-1890			
	>A> 7541350	Aug 03, 2021	DP U-1890			
	>A> 8062264	Apr 05, 2026	DP			
	>A> 8147461	Oct 15, 2028	DP			
	>A> 8347879	Jul 15, 2028	DP			
	>A> 8752543	Apr 05, 2026	DP			
	>A> 9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
>A>	9415009	May 28, 2030	U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001					NCE ODE	Jun 01, 2021 Jun 01, 2023
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	9402874	Aug 19, 2030	U-441			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP			
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	>A> 6613355	Jun 28, 2021	DP		>A> NDF	Aug 09, 2019
	>A> 6790458	May 11, 2021	DP			
	>A> 8252304	Sep 28, 2024	DP			
	>A> 8252305	Sep 28, 2024	U-1891			
	>A> 8715710	Sep 28, 2024	DP			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	>A> 9421200	Jul 25, 2033	U-1810			
	>A> 9433619	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	>A> 9421200	Jul 25, 2033	U-1810			
	>A> 9433619	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	>A> 9421200	Jul 25, 2033	U-1810			
	>A> 9433619	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	>A> 9421200	Jul 25, 2033	U-1810			
	>A> 9433619	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	>A> 9421200	Jul 25, 2033	U-1810			
	>A> 9433619	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	>A> 9421200	Jul 25, 2033	U-1810			
	>A> 9433619	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	>A> 9421200	Jul 25, 2033	U-1810			
	>A> 9433619	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165 I-729 I-736 I-737 ODE ODE	May 06, 2019 Mar 04, 2019 May 06, 2019 May 06, 2019 Mar 04, 2023 May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	6958335	Dec 19, 2021		U-791		
	6958335	Dec 19, 2021		U-1883		
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	6958335	Dec 19, 2021		U-791		
	6958335	Dec 19, 2021		U-1883		
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	7410656	Oct 10, 2020		U-1222		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	7410656	Oct 10, 2020		U-1222		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024		U-1832		
	9233211	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024		U-1832		
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
	9399040	Jul 30, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	9339504	Jul 02, 2028	DP U-1596			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	9339504	Jul 02, 2028	DP U-1596			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158	Feb 12, 2019
	>A> 9393256	Sep 14, 2032	U-1470		D-159	Feb 12, 2019
					D-160	Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 02, 2030	U-1806			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP U-1850			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9339489	Mar 14, 2034	DP U-1850			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9339489	Mar 14, 2034	DP U-1850			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 206263 001					>A> PC	Feb 11, 2017
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	9358338	Apr 27, 2035	U-1870			
	9370622	Sep 28, 2035	U-1870			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	7314938	Mar 10, 2025	DS DP		NCE	Jul 11, 2021
	7745460	Nov 05, 2024	DS DP U-1880			
	7790743	Nov 05, 2024	U-1880			
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029	U-1880			
	8367701	Apr 15, 2029	DP U-1880			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	8592450	May 17, 2026	U-1880			
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	>A> 8748573	Oct 30, 2031	U-1515			
	>A> 8748573	Oct 30, 2031	U-1516			
	>A> 8802628	Dec 08, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	>A> 8748573	Oct 30, 2031	U-1515			
	>A> 8748573	Oct 30, 2031	U-1516			
	>A> 8802628	Dec 08, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
	>A> 9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
	>A> 9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
	>A> 9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	>A> 9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	>A> 9415016	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	>A> 9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	>A> 9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	>A> 9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	>A> 9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	>A> 9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	>A> 9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	>A> 9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	>A> 9433617	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	>A> 6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	>A> 6953787	Apr 10, 2023	DS DP U-1253			
	>A> 6953787	Apr 10, 2023	DS DP U-1254			
	>A> 6953787	Apr 10, 2023	DS DP U-1255			
	>A> 7514422	Apr 10, 2023	U-1252			
	>A> 7514422	Apr 10, 2023	U-1253			
	>A> 7514422	Apr 10, 2023	U-1254			
	>A> 7514422	Apr 10, 2023	U-1255			
	>A> 7977329	Apr 10, 2023	DS DP U-1252			
	>A> 7977329	Apr 10, 2023	DS DP U-1253			
	>A> 7977329	Apr 10, 2023	DS DP U-1254			
	>A> 7977329	Apr 10, 2023	DS DP U-1255			
	>A> 8168624	Apr 18, 2029	DS DP			
	>A> 8207158	Apr 10, 2023	U-1252			
	>A> 8207158	Apr 10, 2023	U-1253			
	>A> 8207158	Apr 10, 2023	U-1254			
	>A> 8207158	Apr 10, 2023	U-1255			
	>A> 8273734	Apr 10, 2023	U-1254			
	>A> 8273734	Apr 10, 2023	U-1255			
	>A> 8367657	Apr 10, 2023	DS DP U-1252			
	>A> 8367657	Apr 10, 2023	DS DP U-1253			
	>A> 8367657	Apr 10, 2023	DS DP U-1254			
	>A> 8367657	Apr 10, 2023	DS DP U-1255			
	>A> 8546379	Apr 10, 2023	DS DP U-1252			
	>A> 8546379	Apr 10, 2023	DS DP U-1253			
	>A> 8546379	Apr 10, 2023	DS DP U-1254			
	>A> 8546379	Apr 10, 2023	DS DP U-1255			
	>A> 8575149	Apr 10, 2023	U-1452			
	>A> 8697686	Dec 20, 2025	DS DP			
	>A> 8946207	Jun 16, 2024	DP			
	>A> 8980881	Dec 20, 2025	U-1252			
	>A> 8980881	Dec 20, 2025	U-1253			
	>A> 8980881	Dec 20, 2025	U-1254			
	>A> 8980881	Dec 20, 2025	U-1255			
	>A> 8999970	Feb 07, 2033	U-1688			
	>A> 8999970	Feb 07, 2033	U-1689			
	>A> 8999970	Feb 07, 2033	U-1692			
	>A> 9169213	Dec 06, 2032	U-1884			
	>A> 9169213	Dec 06, 2032	U-1885			
	>A> 9169213	Dec 06, 2032	U-1886			
	>A> 9169213	Dec 06, 2032	U-1887			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9370629	May 20, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	9382191	Mar 07, 2026	DP			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
>A>	8579865	Mar 19, 2030	DP U-1442			
>A>	8945063	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007 >A>	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
>A>	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
>A>	8579865	Mar 19, 2030	DP U-1442			
>A>	8945063	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
>A>	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
>A>	8579865	Mar 19, 2030	DP U-1442			
>A>	8945063	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	6559158	Nov 03, 2017	U-1185		NP	Jul 19, 2019
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
>A>	9314461	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556		>A> NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556		>A> NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556		>A> NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556		>A> NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 001					>A> NC	Aug 19, 2019
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 002					>A> NC	Aug 19, 2019
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 003					>A> NC	Aug 19, 2019
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 004					>A> NC	Aug 19, 2019
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 005					>A> NC	Aug 19, 2019
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 006					>A> NC	Aug 19, 2019
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	9271975	Sep 09, 2031	U-528			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	9364564	Dec 26, 2027	DP			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9295802*PED	Jul 06, 2031				
	>A> 9408993	Jan 06, 2031	DP U-1824			
	>A> 9408993*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-588	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	>A> 9393318	Aug 03, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Jun 18, 2019	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9296694	Mar 06, 2021	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 006					PC	Jan 01, 2017
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9289446	Jun 22, 2019	DP U-116			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9271968	Feb 27, 2026	DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	>A> 7125879	Apr 21, 2025	DS DP U-1153			
	>A> 7125879	Apr 21, 2025	DS DP U-1307			
	>A> 7125879	Apr 21, 2025	DS DP U-1740			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-1167			
	>A> 9415053	Nov 13, 2024	DP U-1200			
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-1167			
	>A> 9415053	Nov 13, 2024	DP U-1200			
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-1167			
	>A> 9415053	Nov 13, 2024	DP U-1200			
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-1303			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSOPHERES - LUMASON</u>						
N 203684 001					I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPATAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	6956041	Dec 08, 2020	DP			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
>A>	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
>A>	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
>A>	9422223	May 24, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
>A>	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
>A>	9422223	May 24, 2024	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	RE42353	Jun 27, 2022	DS DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					>A> M-183	Aug 12, 2019
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					>A> M-183	Aug 12, 2019
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035	U-1857			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001					>A> M-184	Aug 31, 2019
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm